<?xml version="1.0" encoding="utf-8"?><dg:chunk cp:version="2.21.21.0.1705581103362-1721.0" xmlns:docset="http://www.docugami.com/2021/dgml/docugami/ClinicalTrialProtocols" xmlns:addedChunks="http://www.docugami.com/2021/dgml/docugami/ClinicalTrialProtocols/addedChunks" xmlns:dg="http://www.docugami.com/2021/dgml" xmlns:dgc="http://www.docugami.com/2021/dgml/docugami/contracts" xmlns:dgm="http://www.docugami.com/2021/dgml/docugami/medical" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:cp="http://classifyprocess.com/2018/07/"><dg:chunk><docset:Protocol-section><dg:chunk structure="h1">

              Protocol: </dg:chunk><docset:Protocol structure="div">I8B-MC-ITSA(d) </docset:Protocol></docset:Protocol-section><dg:chunk><docset:StudyDescription structure="p">

              A <dgm:_testRef>Study </dgm:_testRef>to Evaluate the Pharmacokinetics and Glucodynamics of <docset:StudyDrug>LY900014 </docset:StudyDrug>Compared to <dgm:Medication>Humalog </dgm:Medication>in Children, Adolescents, and Adults With Type 1 <dgm:Condition><dgm:Condition>Diabetes </dgm:Condition>Mellitus </dgm:Condition></docset:StudyDescription><dg:chunk><dg:chunk structure="p">

              <docset:ClinicalTrialID>NCT03465878 </docset:ClinicalTrialID></dg:chunk><docset:ApprovalDate-section><dg:chunk structure="h1">

              <dg:chunk>Approval Date</dg:chunk>: </dg:chunk><docset:ApprovalDate structure="div"><docset:Date>20</docset:Date>-<docset:Date>Jul-2018 </docset:Date></docset:ApprovalDate></docset:ApprovalDate-section></dg:chunk></dg:chunk></dg:chunk><docset:Protocol18B-MC-ITSAD-section><dg:chunk structure="h1">

                                           Protocol 18B-MC-ITSA(d) </dg:chunk><docset:Protocol18B-MC-ITSAD structure="div"><docset:StudyDescription structure="p">

                           A <dgm:_testRef>Study </dgm:_testRef>to Evaluate the Pharmacokinetics and Glucodynamics of <docset:StudyName>LY900014 </docset:StudyName>Compared to <dgm:Medication>Humalog </dgm:Medication>in Children, Adolescents, and Adults with Type 1 <dgm:Condition>Diabetes </dgm:Condition>

                                                        Mellitus </docset:StudyDescription><xhtml:table structure="table" style="boundingBox:{left: 569; top: 694; width: 1412; height: 51; page: 2;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 569; top: 694; width: 1412; height: 51; page: 2;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 569; top: 694; width: 1412; height: 51; page: 2;}; "><xhtml:td structure="td" style="boundingBox:{left: 569; top: 694; width: 1412; height: 51; page: 2;}; "><docset:EudractNumber-cell><dg:chunk structure="h1">

                                               EudraCT Number: <docset:Year>2017</docset:Year>-<docset:EudraCTNumber>003220</docset:EudraCTNumber>-<docset:EudraCTNumber>78 </docset:EudraCTNumber></dg:chunk><dg:chunk structure="p">

                                                                                            | </dg:chunk></docset:EudractNumber-cell></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:Protocol18B-MC-ITSAD></docset:Protocol18B-MC-ITSAD-section><dg:chunk><dg:chunk structure="h1">

                                            Confidential Information </dg:chunk><dg:chunk structure="div"><docset:ConfidentialityAgreement structure="p">

                            The information contained in this protocol is confidential and is intended for the use of clinical investigators. It is the property of <dgc:Org><dg:chunk>Eli Lilly </dg:chunk>and Company </dgc:Org>or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of <docset:DrugName>LY900014</docset:DrugName>, unless such persons are bound by a confidentiality agreement with <docset:ConfidentialityAgreement><dg:chunk>Eli Lilly </dg:chunk>and Company </docset:ConfidentialityAgreement>or its subsidiaries. </docset:ConfidentialityAgreement><docset:NotetoRegulatoryAuthorities-section><dg:chunk structure="h1">

                            Note to <dg:chunk>Regulatory Authorities</dg:chunk>: </dg:chunk><docset:NotetoRegulatoryAuthorities structure="div"><docset:ConfidentialInformation structure="p">This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. <docset:ExemptDocument>Eli Lilly </docset:ExemptDocument>and Company requests consultation regarding release/redaction prior to any public release. In the <dg:chunk>United States</dg:chunk>, this document is subject to Freedom of Information Act (<dg:chunk>FOIA) Exemption </dg:chunk>4 and may not be reproduced or otherwise disseminated without the written </docset:ConfidentialInformation><docset:ApprovalofEliLillyAndCompanyOrItsSubsidiaries-section><dg:chunk structure="h1">

                            approval of <docset:CompanyName><dg:chunk>Eli Lilly </dg:chunk>and Company </docset:CompanyName>or its subsidiaries. </dg:chunk><docset:LY900014-section structure="div"><dg:chunk structure="h1">

                                                       <docset:LY900014>LY900014 </docset:LY900014></dg:chunk><docset:LY900014 structure="div"><docset:EliLillyAndCompanyIndianapolisIndianaUSA46285-section><dg:chunk structure="h1">

                                                 <docset:CompanyName><dg:chunk>Eli Lilly </dg:chunk>and <dg:chunk>Company Indianapolis</dg:chunk></docset:CompanyName>, <dg:chunk><dgc:USState>Indiana </dgc:USState>USA </dg:chunk><docset:ZipCode>46285 </docset:ZipCode></dg:chunk><docset:ClinicalPharmacologyProtocolElectronicallySignedAndApprovedbyLilly-secti structure="div"><dg:chunk structure="h1">

                    <dg:chunk>Clinical Pharmacology Protocol </dg:chunk>Electronically Signed and Approved by <docset:ElectronicSignature>Lilly</docset:ElectronicSignature>: </dg:chunk><docset:_12October2017-section structure="div"><dg:chunk structure="h1">

                                                   <docset:Date><docset:Date>12 </docset:Date><docset:Month>October </docset:Month><docset:Date>2017 </docset:Date></docset:Date></dg:chunk><docset:_12October2017 structure="div"><dg:chunk><docset:ElectronicSignatureandApproval structure="p">

                  Amendment (a) Electronically Signed and Approved by Lilly: <docset:AmendmentDate><docset:AmendmentDate>21 </docset:AmendmentDate><docset:AmendmentDate>December </docset:AmendmentDate><docset:AmendmentDate>2017 </docset:AmendmentDate></docset:AmendmentDate>Amendment (b) Electronically Signed and Approved by Lilly: <docset:AmendmentDate><docset:AmendmentDate>19 </docset:AmendmentDate><docset:AmendmentDate>March </docset:AmendmentDate><docset:AmendmentDate>2018 </docset:AmendmentDate></docset:AmendmentDate>Amendment (c) Electronically Signed and Approved by Lilly: <docset:LastAmendmentDate><docset:AmendmentDate>17 </docset:AmendmentDate><docset:AmendmentDate>April </docset:AmendmentDate><dgc:Year>2018 </dgc:Year></docset:LastAmendmentDate></docset:ElectronicSignatureandApproval><dg:chunk><dg:chunk structure="p">

                             Amendment (d) Electronically Signed and Approved by Lilly </dg:chunk><dg:chunk structure="p">

                                          on approval date provided below. </dg:chunk></dg:chunk></dg:chunk><docset:ApprovalDate-section><dg:chunk structure="h1">

                                                            <dg:chunk>Approval Date</dg:chunk>: </dg:chunk><docset:ApprovalDate structure="div"><dg:chunk structure="p"><docset:Date><docset:Date>20</docset:Date>-<docset:Date>Jul-2018 </docset:Date></docset:Date>GMT </dg:chunk><docset:TableofContents-section><dg:chunk structure="h1">

                                               Table of Contents </dg:chunk><docset:TableofContents structure="div"><docset:StudyDescription structure="p">

                         A <dgm:_testRef>Study </dgm:_testRef>to Evaluate the Pharmacokinetics and Glucodynamics of <docset:StudyDrug>LY900014 </docset:StudyDrug>compared to <dgm:Medication>Humalog </dgm:Medication>in Children, Adolescents, and Adults with Type <docset:StudyDescription>1 </docset:StudyDescription><dgm:Condition>Diabetes </dgm:Condition></docset:StudyDescription><docset:Mellitus-section><dg:chunk structure="h1">

                                                      <docset:Diabetes>Mellitus </docset:Diabetes></dg:chunk><docset:Mellitus structure="div"><dg:chunk structure="p">

              Section </dg:chunk><docset:Page-section><dg:chunk structure="h1">

                                                                                                    Page </dg:chunk><docset:Page structure="div"><dg:chunk><dg:chunk><dg:chunk structure="p">

              Protocol I8B-MC-ITSA(d) A <dgm:_testRef>Study </dgm:_testRef>to Evaluate the Pharmacokinetics and </dg:chunk><dg:chunk><docset:StudyDesign structure="p">

                   Glucodynamics of <docset:StudyName>LY900014 </docset:StudyName>Compared to <dgm:Medication>Humalog </dgm:Medication>in Children, Adolescents, and Adults with Type <docset:StudyDesign>1 </docset:StudyDesign><dgm:Condition><dgm:Condition>Diabetes </dgm:Condition>Mellitus</dgm:Condition>. </docset:StudyDesign><docset:Main structure="p">

                                                                                                         <dgc:Number>1 </dgc:Number></docset:Main></dg:chunk></dg:chunk><dg:chunk structure="p">

              Table of Contents </dg:chunk></dg:chunk><docset:_2-section><dg:chunk structure="h1">

                                                                                                        <dgc:Number>.2 </dgc:Number></dg:chunk><docset:_2 structure="div"><docset:StudyDesign structure="ol" style="list-style-type: decimal; boundingBox:{left: 296; top: 1128; width: 1955; height: 662; page: 3;}; "><dg:chunk structure="li" style="boundingBox:{left: 396; top: 1129; width: 1850; height: 57; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 298; top: 1128; width: 48; height: 50; page: 3;}; ">

              1. </dg:chunk><dg:chunk><dg:chunk>Protocol Synopsis </dg:chunk><docset:ProtocolSynopsis>8 </docset:ProtocolSynopsis></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 400; top: 1208; width: 1847; height: 51; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300; top: 1209; width: 43; height: 48; page: 3;}; ">

              2. </dg:chunk><dg:chunk structure="h1">Schedule of Activities <docset:ScheduleofActivities>11 </docset:ScheduleofActivities></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 394; top: 1286; width: 1854; height: 52; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 319; top: 1283; width: 30; height: 54; page: 3;}; ">

               . </dg:chunk><dg:chunk structure="h1">Introduction <docset:Introduction>23 </docset:Introduction></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 463; top: 1360; width: 1783; height: 50; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 326; top: 1360; width: 90; height: 47; page: 3;}; ">

               3.1. </dg:chunk><dg:chunk structure="p"><dg:chunk><dgm:_testRef>Study </dgm:_testRef>Rationale </dg:chunk><docset:StudyRationale>23 </docset:StudyRationale></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 462; top: 1434; width: 1785; height: 49; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 329; top: 1432; width: 66; height: 47; page: 3;}; ">

               3.2 </dg:chunk><dg:chunk>Background <docset:BackgroundColor>23 </docset:BackgroundColor></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 461; top: 1499; width: 1786; height: 51; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 330; top: 1497; width: 88; height: 47; page: 3;}; ">

                3.3. </dg:chunk><dg:chunk structure="p">Benefit/Risk Assessment <docset:BenefitRiskAssessment>25 </docset:BenefitRiskAssessment></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 393; top: 1580; width: 1858; height: 54; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 296; top: 1581; width: 57; height: 52; page: 3;}; ">

              4. </dg:chunk><dg:chunk structure="p">Objectives and Endpoints <docset:ObjectivesandEndpoints>.27 </docset:ObjectivesandEndpoints></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 396; top: 1663; width: 1852; height: 51; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 295; top: 1660; width: 53; height: 51; page: 3;}; ">

              5. </dg:chunk><dg:chunk structure="p"><dg:chunk><dgm:_testRef>Study </dgm:_testRef>Design</dg:chunk>. <docset:StudyDesign>.28 </docset:StudyDesign></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 298.0; top: 1735; width: 1954.0; height: 1253.0; page: 3;}; boundingBox:{left: 293; top: 305; width: 1958; height: 2674.7; page: 4;}; boundingBox:{left: 299.0; top: 305.0; width: 1955.0; height: 1960.0; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 325; top: 1735; width: 93; height: 50; page: 3;}; ">

               5.1. </dg:chunk><dg:chunk><dg:chunk structure="p"><dg:chunk>Overall Design </dg:chunk><docset:OverallDesign>28 </docset:OverallDesign></dg:chunk><docset:StudyDesign structure="ol" style="list-style-type: decimal; boundingBox:{left: 298.0; top: 1804.2; width: 1954.0; height: 1183.8; page: 3;}; boundingBox:{left: 293; top: 305; width: 1958; height: 2674.7; page: 4;}; boundingBox:{left: 299.0; top: 305.0; width: 1955.0; height: 1960.0; page: 5;}; "><dg:chunk structure="li" style="boundingBox:{left: 564; top: 1805; width: 1682; height: 50; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 370; top: 1802; width: 128; height: 52; page: 3;}; ">

                 5.1.1. </dg:chunk><dg:chunk structure="p">Part A <docset:TextField>29 </docset:TextField></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 637; top: 1873; width: 1610; height: 50; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 407; top: 1872; width: 160; height: 49; page: 3;}; ">

                   5.1.1.1. </dg:chunk><dg:chunk><dg:chunk>Inpatient Procedures </dg:chunk>for <dg:chunk>Part A </dg:chunk><docset:InpatientProcedures>31 </docset:InpatientProcedures></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 565; top: 1945; width: 1683; height: 47; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 369; top: 1943; width: 126; height: 49; page: 3;}; ">

                 5.1.2. </dg:chunk><dg:chunk structure="h1"><dg:chunk>Part B </dg:chunk><docset:PartB>34 </docset:PartB></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 636; top: 2012; width: 1608; height: 53; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 413; top: 2012; width: 159; height: 52; page: 3;}; ">

                   5.1.2.1. </dg:chunk><dg:chunk structure="p"><dg:chunk>Inpatient Procedures </dg:chunk>for <dg:chunk>Part B </dg:chunk><docset:InpatientProceduresforPartB>36 </docset:InpatientProceduresforPartB></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 458; top: 2082; width: 1786; height: 53; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 328; top: 2082; width: 91; height: 50; page: 3;}; ">

               5.2. </dg:chunk><dg:chunk structure="p">Number of Participants <docset:NumberofParticipants>40 </docset:NumberofParticipants></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 466; top: 2153; width: 1778; height: 52; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 328; top: 2151; width: 69; height: 49; page: 3;}; ">

               5.3 </dg:chunk><dg:chunk structure="p">End of <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Definition </dg:chunk><docset:StudyDefinition>40 </docset:StudyDefinition></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 459; top: 2224; width: 1787; height: 57; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 329; top: 2225; width: 66; height: 45; page: 3;}; ">

               5.4 </dg:chunk><dg:chunk structure="p"><dg:chunk>Scientific Rationale </dg:chunk>for <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Design </dg:chunk><docset:ScientificRationale>40 </docset:ScientificRationale></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 459; top: 2293; width: 1788; height: 49; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 329; top: 2291; width: 89; height: 48; page: 3;}; ">

               5.5. </dg:chunk><dg:chunk structure="p">Justification for Dose <docset:DoseJustification>40 </docset:DoseJustification></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 394; top: 2369; width: 1858; height: 59; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 298; top: 2368; width: 55; height: 57; page: 3;}; ">

              6. </dg:chunk><dg:chunk><dg:chunk><dgm:_testRef>Study </dgm:_testRef>Population </dg:chunk><docset:StudyPopulation>42 </docset:StudyPopulation></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 458; top: 2446; width: 1793; height: 50; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 325; top: 2446; width: 93; height: 52; page: 3;}; ">

               6.1. </dg:chunk><dg:chunk structure="h1"><dg:chunk>Inclusion Criteria </dg:chunk><docset:InclusionCriteria>42 </docset:InclusionCriteria></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 459; top: 2515; width: 1792; height: 51; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 328; top: 2515; width: 91; height: 52; page: 3;}; ">

               6.2. </dg:chunk><dg:chunk structure="h1"><dg:chunk>Exclusion Criteria </dg:chunk><docset:ExclusionCriteria>44 </docset:ExclusionCriteria></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 565; top: 2581; width: 1686; height: 57; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 370; top: 2583; width: 131; height: 50; page: 3;}; ">

                 6.2.1. </dg:chunk><dg:chunk structure="p"><dg:chunk>Additional Exclusion Criteria </dg:chunk>for <dg:chunk>Inpatient Dosing Days </dg:chunk><docset:InpatientDosingDays>46 </docset:InpatientDosingDays></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 565; top: 2656; width: 1685; height: 51; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 374; top: 2653; width: 125; height: 51; page: 3;}; ">

                  6.2.2. </dg:chunk><dg:chunk>Rationale for Exclusion of <dg:chunk>Certain <dgm:_testRef>Study </dgm:_testRef>Candidates </dg:chunk><docset:RationaleforExclusion>46 </docset:RationaleforExclusion></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 457; top: 2723; width: 1792; height: 54; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 324; top: 2723; width: 97; height: 52; page: 3;}; ">

               6.3. </dg:chunk><dg:chunk structure="p">Lifestyle and/or Dietary Requirements <docset:LifestyleandorDietaryRequirements>47 </docset:LifestyleandorDietaryRequirements></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 568; top: 2792; width: 1679; height: 54; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 371; top: 2796; width: 120; height: 48; page: 3;}; ">

                 6.3.1. </dg:chunk><dg:chunk structure="p">Meals and <dg:chunk>Dietary Restrictions</dg:chunk>. <docset:MealsandDietaryRestrictions>47 </docset:MealsandDietaryRestrictions></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 573; top: 2864; width: 1678; height: 51; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 375; top: 2868; width: 117; height: 47; page: 3;}; ">

                  6.3.2. </dg:chunk><dg:chunk><dgm:Medication>Caffeine</dgm:Medication>, Alcohol, and Tobacco <docset:CaffeineAlcoholandTobacco>.47 </docset:CaffeineAlcoholandTobacco></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 373; top: 2936.0; width: 364; height: 52.0; page: 3;}; "><dg:chunk structure="lim" style="boundingBox:{left: 373; top: 2934; width: 117; height: 46; page: 3;}; ">

                  6.3.3. </dg:chunk><dg:chunk structure="h1">Activity </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 461; top: 305; width: 1785; height: 49; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 330; top: 307; width: 91; height: 47; page: 4;}; ">

                6.4. </dg:chunk><dg:chunk structure="p"><dgm:_testRef>Screen </dgm:_testRef>Failures <docset:ScreenFailures>48 </docset:ScreenFailures></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 404; top: 385; width: 1841; height: 48; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300; top: 383; width: 48; height: 50; page: 4;}; ">

              7. </dg:chunk><dg:chunk structure="p">Treatment. <docset:Treatment>49 </docset:Treatment></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 463; top: 452; width: 1784; height: 52; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 334; top: 453; width: 85; height: 51; page: 4;}; ">

                7.1. </dg:chunk><dg:chunk>Treatment Administered <docset:TreatmentAdministered>49 </docset:TreatmentAdministered></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 564; top: 521; width: 1682; height: 57; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 374; top: 522; width: 126; height: 52; page: 4;}; ">

                  7.1.1. </dg:chunk><dg:chunk structure="h1">Packaging and Labelling <docset:PackagingandLabelling>49 </docset:PackagingandLabelling></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 457; top: 593; width: 1784; height: 56; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 331; top: 593; width: 90; height: 50; page: 4;}; ">

                7.2. </dg:chunk><dg:chunk structure="p">Method of <dg:chunk>Treatment Assignment </dg:chunk><docset:TreatmentAssignment>50 </docset:TreatmentAssignment></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 566; top: 663; width: 1679; height: 55; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 373; top: 662; width: 126; height: 55; page: 4;}; ">

                  7.2.1. </dg:chunk><dg:chunk>Selection and Timing of Doses. <docset:SelectionandTimingofDoses>50 </docset:SelectionandTimingofDoses></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 457; top: 732; width: 1789; height: 52; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 330; top: 732; width: 88; height: 50; page: 4;}; ">

                7.3. </dg:chunk><dg:chunk structure="p">Blinding <docset:Blinding>50 </docset:Blinding></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 458; top: 803; width: 1791; height: 51; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 332; top: 805; width: 90; height: 50; page: 4;}; ">

                7.4. </dg:chunk><dg:chunk structure="h1"><dg:chunk>Dose Modification </dg:chunk><docset:DoseModification>51 </docset:DoseModification></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 565; top: 873; width: 1680; height: 56; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 379; top: 873; width: 119; height: 55; page: 4;}; ">

                  7.4.1. </dg:chunk><dg:chunk structure="p"><dg:chunk>Special Treatment Considerations </dg:chunk><docset:SpecialTreatmentConsiderations>51 </docset:SpecialTreatmentConsiderations></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 457; top: 941; width: 1793; height: 54; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 341; top: 940; width: 81; height: 54; page: 4;}; ">

                7.5. </dg:chunk><dg:chunk>Preparation/Handling/Storage/Accountability <docset:PreparationHandlingStorageAccountability>51 </docset:PreparationHandlingStorageAccountability></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 466; top: 1013; width: 1779; height: 55; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 332; top: 1014; width: 66; height: 49; page: 4;}; ">

                7.6 </dg:chunk><dg:chunk structure="p"><dg:chunk>Treatment Compliance </dg:chunk><docset:TreatmentCompliance>.51 </docset:TreatmentCompliance></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 461; top: 1084; width: 1785; height: 55; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 335; top: 1082; width: 78; height: 46; page: 4;}; ">

                7.7. </dg:chunk><dg:chunk structure="p"><dg:chunk>Concomitant Therapy </dg:chunk><docset:ConcomitantTherapy>51 </docset:ConcomitantTherapy></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 464; top: 1148; width: 1782; height: 58; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 337; top: 1152; width: 82; height: 48; page: 4;}; ">

                7.8. </dg:chunk><dg:chunk>Treatment after the End of the <dgm:_testRef>Study </dgm:_testRef><docset:TreatmentAfterStudyEnd>52 </docset:TreatmentAfterStudyEnd></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 394; top: 1233; width: 1852; height: 54; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 298; top: 1232; width: 53; height: 54; page: 4;}; ">

              8. </dg:chunk><dg:chunk structure="h1"><dg:chunk>Discontinuation Criteria </dg:chunk><docset:DiscontinuationCriteria>53 </docset:DiscontinuationCriteria></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 457; top: 1304; width: 1790; height: 54; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 327; top: 1304; width: 93; height: 52; page: 4;}; ">

               8.1. </dg:chunk><dg:chunk structure="p">Discontinuation from <dgm:_testRef>Study </dgm:_testRef>Treatment <docset:DiscontinuationReason>.53 </docset:DiscontinuationReason></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 562; top: 1374; width: 1684; height: 53; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 371; top: 1374; width: 123; height: 49; page: 4;}; ">

                 8.1.1. </dg:chunk><dg:chunk structure="p">Discontinuation of Inadvertently Enrolled Patients <docset:DiscontinuationofInadvertentlyEnrolledPatients>53 </docset:DiscontinuationofInadvertentlyEnrolledPatients></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 459; top: 1446; width: 1787; height: 54; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 330; top: 1445; width: 87; height: 52; page: 4;}; ">

                8.2. </dg:chunk><dg:chunk>Discontinuation from the <dgm:_testRef>Study </dgm:_testRef><docset:DiscontinuationReason>.53 </docset:DiscontinuationReason></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 458; top: 1515; width: 1790; height: 55; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 326; top: 1515; width: 91; height: 49; page: 4;}; ">

               8.3. </dg:chunk><dg:chunk structure="p">Patients Lost to Follow-up <docset:PatientsLosttoFollow-up>54 </docset:PatientsLosttoFollow-up></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 399; top: 1595; width: 1848; height: 53; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 293; top: 1593; width: 54; height: 56; page: 4;}; ">

              9. </dg:chunk><dg:chunk structure="p"><dgm:_testRef>Study </dgm:_testRef>Assessments and Procedures <docset:StudyAssessmentsandProcedures>55 </docset:StudyAssessmentsandProcedures></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 460; top: 1665; width: 1788; height: 51; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 323; top: 1665; width: 94; height: 48; page: 4;}; ">

               9.1. </dg:chunk><dg:chunk>Efficacy Assessments <docset:EfficacyAssessment>.55 </docset:EfficacyAssessment></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 460; top: 1737; width: 1789; height: 51; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 325; top: 1738; width: 94; height: 51; page: 4;}; ">

               9.2. </dg:chunk><dg:chunk structure="p">Adverse Events <docset:AdverseEvents>.55 </docset:AdverseEvents></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 564; top: 1805; width: 1681; height: 51; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 366; top: 1804; width: 134; height: 51; page: 4;}; ">

                 9.2.1. </dg:chunk><dg:chunk structure="p"><dg:chunk>Serious Adverse Events </dg:chunk><docset:SeriousAdverseEvents>56 </docset:SeriousAdverseEvents></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 636; top: 1876; width: 1615; height: 54; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 412; top: 1875; width: 158; height: 51; page: 4;}; ">

                   9.2.1.1. </dg:chunk><dg:chunk structure="p"><dg:chunk>Suspected Unexpected Serious Adverse Reactions </dg:chunk><docset:SuspectedUnexpectedSeriousAdverseReactions>57 </docset:SuspectedUnexpectedSeriousAdverseReactions></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 560; top: 1945; width: 1687; height: 57; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 365; top: 1946; width: 137; height: 54; page: 4;}; ">

                 9.2.2. </dg:chunk><dg:chunk><dg:chunk>Complaint Handling </dg:chunk><docset:ComplaintHandling>57 </docset:ComplaintHandling></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 463; top: 2014; width: 1786; height: 53; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 323; top: 2011; width: 97; height: 57; page: 4;}; ">

               9.3. </dg:chunk><dg:chunk structure="p">Treatment of Overdose <docset:TreatmentofOverdose>57 </docset:TreatmentofOverdose></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 460; top: 2087; width: 1787; height: 50; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 324; top: 2085; width: 98; height: 51; page: 4;}; ">

               9.4. </dg:chunk><dg:chunk structure="p">Safety <docset:Safety>57 </docset:Safety></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 568; top: 2155; width: 1681; height: 53; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 368; top: 2156; width: 119; height: 48; page: 4;}; ">

                 9.4.1. </dg:chunk><dg:chunk>Laboratory Tests <docset:LaboratoryTests>57 </docset:LaboratoryTests></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 572; top: 2227; width: 1674; height: 50; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 369; top: 2228; width: 122; height: 48; page: 4;}; ">

                 9.4.2. </dg:chunk><dg:chunk structure="p"><dgm:MedicalTest>Vital Signs </dgm:MedicalTest><docset:VitalSigns>58 </docset:VitalSigns></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 572; top: 2296; width: 1670; height: 50; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 374; top: 2298; width: 119; height: 43; page: 4;}; ">

                  9.4.3. </dg:chunk><dg:chunk structure="h1">Electrocardiograms <docset:Electrocardiograms>58 </docset:Electrocardiograms></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 567; top: 2367; width: 1679; height: 51; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 369; top: 2367; width: 125; height: 49; page: 4;}; ">

                 9.4.4. </dg:chunk><dg:chunk structure="p">Other Tests <docset:OtherTests>58 </docset:OtherTests></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 636; top: 2436; width: 1609; height: 54; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 408; top: 2440; width: 145; height: 44; page: 4;}; ">

                   9.4.4.1. </dg:chunk><dg:chunk>Hip and <dg:chunk>Waist Circumference </dg:chunk><docset:HipandWaistCircumference>58 </docset:HipandWaistCircumference></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 639; top: 2504; width: 1605; height: 55; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 409; top: 2506; width: 158; height: 47; page: 4;}; ">

                   9.4.4.2. </dg:chunk><dg:chunk structure="p"><dg:chunk>Body Weight </dg:chunk>and <docset:Height><docset:Height>Height </docset:Height><docset:BodyWeightandHeight>58 </docset:BodyWeightandHeight></docset:Height></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 566; top: 2577; width: 1682; height: 51; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 366; top: 2576; width: 134; height: 53; page: 4;}; ">

                 9.4.5. </dg:chunk><dg:chunk structure="p"><dg:chunk>Safety Monitoring </dg:chunk><docset:SafetyMonitoring>59 </docset:SafetyMonitoring></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 639; top: 2647; width: 1607; height: 53; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 409; top: 2647; width: 148; height: 46; page: 4;}; ">

                   9.4.5.1. </dg:chunk><dg:chunk><dg:chunk>Hepatic Safety </dg:chunk><docset:HepaticSafety>59 </docset:HepaticSafety></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 642; top: 2713; width: 1605; height: 58; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 404; top: 2718; width: 160; height: 47; page: 4;}; ">

                   9.4.5.2. </dg:chunk><dg:chunk structure="p"><dg:chunk>Glucose Monitoring</dg:chunk>. <docset:GlucoseMonitoring>59 </docset:GlucoseMonitoring></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 638; top: 2786; width: 1605; height: 58; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 405; top: 2788; width: 160; height: 48; page: 4;}; ">

                   9.4.5.3. </dg:chunk><dg:chunk structure="p"><dg:chunk>Severe Hypoglycaemia </dg:chunk><docset:SevereHypoglycaemia>60 </docset:SevereHypoglycaemia></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 637; top: 2854; width: 1612; height: 59; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 408; top: 2857; width: 159; height: 46; page: 4;}; ">

                   9.4.5.4. </dg:chunk><dg:chunk structure="p"><dg:chunk>Injection-Site Assessments </dg:chunk>(<dg:chunk>Local Tolerability</dg:chunk>) <docset:InjectionSiteAssessment>61 </docset:InjectionSiteAssessment></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 373; top: 2924.1; width: 1218; height: 55.6; page: 4;}; "><dg:chunk structure="lim" style="boundingBox:{left: 373; top: 2926; width: 119; height: 50; page: 4;}; ">

                  9.4.6. </dg:chunk><dg:chunk structure="p">Treatment of Hyperglycaemia and Hypoglycaemia </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 458; top: 306; width: 1792; height: 50; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 329; top: 304; width: 90; height: 49; page: 5;}; ">

               9.5. </dg:chunk><dg:chunk structure="p">Pharmacokinetics <docset:Pharmacokinetics>61 </docset:Pharmacokinetics></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 568; top: 370; width: 1682; height: 54; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 370; top: 374; width: 117; height: 48; page: 5;}; ">

                 9.5.1. </dg:chunk><dg:chunk structure="p">Bioanalysis <docset:Bioanalysis>61 </docset:Bioanalysis></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 456; top: 440; width: 1791; height: 53; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 324; top: 438; width: 98; height: 55; page: 5;}; ">

               9.6. </dg:chunk><dg:chunk structure="p">Pharmacodynamics <docset:Pharmacodynamics>62 </docset:Pharmacodynamics></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 565; top: 510; width: 1684; height: 60; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 370; top: 513; width: 126; height: 53; page: 5;}; ">

                 9.6.1. </dg:chunk><dg:chunk structure="p"><dg:chunk>Glucodynamic Samples </dg:chunk><docset:GlucodynamicSamples>62 </docset:GlucodynamicSamples></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 638; top: 580; width: 1611; height: 56; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 409; top: 581; width: 162; height: 53; page: 5;}; ">

                   9.6.1.1. </dg:chunk><dg:chunk structure="p"><dg:chunk>Glucose Samples </dg:chunk>(<dg:chunk>Run-In Period</dg:chunk>) <docset:GlucoseSampleValue>62 </docset:GlucoseSampleValue></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 637; top: 651; width: 1611; height: 57; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 405; top: 653; width: 158; height: 44; page: 5;}; ">

                   9.6.1.2. </dg:chunk><dg:chunk structure="p"><dg:chunk>Glucose Samples </dg:chunk>(MMTT) <docset:GlucoseSampleValue>62 </docset:GlucoseSampleValue></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 563; top: 722; width: 1687; height: 52; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 370; top: 721; width: 129; height: 49; page: 5;}; ">

                 9.6.2. </dg:chunk><dg:chunk structure="p">Immunogenicity Assessments <docset:ImmunogenicityAssessments>.62 </docset:ImmunogenicityAssessments></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 459; top: 793; width: 1791; height: 50; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 328; top: 792; width: 89; height: 48; page: 5;}; ">

               9.7. </dg:chunk><dg:chunk structure="p">Genetics <docset:GeneticsScore>.63 </docset:GeneticsScore></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 459; top: 862; width: 1789; height: 46; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 326; top: 862; width: 92; height: 45; page: 5;}; ">

               9.8. </dg:chunk><dg:chunk structure="p">Biomarkers <docset:Biomarkers>63 </docset:Biomarkers></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 459; top: 932; width: 1790; height: 49; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 324; top: 931; width: 97; height: 49; page: 5;}; ">

               9.9. </dg:chunk><dg:chunk structure="p"><dg:chunk>Health Economics </dg:chunk><docset:HealthEconomics>63 </docset:HealthEconomics></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 396; top: 1013; width: 1854; height: 55; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 298; top: 1012; width: 78; height: 56; page: 5;}; ">

              10. </dg:chunk><dg:chunk structure="p"><dg:chunk>Statistical Considerations </dg:chunk>and <dg:chunk>Data Analysis </dg:chunk><docset:StatisticalConsiderationsandDataAnalysis>64 </docset:StatisticalConsiderationsandDataAnalysis></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 460; top: 1082; width: 1792; height: 53; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 333; top: 1082; width: 111; height: 55; page: 5;}; ">

                10.1. </dg:chunk><dg:chunk structure="h1"><dg:chunk>Sample Size Determination </dg:chunk><docset:SampleSizeDetermination>64 </docset:SampleSizeDetermination></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 455; top: 1149; width: 1795; height: 55; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 330; top: 1149; width: 115; height: 55; page: 5;}; ">

                10.2. </dg:chunk><dg:chunk structure="p">Populations for Analyses <docset:PopulationsforAnalyses>64 </docset:PopulationsforAnalyses></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 564; top: 1223; width: 1685; height: 57; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 374; top: 1221; width: 149; height: 57; page: 5;}; ">

                  10.2.1. </dg:chunk><dg:chunk structure="p"><dg:chunk><dgm:_testRef>Study </dgm:_testRef>Participant Disposition </dg:chunk><docset:StudyParticipantDisposition>64 </docset:StudyParticipantDisposition></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 565; top: 1291; width: 1685; height: 55; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 377; top: 1291; width: 147; height: 54; page: 5;}; ">

                  10.2.2. </dg:chunk><dg:chunk structure="p"><dg:chunk><dgm:_testRef>Study </dgm:_testRef>Participant Characteristics </dg:chunk><docset:StudyParticipantCharacteristics>64 </docset:StudyParticipantCharacteristics></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 459; top: 1361; width: 1791; height: 52; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 329; top: 1360; width: 115; height: 53; page: 5;}; ">

               10.3. </dg:chunk><dg:chunk structure="h1"><dg:chunk>Statistical Analyses </dg:chunk><docset:StatisticalAnalyses>64 </docset:StatisticalAnalyses></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 563; top: 1434; width: 1684; height: 53; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 377; top: 1435; width: 146; height: 52; page: 5;}; ">

                  10.3.1. </dg:chunk><dg:chunk structure="p"><dg:chunk>Safety Analyses</dg:chunk>. <docset:SafetyAnalyses>.65 </docset:SafetyAnalyses></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 634; top: 1500; width: 1614; height: 57; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 406; top: 1501; width: 191; height: 52; page: 5;}; ">

                   10.3.1.1. </dg:chunk><dg:chunk structure="p"><dg:chunk>Clinical Evaluation </dg:chunk>of Safety <docset:ClinicalEvaluationofSafety>65 </docset:ClinicalEvaluationofSafety></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 637; top: 1571; width: 1615; height: 53; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 407; top: 1573; width: 189; height: 48; page: 5;}; ">

                   10.3.1.2. </dg:chunk><dg:chunk structure="p"><dg:chunk>Statistical Evaluation </dg:chunk>of Safety <docset:StatisticalEvaluationofSafety>.65 </docset:StatisticalEvaluationofSafety></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 561; top: 1645; width: 1690; height: 53; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 370; top: 1645; width: 153; height: 50; page: 5;}; ">

                 10.3.2. </dg:chunk><dg:chunk structure="p"><dg:chunk>Pharmacokinetic Analyses </dg:chunk><docset:PharmacokineticAnalyses>65 </docset:PharmacokineticAnalyses></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 634; top: 1712; width: 1616; height: 52; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 407; top: 1712; width: 189; height: 52; page: 5;}; ">

                   10.3.2.1. </dg:chunk><dg:chunk><dg:chunk>Pharmacokinetic Parameter Estimation </dg:chunk><docset:PharmacokineticParameterEstimation>.65 </docset:PharmacokineticParameterEstimation></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 636; top: 1781; width: 1612; height: 50; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 409; top: 1781; width: 189; height: 50; page: 5;}; ">

                   10.3.2.2. </dg:chunk><dg:chunk structure="p"><dg:chunk>Pharmacokinetic Statistical Inference </dg:chunk><docset:PharmacokineticStatisticalInference>66 </docset:PharmacokineticStatisticalInference></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 564; top: 1852; width: 1686; height: 54; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 374; top: 1852; width: 152; height: 53; page: 5;}; ">

                  10.3.3. </dg:chunk><dg:chunk structure="p"><dg:chunk>Glucodynamic Analyses </dg:chunk><docset:GlucodynamicAnalyses>.66 </docset:GlucodynamicAnalyses></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 634; top: 1921; width: 1614; height: 54; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 410; top: 1921; width: 188; height: 54; page: 5;}; ">

                   10.3.3.1. </dg:chunk><dg:chunk structure="p"><dg:chunk>Glucodynamic Parameter Estimation </dg:chunk><docset:GlucodynamicParameterEstimation>66 </docset:GlucodynamicParameterEstimation></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 632; top: 1991; width: 1618; height: 54; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 408; top: 1991; width: 193; height: 52; page: 5;}; ">

                   10.3.3.2. </dg:chunk><dg:chunk structure="p"><dg:chunk><docset:GlucodynamicStatisticalInference>Glucodynamic </docset:GlucodynamicStatisticalInference>Statistical Inference </dg:chunk><docset:GlucodynamicStatisticalInference>67 </docset:GlucodynamicStatisticalInference></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 562; top: 2061; width: 1692; height: 60; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 375; top: 2062; width: 152; height: 53; page: 5;}; ">

                  10.3.4. </dg:chunk><dg:chunk structure="p">Evaluation of Immunogenicity <docset:ImmunogenicityEvaluation>.67 </docset:ImmunogenicityEvaluation></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 561; top: 2134; width: 1687; height: 53; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 373; top: 2132; width: 153; height: 53; page: 5;}; ">

                  10.3.5. </dg:chunk><dg:chunk structure="p"><dg:chunk>Interim Analyses </dg:chunk><docset:InterimAnalyses>67 </docset:InterimAnalyses></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 397; top: 2216; width: 1848; height: 49; page: 5;}; "><dg:chunk structure="lim" style="boundingBox:{left: 298; top: 2214; width: 72; height: 51; page: 5;}; ">

              11. </dg:chunk><dg:chunk structure="p">References <docset:References>68 </docset:References></dg:chunk></dg:chunk></docset:StudyDesign></dg:chunk></dg:chunk></docset:StudyDesign><dg:chunk><docset:ListofTables-section><dg:chunk structure="h1">

                                                    List of Tables </dg:chunk><docset:ListofTables><xhtml:table structure="table" style="boundingBox:{left: 296.3; top: 371.4; width: 1955.5; height: 330.7; page: 6;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 296.3; top: 371.4; width: 1955.5; height: 330.7; page: 6;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 296.3; top: 371.4; width: 1955.5; height: 70.4; page: 6;}; "><xhtml:td structure="td" style="boundingBox:{left: 296.3; top: 371.4; width: 370.2; height: 70.4; page: 6;}; "><dg:chunk structure="h1">

              Table </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 666.5; top: 371.4; width: 1382.8; height: 70.4; page: 6;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2049.4; top: 371.4; width: 202.5; height: 70.4; page: 6;}; ">

                 Page </xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 296.3; top: 441.8; width: 1955.5; height: 93.4; page: 6;}; "><xhtml:td structure="td" style="boundingBox:{left: 296.3; top: 441.8; width: 370.2; height: 93.4; page: 6;}; "><docset:TableTableITSA1>

              Table <docset:ITSA>ITSA.1</docset:ITSA>. </docset:TableTableITSA1></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 666.5; top: 441.8; width: 1382.8; height: 93.4; page: 6;}; "><docset:TableITSA1>

                  Objectives and Endpoints </docset:TableITSA1></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2049.4; top: 441.8; width: 202.5; height: 93.4; page: 6;}; "><docset:TableITSA1Page>

                     <dgc:Number>27 </dgc:Number></docset:TableITSA1Page></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 296.3; top: 535.2; width: 1955.5; height: 93.9; page: 6;}; "><xhtml:td structure="td" style="boundingBox:{left: 296.3; top: 535.2; width: 370.2; height: 93.9; page: 6;}; "><docset:TableTableITSA2>

              Table <docset:ITSA2>ITSA.2</docset:ITSA2>. </docset:TableTableITSA2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 666.5; top: 535.2; width: 1382.8; height: 93.9; page: 6;}; "><docset:TableITSA2 structure="h1">

                  Volume of <dg:chunk>Standardised Meal </dg:chunk>According to <dg:chunk>Body Weight </dg:chunk></docset:TableITSA2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2049.4; top: 535.2; width: 202.5; height: 93.9; page: 6;}; "><docset:TableITSA2Page>

                     <dgc:Number>47 </dgc:Number></docset:TableITSA2Page></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 296.3; top: 629.1; width: 1955.5; height: 73.0; page: 6;}; "><xhtml:td structure="td" style="boundingBox:{left: 296.3; top: 629.1; width: 370.2; height: 73.0; page: 6;}; "><docset:TableTableITSA3>

              Table <docset:ITSA3>ITSA.3</docset:ITSA3>. </docset:TableTableITSA3></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 666.5; top: 629.1; width: 1382.8; height: 73.0; page: 6;}; "><docset:TableITSA3>

                  Treatments Administered </docset:TableITSA3></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2049.4; top: 629.1; width: 202.5; height: 73.0; page: 6;}; "><docset:TableITSA3Page>

                     <dgc:Number>49 </dgc:Number></docset:TableITSA3Page></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:ListofTables></docset:ListofTables-section><docset:ListofFigures-section><dg:chunk structure="h1">

                                                    List of Figures </dg:chunk><docset:ListofFigures><xhtml:table structure="table" style="boundingBox:{left: 298.0; top: 371.1; width: 1957.4; height: 423.9; page: 7;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 298.0; top: 371.1; width: 1957.4; height: 423.9; page: 7;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 298.0; top: 371.1; width: 1957.4; height: 73.6; page: 7;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.0; top: 371.1; width: 374.8; height: 73.6; page: 7;}; ">

              Figure </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 672.9; top: 371.1; width: 1174.1; height: 73.6; page: 7;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1847.0; top: 371.1; width: 408.5; height: 73.6; page: 7;}; ">

                           Page </xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.0; top: 444.7; width: 1957.4; height: 92.5; page: 7;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.0; top: 444.7; width: 374.8; height: 92.5; page: 7;}; "><docset:FigureFigureITSA1>

              Figure <docset:ITSAFigure>ITSA.1</docset:ITSAFigure>. </docset:FigureFigureITSA1></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 672.9; top: 444.7; width: 1174.1; height: 92.5; page: 7;}; "><docset:FigureITSA1 structure="h1">

                 Illustration of <dgm:_testRef>study </dgm:_testRef>design for <dg:chunk>Part A </dg:chunk></docset:FigureITSA1></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1847.0; top: 444.7; width: 408.5; height: 92.5; page: 7;}; "><docset:FigureITSA1Page>

                               <dgc:Number>30 </dgc:Number></docset:FigureITSA1Page></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.0; top: 537.2; width: 1957.4; height: 89.6; page: 7;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.0; top: 537.2; width: 374.8; height: 89.6; page: 7;}; "><docset:FigureFigureITSA2>

              Figure <docset:ITSA2>ITSA.2</docset:ITSA2>. </docset:FigureFigureITSA2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 672.9; top: 537.2; width: 1174.1; height: 89.6; page: 7;}; "><docset:FigureITSA2 structure="h1">

                 Inpatient procedure in Part A. </docset:FigureITSA2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1847.0; top: 537.2; width: 408.5; height: 89.6; page: 7;}; "><docset:FigureITSA2Page>

                               <dgc:Number>33 </dgc:Number></docset:FigureITSA2Page></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.0; top: 626.8; width: 1957.4; height: 93.2; page: 7;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.0; top: 626.8; width: 374.8; height: 93.2; page: 7;}; "><docset:FigureFigureITSA3>

              Figure <docset:ITSA3>ITSA.3</docset:ITSA3>. </docset:FigureFigureITSA3></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 672.9; top: 626.8; width: 1174.1; height: 93.2; page: 7;}; "><docset:FigureITSA3 structure="h1">

                 Illustration of <dgm:_testRef>study </dgm:_testRef>design for <dg:chunk>Part B </dg:chunk></docset:FigureITSA3></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1847.0; top: 626.8; width: 408.5; height: 93.2; page: 7;}; "><docset:FigureITSA3Page>

                               <dgc:Number>35 </dgc:Number></docset:FigureITSA3Page></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.0; top: 720.0; width: 1957.4; height: 75.0; page: 7;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.0; top: 720.0; width: 374.8; height: 75.0; page: 7;}; "><docset:FigureFigureITSA4>

              Figure <docset:ITSA4>ITSA.4</docset:ITSA4>. </docset:FigureFigureITSA4></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 672.9; top: 720.0; width: 1174.1; height: 75.0; page: 7;}; "><docset:FigureITSA4 structure="h1">

                 Inpatient procedure in <dg:chunk>Part B </dg:chunk></docset:FigureITSA4></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1847.0; top: 720.0; width: 408.5; height: 75.0; page: 7;}; "><docset:FigureITSA4Page>

                               <dgc:Number>39 </dgc:Number></docset:FigureITSA4Page></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:ListofFigures></docset:ListofFigures-section></dg:chunk></docset:_2></docset:_2-section></docset:Page></docset:Page-section></docset:Mellitus></docset:Mellitus-section></docset:TableofContents></docset:TableofContents-section></docset:ApprovalDate></docset:ApprovalDate-section></docset:_12October2017></docset:_12October2017-section></docset:ClinicalPharmacologyProtocolElectronicallySignedAndApprovedbyLilly-secti></docset:EliLillyAndCompanyIndianapolisIndianaUSA46285-section><docset:ListofAppendices-section><dg:chunk structure="h1">

                                                 List of Appendices </dg:chunk><docset:ListofAppendices structure="div"><dg:chunk><docset:ListofAppendices><xhtml:table structure="table" style="boundingBox:{left: 298.4; top: 370.6; width: 1956.5; height: 795.4; page: 8;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 298.4; top: 370.6; width: 1956.5; height: 795.4; page: 8;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 298.4; top: 370.6; width: 1956.5; height: 69.4; page: 8;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.4; top: 370.6; width: 346.1; height: 69.4; page: 8;}; "><dg:chunk structure="h1">

              Appendix </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 644.5; top: 370.6; width: 1484.5; height: 69.4; page: 8;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2129.0; top: 370.6; width: 125.9; height: 69.4; page: 8;}; "><dg:chunk structure="h1">

              Page </dg:chunk></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.4; top: 440.0; width: 1956.5; height: 94.0; page: 8;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.4; top: 440.0; width: 346.1; height: 94.0; page: 8;}; "><docset:AppendixAppendix1>

              Appendix 1. </docset:AppendixAppendix1></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 644.5; top: 440.0; width: 1484.5; height: 94.0; page: 8;}; "><docset:Appendix1>

                   Abbreviations and Definitions </docset:Appendix1></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2129.0; top: 440.0; width: 125.9; height: 94.0; page: 8;}; "><docset:Appendix1Page>

                 <dgc:Number>70 </dgc:Number></docset:Appendix1Page></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.4; top: 534.0; width: 1956.5; height: 93.8; page: 8;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.4; top: 534.0; width: 346.1; height: 93.8; page: 8;}; "><docset:AppendixAppendix2>

              Appendix <docset:Appendix2>2</docset:Appendix2>. </docset:AppendixAppendix2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 644.5; top: 534.0; width: 1484.5; height: 93.8; page: 8;}; "><docset:Appendix2>

                   <dg:chunk>Clinical Laboratory Tests</dg:chunk>. </docset:Appendix2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2129.0; top: 534.0; width: 125.9; height: 93.8; page: 8;}; "><docset:Appendix2Page>

                 <dgc:Number>.74 </dgc:Number></docset:Appendix2Page></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.4; top: 627.8; width: 1956.5; height: 93.2; page: 8;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.4; top: 627.8; width: 346.1; height: 93.2; page: 8;}; "><docset:AppendixAppendix3>

              Appendix 3. </docset:AppendixAppendix3></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 644.5; top: 627.8; width: 1484.5; height: 93.2; page: 8;}; "><docset:Appendix3 structure="p">

                   <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Governance</dg:chunk>, Regulatory, and <dg:chunk>Ethical Considerations </dg:chunk></docset:Appendix3></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2129.0; top: 627.8; width: 125.9; height: 93.2; page: 8;}; "><docset:Appendix3Page>

                 <dgc:Number>75 </dgc:Number></docset:Appendix3Page></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.4; top: 721.0; width: 1956.5; height: 85.6; page: 8;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.4; top: 721.0; width: 346.1; height: 85.6; page: 8;}; "><docset:AppendixAppendix4 structure="h1">

              Appendix 4. </docset:AppendixAppendix4></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 644.5; top: 721.0; width: 1484.5; height: 85.6; page: 8;}; "><docset:Appendix4 structure="h1">

                   <dg:chunk>Hepatic Monitoring Tests </dg:chunk>for <dg:chunk>Treatment-Emergent Abnormality </dg:chunk></docset:Appendix4></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2129.0; top: 721.0; width: 125.9; height: 85.6; page: 8;}; "><docset:Appendix4Page>

                 <dgc:Number>.78 </dgc:Number></docset:Appendix4Page></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.4; top: 806.6; width: 1956.5; height: 98.4; page: 8;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.4; top: 806.6; width: 346.1; height: 98.4; page: 8;}; "><docset:AppendixAppendix5>

              Appendix 5. </docset:AppendixAppendix5></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 644.5; top: 806.6; width: 1484.5; height: 98.4; page: 8;}; "><docset:Appendix5>

                   <dg:chunk><dgm:MedicalTest>Blood Sampling </dgm:MedicalTest>Summary </dg:chunk></docset:Appendix5></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2129.0; top: 806.6; width: 125.9; height: 98.4; page: 8;}; "><docset:Appendix5Page>

                 <dgc:Number>79 </dgc:Number></docset:Appendix5Page></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.4; top: 905.0; width: 1956.5; height: 76.1; page: 8;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.4; top: 905.0; width: 346.1; height: 76.1; page: 8;}; "><docset:AppendixAppendix6>

              Appendix <docset:Appendix6>6</docset:Appendix6>. </docset:AppendixAppendix6></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 644.5; top: 905.0; width: 1484.5; height: 76.1; page: 8;}; "><docset:Appendix6>

                   Protocol Amendment I8B-MC-ITSA(d) Summary </docset:Appendix6></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2129.0; top: 905.0; width: 125.9; height: 76.1; page: 8;}; "><docset:Appendix6Page /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.4; top: 981.1; width: 1956.5; height: 88.1; page: 8;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.4; top: 981.1; width: 346.1; height: 88.1; page: 8;}; " /><xhtml:td structure="td" style="boundingBox:{left: 644.5; top: 981.1; width: 1484.5; height: 184.9; page: 8;}; " rowspan="2"><docset:StudyDescription structure="p">

                   A <dgm:_testRef>Study </dgm:_testRef>to Evaluate the Pharmacokinetics and Glucodynamics of <docset:StudyDrug>LY900014 </docset:StudyDrug>Compared to <dgm:Medication>Humalog </dgm:Medication>in Children, Adolescents, and Adults with Type 1 <dgm:Condition><dgm:Condition>Diabetes </dgm:Condition>Mellitus </dgm:Condition></docset:StudyDescription></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2129.0; top: 981.1; width: 125.9; height: 88.1; page: 8;}; "><docset:Page /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 298.4; top: 1069.2; width: 1956.5; height: 96.8; page: 8;}; "><xhtml:td structure="td" style="boundingBox:{left: 298.4; top: 1069.2; width: 346.1; height: 96.8; page: 8;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2129.0; top: 1069.2; width: 125.9; height: 96.8; page: 8;}; ">

                 <dgc:Number>80 </dgc:Number></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:ListofAppendices><dg:chunk><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 941.7; top: 308.3; width: 662.5; height: 66.7; page: 9;}; "><dg:chunk structure="li" style="boundingBox:{left: 941.7; top: 308.3; width: 662.5; height: 66.7; page: 9;}; "><dg:chunk structure="lim" style="boundingBox:{left: 941.7; top: 308.3; width: 58.3; height: 66.7; page: 9;}; ">

                                            1. </dg:chunk><dg:chunk structure="h1">Protocol Synopsis </dg:chunk></dg:chunk></dg:chunk><dg:chunk><dg:chunk><dg:chunk structure="h1">

              Title of <dgm:_testRef>Study</dgm:_testRef>: </dg:chunk><docset:StudyDescription structure="p">

              A <dgm:_testRef>study </dgm:_testRef>to evaluate the pharmacokinetics and glucodynamics of <docset:StudyDrug>LY900014 </docset:StudyDrug>compared to <dgm:Medication>Humalog </dgm:Medication>in children, adolescents, and adults with type 1 <dgm:Condition><dgm:Condition>diabetes </dgm:Condition>mellitus </dgm:Condition></docset:StudyDescription></dg:chunk><dg:chunk><dg:chunk structure="h1">

              Rationale: </dg:chunk><docset:StudyObjective structure="p">

              A prandial <dgm:Medication>insulin </dgm:Medication>with faster-on and/or faster-off characteristics might reduce glycaemic excursions and the incidence of postprandial hypoglycaemia compared to currently available fast-acting <dgm:Medication>insulin </dgm:Medication>analogues. LY900014 is an ultra-rapid-acting <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>formulation with increased early absorption compared to commercially available <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>formulation (<docset:ComparatorInsulin><dgm:Medication>Humalog</dgm:Medication>®</docset:ComparatorInsulin>; <docset:CompanyName><dg:chunk>Eli Lilly </dg:chunk>and Company)</docset:CompanyName>. <dg:chunk>LY900014 </dg:chunk>aims to mimic the physiological prandial <dgm:Medication>insulin </dgm:Medication>secretion pattern, which may more effectively control postprandial glucose excursions. </docset:StudyObjective></dg:chunk><docset:StudyObjectives structure="p">

              The aim of the <dgm:_testRef>study </dgm:_testRef>is to evaluate <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>pharmacokinetics (PK), glucodynamics (GD), safety, and tolerability of <docset:StudyDescription>LY900014 </docset:StudyDescription>in comparison with <dgm:Medication>Humalog </dgm:Medication>following a single subcutaneous (SC) dose administration immediately prior to a standardised liquid meal in paediatric and adult patients with type 1 <dgm:Condition><dgm:Condition>diabetes </dgm:Condition>mellitus </dgm:Condition>(<dg:chunk>T1DM</dg:chunk>). This will be the first <dgm:_testRef>study </dgm:_testRef>to evaluate LY900014 in paediatric patients with <dg:chunk>T1DM</dg:chunk>. </docset:StudyObjectives></dg:chunk></dg:chunk></dg:chunk><dg:chunk><dg:chunk structure="h1">

              Objectives/Endpoints: </dg:chunk><dg:chunk structure="div"><docset:ProtocolSynopsis><xhtml:table structure="table" style="boundingBox:{left: 276.9; top: 1475.8; width: 1974.0; height: 1158.0; page: 9;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 276.9; top: 1475.8; width: 1974.0; height: 1158.0; page: 9;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 276.9; top: 1475.8; width: 1974.0; height: 98.0; page: 9;}; "><xhtml:td structure="td" style="boundingBox:{left: 276.9; top: 1475.8; width: 1130.0; height: 98.0; page: 9;}; "><dg:chunk structure="h1">

              Objectives </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1406.9; top: 1475.8; width: 844.0; height: 98.0; page: 9;}; "><docset:Objectives structure="h1">

              Endpoints </docset:Objectives></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 276.9; top: 1574.8; width: 1974.0; height: 525.0; page: 9;}; "><xhtml:td structure="td" style="boundingBox:{left: 276.9; top: 1573.8; width: 1130.0; height: 526.0; page: 9;}; "><docset:Primary-section><dg:chunk structure="h1">

              Primary </dg:chunk><docset:Primary structure="ol" style="list-style-type: decimal; boundingBox:{left: 300.0; top: 1662.5; width: 1079.2; height: 405.7; page: 9;}; "><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 1662.5; width: 1079.2; height: 183.3; page: 9;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 1662.5; width: 29.2; height: 41.7; page: 9;}; ">

              1. </dg:chunk><docset:StudyObjective structure="p">Part A: To evaluate the PK of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>following a single SC dose administered through injection of <docset:StudyDrug>LY900014 </docset:StudyDrug>compared to <dgm:Medication>Humalog </dgm:Medication>in children, adolescents, and adults with <dg:chunk>T1DM </dg:chunk></docset:StudyObjective></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 1883.3; width: 1050.0; height: 184.8; page: 9;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 1883.3; width: 29.2; height: 41.7; page: 9;}; ">

              2. </dg:chunk><dg:chunk><dg:chunk>Part B</dg:chunk>: To evaluate the PK of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>following a single SC bolus dose administered through CSII of <docset:StudyDrug>LY900014 </docset:StudyDrug>compared to <dgm:Medication>Humalog </dgm:Medication>in children, adolescents, and adults with <dg:chunk>T1DM </dg:chunk></dg:chunk></dg:chunk></docset:Primary></docset:Primary-section></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1406.9; top: 1573.8; width: 844.0; height: 526.0; page: 9;}; "><docset:Endpoints structure="ol" style="list-style-type: decimal; boundingBox:{left: 1425.0; top: 1675.0; width: 670.8; height: 225.0; page: 9;}; "><dg:chunk structure="li" style="boundingBox:{left: 1425.0; top: 1675.0; width: 670.8; height: 50.0; page: 9;}; "><dg:chunk structure="lim" style="boundingBox:{left: 1425.0; top: 1675.0; width: 29.2; height: 50.0; page: 9;}; ">

              1. </dg:chunk><dg:chunk structure="p">Early <docset:EarlyAbsorption>50% </docset:EarlyAbsorption>tmax and <docset:AUC0-30min>AUC(0</docset:AUC0-30min><docset:EarlyAUC>-<dg:chunk>30min</dg:chunk></docset:EarlyAUC>) </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 1425.0; top: 1854.2; width: 670.8; height: 45.8; page: 9;}; "><dg:chunk structure="lim" style="boundingBox:{left: 1425.0; top: 1854.2; width: 33.3; height: 45.8; page: 9;}; ">

              2. </dg:chunk><dg:chunk structure="p">Early <docset:EarlyAbsorption>50% </docset:EarlyAbsorption>tmax and <docset:AUC0-30min>AUC(0</docset:AUC0-30min><docset:EarlyAUC>-<dg:chunk>30min</dg:chunk></docset:EarlyAUC>) </dg:chunk></dg:chunk></docset:Endpoints></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 276.9; top: 2100.8; width: 1974.0; height: 533.0; page: 9;}; "><xhtml:td structure="td" style="boundingBox:{left: 276.9; top: 2099.8; width: 1130.0; height: 534.0; page: 9;}; "><docset:Secondary-section><dg:chunk structure="h1">

              Secondary </dg:chunk><docset:Secondary structure="ol" style="list-style-type: decimal; boundingBox:{left: 300.0; top: 2200.0; width: 1054.2; height: 362.4; page: 9;}; "><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 2200.0; width: 1054.2; height: 187.5; page: 9;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 2200.0; width: 29.2; height: 45.8; page: 9;}; ">

              1. </dg:chunk><docset:StudyDesign structure="p">Part A and Part B: To evaluate the difference in GD response to <docset:StudyDrug>LY900014 </docset:StudyDrug>and <dgm:Medication>Humalog </dgm:Medication>administered through SC bolus injection or <docset:ContinuousSubcutaneousInsulinInfusion>CSII</docset:ContinuousSubcutaneousInsulinInfusion>, as assessed using the liquid MMTT in children, adolescents, and adults with <dg:chunk>T1DM </dg:chunk></docset:StudyDesign></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 2425.0; width: 979.2; height: 137.4; page: 9;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 2425.0; width: 29.2; height: 41.7; page: 9;}; ">

              2. </dg:chunk><docset:StudyObjectives structure="p"><dg:chunk>Part A </dg:chunk>and <dg:chunk>Part B</dg:chunk>: To evaluate the tolerability of <docset:StudyDrug>LY900014 </docset:StudyDrug>following SC injection or CSII in children, adolescents, and adults with <dg:chunk>T1DM </dg:chunk></docset:StudyObjectives></dg:chunk></docset:Secondary></docset:Secondary-section></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1406.9; top: 2099.8; width: 844.0; height: 534.0; page: 9;}; "><docset:Endpoints structure="ol" style="list-style-type: decimal; boundingBox:{left: 1425.0; top: 2201.0; width: 775.0; height: 401.5; page: 9;}; "><dg:chunk structure="li" style="boundingBox:{left: 1425.0; top: 2201.0; width: 529.2; height: 42.4; page: 9;}; "><dg:chunk structure="lim" style="boundingBox:{left: 1425.0; top: 2200.0; width: 29.2; height: 45.8; page: 9;}; ">

              1. </dg:chunk><dg:chunk structure="p"><dgc:Number>∆AUC(0</dgc:Number>-<docset:_2-HourAUC>2h</docset:_2-HourAUC>), <docset:AUCDelta>∆AUC(0</docset:AUCDelta>-<docset:AUC0-5h>5h</docset:AUC0-5h>) </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 1425.0; top: 2466.7; width: 775.0; height: 135.8; page: 9;}; "><dg:chunk structure="lim" style="boundingBox:{left: 1425.0; top: 2466.7; width: 33.3; height: 41.7; page: 9;}; ">

              2. </dg:chunk><docset:AdverseEvents structure="p">AEs including injection/catheter insertion site reactions/pain, hypoglycaemia, and anti-<dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>antibodies </docset:AdverseEvents></dg:chunk></docset:Endpoints></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:ProtocolSynopsis><dg:chunk><docset:Abbreviations-section><dg:chunk structure="h1">

              Abbreviations: </dg:chunk><docset:Abbreviations structure="div"><docset:StudyDesign structure="p">AE = adverse event; AUC = area under the concentration versus time curve; AUC(0-<docset:TimeFrame>30min</docset:TimeFrame>) = AUC from time zero to <docset:StudyDuration>30 minutes</docset:StudyDuration>; CSII = continuous subcutaneous <dgm:Medication>insulin </dgm:Medication>infusion; ∆AUC = area under the baseline subtracted glucose concentration versus time curve; ∆AUC(0-2h) = ∆AUC from time 0 to <docset:PostmealTimePeriod>2 hours </docset:PostmealTimePeriod>postmeal; <docset:AUC0-5h>∆AUC(0</docset:AUC0-5h>-<docset:StudyDesign>5h</docset:StudyDesign>) = ∆AUC from time <docset:GlucodynamicsStudy>0 </docset:GlucodynamicsStudy>to <docset:PostmealGlucoseExcursion>5 hours </docset:PostmealGlucoseExcursion>postmeal; early <docset:GlucodynamicsStudy>50% </docset:GlucodynamicsStudy>tmax = time to early half-maximal drug concentration; GD = glucodynamics; MMTT = mixed meal <dgm:MedicalTest>tolerance <dgm:_testRef>test</dgm:_testRef></dgm:MedicalTest>; PK = pharmacokinetics; SC = subcutaneous; <dg:chunk>T1DM </dg:chunk>= type 1 <dgm:Condition><dgm:Condition>diabetes </dgm:Condition>mellitus</dgm:Condition>. </docset:StudyDesign><dg:chunk><dg:chunk structure="h1">

              Summary of <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Design</dg:chunk>: </dg:chunk><docset:StudyDesign structure="p">

              <dgm:_testRef>Study </dgm:_testRef>I8B-MC-ITSA is a randomised, patient- and investigator-blind, 2-part <dgm:_testRef>study</dgm:_testRef>, with each part containing a <docset:StudyDesign>2- </docset:StudyDesign>period crossover assessment in children (age <docset:StudyDesign>6 </docset:StudyDesign>to &lt;<docset:StudyDuration>12 years</docset:StudyDuration>), adolescents (age <docset:StudyDesign>12 </docset:StudyDesign>to &lt;<docset:AgeRange>18 years</docset:AgeRange>), and adults (age <docset:StudyDesign>18 </docset:StudyDesign>to &lt;<docset:AgeRange>65 years</docset:AgeRange>) with <dg:chunk>T1DM </dg:chunk>to evaluate the <dg:chunk>PK, GD</dg:chunk>, and tolerability of <docset:StudyDescription>LY900014 </docset:StudyDescription>compared to <dgm:Medication>Humalog </dgm:Medication>given as a bolus either as a SC injection or via a continuous subcutaneous <dgm:Medication>insulin </dgm:Medication>infusion (CSII) pump. </docset:StudyDesign></dg:chunk></docset:Abbreviations></docset:Abbreviations-section><dg:chunk><dg:chunk structure="h1">

              <dg:chunk>Treatment Arms </dg:chunk>and <dg:chunk>Planned Duration </dg:chunk>for an <dg:chunk>Individual Patient</dg:chunk>: </dg:chunk><dg:chunk structure="div"><docset:StudyDesign structure="p">

              The <dgm:_testRef>study </dgm:_testRef>will be conducted in <docset:StudyDuration>2 </docset:StudyDuration>parts, <dg:chunk>Part A </dg:chunk>and Part B. Each part consists of a 2-period crossover to compare LY900014 and <dgm:Medication>Humalog </dgm:Medication>administered prior to a mixed meal <dgm:MedicalTest>tolerance <dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest>(MMTT). All <dgm:_testRef>study </dgm:_testRef>and treatment procedures will be conducted during inpatient stays of approximately <docset:StudyDuration>2 days </docset:StudyDuration>per period and require a minimum of <docset:StudyDuration>3 days </docset:StudyDuration>and a maximum of <docset:StudyDuration>23 days </docset:StudyDuration>to complete both periods. In each part, after completion of the last <dgm:_testRef>study </dgm:_testRef>period (Period 2), a <docset:SafetyFollow-upPeriod>14-day </docset:SafetyFollow-upPeriod>safety follow-up is planned. Total duration of each part is expected to be up to <docset:StudyDuration>68 days</docset:StudyDuration>. Patients are encouraged to participate in both <dg:chunk>Part A </dg:chunk>and <dg:chunk>Part B </dg:chunk>of the <dgm:_testRef>study</dgm:_testRef>; however, <dgm:_testRef>study </dgm:_testRef>participation is not contingent on patients’ participation in both parts of the <dgm:_testRef>study</dgm:_testRef>. </docset:StudyDesign><docset:StudyDesign structure="p">

              Patients may be screened up to <docset:ScreeningPeriod>28 days </docset:ScreeningPeriod>prior to Day -1 of Period 1 of <dg:chunk>Part A </dg:chunk>and Part B. Patients will be admitted to the <dgm:_testRef>study </dgm:_testRef>site the day before the MMTT day each period and will remain until all assessments are completed on Day 1. On Day 1 in Period 1 for <dg:chunk>Part A </dg:chunk>and on Day <dg:chunk>-1 </dg:chunk>in Period 1 for <dg:chunk>Part B</dg:chunk>, patients will be randomised to <docset:StudyDesign>1 </docset:StudyDesign>of <docset:StudyDesign>2 </docset:StudyDesign>treatment sequences. In <dg:chunk>Part A</dg:chunk>, each patient will receive a single SC injection of both <dg:chunk>LY900014 </dg:chunk>and <dgm:Medication>Humalog </dgm:Medication>immediately prior to an MMTT assessment in a crossover design. Initiation of <dg:chunk>Part B </dg:chunk>of the <dgm:_testRef>study </dgm:_testRef>may begin pending the review of the PK, GD, safety, and tolerability data from <dg:chunk>Part A </dg:chunk>and ongoing or planned adult CSII Phase 1b studies. In <dg:chunk>Part B</dg:chunk>, patients will receive a single SC bolus dose of both <dg:chunk>LY900014 </dg:chunk>and <dgm:Medication>Humalog </dgm:Medication>via <docset:StudyDesign>CSII </docset:StudyDesign>pump immediately prior to an MMTT assessment in a crossover design. Patients will undergo a follow-up visit at least <docset:Follow-upVisit>14 days </docset:Follow-upVisit>after the last dose of the <dgm:_testRef>study </dgm:_testRef>drug in each part. </docset:StudyDesign></dg:chunk></dg:chunk><docset:Treatment-section><dg:chunk structure="h1">

              Treatment: </dg:chunk><docset:Treatment structure="div"><docset:PartA-section><dg:chunk structure="h1">

              Part A: </dg:chunk><docset:PartA structure="div">Each patient will receive a single SC bolus injection of <docset:LY900014Dose>LY900014 </docset:LY900014Dose>and <dgm:Medication>Humalog</dgm:Medication>. </docset:PartA></docset:PartA-section><docset:PartB-section><dg:chunk structure="h1">

              <dg:chunk>Part B</dg:chunk>: </dg:chunk><docset:PartB structure="div">Each patient will receive a single SC bolus of <docset:LY900014Dose>LY900014 </docset:LY900014Dose>and <dgm:Medication>Humalog </dgm:Medication>via <docset:InsulinDeliveryMethod>CSII </docset:InsulinDeliveryMethod>pump. </docset:PartB></docset:PartB-section></docset:Treatment></docset:Treatment-section><docset:NumberofPatients-section><dg:chunk structure="h1">

              Number of Patients: </dg:chunk><docset:NumberofPatients structure="div"><docset:StudyEnrollment structure="p">

              Approximately <docset:MaximumNumberofPatients>45 </docset:MaximumNumberofPatients>patients may be enrolled into the <dgm:_testRef>study </dgm:_testRef>so that approximately <docset:NumberofPatients>36 </docset:NumberofPatients>patients (<docset:NumberofPatients>12 </docset:NumberofPatients>patients in each age group [<docset:NumberofPatients>6 </docset:NumberofPatients>to &lt;<dgc:TimeDuration>12 </dgc:TimeDuration>years, <dgc:Number>12 </dgc:Number>to &lt;<docset:AgeEligibility>18 years</docset:AgeEligibility>, and <docset:NumberofPatients>18 </docset:NumberofPatients>to &lt;<docset:MaximumAge>65 years</docset:MaximumAge>] based on the age at initial <dgm:_testRef>screening</dgm:_testRef>) complete both inpatient periods in both parts of the <dgm:_testRef>study</dgm:_testRef>. </docset:StudyEnrollment><docset:StudyParticipation structure="p">

              Patients participating in <dg:chunk>Part A </dg:chunk>may continue participation in Part B. If patients from Part A decline participation in <dg:chunk>Part B </dg:chunk>or drop out from <dg:chunk>Part A</dg:chunk>, additional patients will be enrolled to ensure approximately <docset:NumberofParticipants>36 </docset:NumberofParticipants>patients (<docset:NumberofParticipants>12 </docset:NumberofParticipants>patients in each age group) complete both periods in <dg:chunk>Part B </dg:chunk>of the <dgm:_testRef>study</dgm:_testRef>. </docset:StudyParticipation></docset:NumberofPatients></docset:NumberofPatients-section><docset:StatisticalAnalysis-section><dg:chunk structure="h1">

              <dg:chunk>Statistical Analysis</dg:chunk>: </dg:chunk><docset:StatisticalAnalysis structure="div">

              The analyses for <dg:chunk>Part A </dg:chunk>and <dg:chunk>Part B </dg:chunk>will be conducted separately using similar statistical methods. Primary statistical analyses will be conducted on the set of patients who complete both treatment periods. Supportive analyses may be done on the key parameters for the patients who complete at least <dgc:Number>1 </dgc:Number>treatment period. Safety analyses will be conducted for the set of patients receiving at least <docset:StatisticalAnalysisPlan>1 </docset:StatisticalAnalysisPlan>dose of the <dgm:_testRef>study </dgm:_testRef>drug, whether or not they completed all protocol requirements. </docset:StatisticalAnalysis></docset:StatisticalAnalysis-section><docset:Safety-section><dg:chunk structure="h1">

              Safety: </dg:chunk><docset:Safety structure="div">All <dgm:_testRef>study </dgm:_testRef>drug- and protocol procedure-related adverse events will be listed, and if the frequency of events allows, safety data (including hypoglycaemic events) will be summarised using descriptive methodology. Safety parameters will be listed, and may be summarised using standard descriptive statistics. </docset:Safety></docset:Safety-section><docset:Pharmacokinetic-section><dg:chunk structure="h1">

              Pharmacokinetic: </dg:chunk><docset:Pharmacokinetic structure="div"><docset:StatisticalAnalysis structure="p">Log-transformed PK parameters for <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>will be evaluated to estimate least-squares geometric means, ratios of geometric means between <docset:TreatmentGroup>LY900014 </docset:TreatmentGroup>and <dgm:Medication>Humalog</dgm:Medication>, and their corresponding <docset:ConfidenceInterval>95% </docset:ConfidenceInterval>CIs of the ratios using the mixed-effect model that includes treatment, sequence, period, age group, and treatment by age group interaction as fixed effects and patient within sequence as a random effect. </docset:StatisticalAnalysis><docset:StatisticalAnalysis structure="p">

              The same model without log transformation will be used for the analysis of the PK time parameters (time to early half-maximal drug concentration [early <dgc:Percent>50% </dgc:Percent>tmax], time to late half-maximal drug concentration [late <docset:TreatmentDifference>50% </docset:TreatmentDifference>tmax], time of maximum observed drug concentration (tmax). Least-squares means (LSmeans), treatment differences in LSmeans, and the corresponding <docset:ConfidenceInterval>95% </docset:ConfidenceInterval>CIs for the treatment differences will be estimated from the model. The treatment ratios and <dgc:Percent>95% </dgc:Percent>CIs for the ratios using the Fieller’s theorem will be provided. </docset:StatisticalAnalysis></docset:Pharmacokinetic></docset:Pharmacokinetic-section><docset:Glucodynamic-section><dg:chunk structure="h1">

              Glucodynamic: </dg:chunk><docset:Glucodynamic structure="div"><docset:ResearchFindings structure="p">Data will be analysed for the patients during each MMTT. The change from baseline values (the average of <docset:BaselineGlucose>-30</docset:BaselineGlucose>, <docset:BaselineSubtractedAUC>-15</docset:BaselineSubtractedAUC>, and 0 minutes) represented as the <dgc:TimeDuration>0</dgc:TimeDuration>-<docset:TimeInterval>hour </docset:TimeInterval>time point following the start of the MMTT for each patient will be calculated. The area under the baseline subtracted glucose concentration versus time curve (∆AUC) from time <docset:GlucoseAUCCalculations>0 </docset:GlucoseAUCCalculations>to <docset:AUC0-2h>2 hours </docset:AUC0-2h>postmeal (<dg:chunk>∆AUC[0</dg:chunk>-2h]) and ∆AUC from time 0 to <dgc:TimeDuration>5 hours </dgc:TimeDuration>postmeal (<dg:chunk>∆AUC[0</dg:chunk>-5h]) will be calculated. In addition, the change from baseline maximum glucose observed during the <docset:MaximumGlucoseChange>5 hours </docset:MaximumGlucoseChange>postmeal and change from baseline <docset:GlucoseAUCCalculations>1 </docset:GlucoseAUCCalculations>hour glucose and <docset:GlucoseMetrics>2 </docset:GlucoseMetrics>hour glucose after the start of the meal will be calculated. Other partial ∆AUCs may be calculated as deemed appropriate. </docset:ResearchFindings><dg:chunk><dg:chunk><docset:StatisticalAnalysis structure="p">

              Summary statistics (including number of patients, mean, standard deviation or standard error, minimum, and maximum) will be presented by treatment for each age group. The GD parameters on the original scale (not log transformed) will be analysed using the same model used for PK parameters. Least-squares means, treatment differences in LSmeans, and the corresponding <dgc:Percent>95% </dgc:Percent>CIs for the treatment differences will be estimated from the model. The treatment ratios and <docset:ConfidenceInterval>95% </docset:ConfidenceInterval>CIs for the ratios will be calculated using the <docset:FiellersTheorem>Fieller</docset:FiellersTheorem>’s theorem. </docset:StatisticalAnalysis><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 1262.5; top: 308.3; width: 770.8; height: 66.7; page: 12;}; "><dg:chunk structure="li" style="boundingBox:{left: 1262.5; top: 308.3; width: 770.8; height: 66.7; page: 12;}; "><dg:chunk structure="lim" style="boundingBox:{left: 1262.5; top: 308.3; width: 58.3; height: 66.7; page: 12;}; ">

                                                           2. </dg:chunk><dg:chunk structure="h1">Schedule of Activities </dg:chunk></dg:chunk></dg:chunk></dg:chunk><dg:chunk><dg:chunk structure="h1">

              <dgm:_testRef>Study </dgm:_testRef>Schedule Protocol I8B-MC-ITSA (<dg:chunk>Part A</dg:chunk>) </dg:chunk><docset:ScheduleofActivities><xhtml:table structure="table" style="boundingBox:{left: 300.0; top: 473.0; width: 2696.0; height: 1767.0; page: 12;}; boundingBox:{left: 300; top: 303; width: 2694; height: 1916; page: 13;}; boundingBox:{left: 300; top: 307; width: 2694; height: 1910; page: 14;}; boundingBox:{left: 300.0; top: 301.0; width: 2696.0; height: 1911.0; page: 15;}; boundingBox:{left: 300.0; top: 301.0; width: 2696.0; height: 938.0; page: 16;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 300.0; top: 473.0; width: 2696.0; height: 1767.0; page: 12;}; boundingBox:{left: 300; top: 303; width: 2694; height: 1916; page: 13;}; boundingBox:{left: 300; top: 307; width: 2694; height: 1910; page: 14;}; boundingBox:{left: 300.0; top: 301.0; width: 2696.0; height: 1911.0; page: 15;}; boundingBox:{left: 300.0; top: 301.0; width: 2696.0; height: 938.0; page: 16;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 473.0; width: 2696.0; height: 167.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 473.0; width: 600.0; height: 279.0; page: 12;}; " rowspan="2">

                          Visits </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 473.0; width: 480.0; height: 168.0; page: 12;}; " colspan="2"><dg:chunk structure="h1">

                     <dgm:_testRef>Screening </dgm:_testRef></dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 473.0; width: 658.0; height: 168.0; page: 12;}; " colspan="2"><dg:chunk structure="h1">

                        <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Periods </dg:chunk>(Periods <docset:StudyPeriods>1 </docset:StudyPeriods>and <docset:StudyPeriods>2</docset:StudyPeriods>) </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 473.0; width: 350.0; height: 168.0; page: 12;}; "><dg:chunk structure="h1">

                   Follow- upa/Early Discontinuationb </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 473.0; width: 608.0; height: 168.0; page: 12;}; "><dg:chunk structure="h1">

                        Comments </dg:chunk></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 641.0; width: 2696.0; height: 111.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 641.0; width: 250.0; height: 111.0; page: 12;}; "><docset:Visits101>

                                               <dgc:Number>101 </dgc:Number></docset:Visits101></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 641.0; width: 230.0; height: 111.0; page: 12;}; "><docset:_101Screening>

                                           <dg:chunk>Telephone Visit </dg:chunk></docset:_101Screening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 641.0; width: 658.0; height: 111.0; page: 12;}; " colspan="2"><docset:_101StudyPeriodsPeriods1And2>

                                                       <docset:NumberofPlayers>1 </docset:NumberofPlayers>and <docset:NumberofFields>2 </docset:NumberofFields></docset:_101StudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 641.0; width: 350.0; height: 111.0; page: 12;}; "><docset:_101Follow-UpaEarlyDiscontinuationb>

                                                 <dgc:Number>801 </dgc:Number></docset:_101Follow-UpaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 641.0; width: 608.0; height: 111.0; page: 12;}; "><docset:_101Comments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 753.0; width: 2696.0; height: 163.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 752.0; width: 600.0; height: 164.0; page: 12;}; "><docset:VisitsDay>

                           Day </docset:VisitsDay></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 752.0; width: 250.0; height: 164.0; page: 12;}; "><docset:DayScreening structure="h1">

                Within <docset:DaysPriortoDay-1>28 days </docset:DaysPriortoDay-1>Prior to Day <docset:DayBeforeEvent>-1 </docset:DayBeforeEvent></docset:DayScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 752.0; width: 230.0; height: 164.0; page: 12;}; "><docset:DayStudyPeriodsPeriods1And2>

               ≥Day -10c </docset:DayStudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 752.0; width: 221.0; height: 164.0; page: 12;}; "><docset:DayFollow-UpaEarlyDiscontinuationb>

                  -1d </docset:DayFollow-UpaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 752.0; width: 437.0; height: 164.0; page: 12;}; "><docset:DayComments>

                        <dgc:Number>1 </dgc:Number></docset:DayComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 752.0; width: 350.0; height: 164.0; page: 12;}; "><docset:Day structure="h1">

                <docset:StudyDrugDuration>≥14 days </docset:StudyDrugDuration>After <dg:chunk>Last Dose </dg:chunk>of <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Drug </dg:chunk></docset:Day></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 752.0; width: 608.0; height: 164.0; page: 12;}; "><docset:Day /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 917.0; width: 2696.0; height: 163.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 916.0; width: 600.0; height: 164.0; page: 12;}; "><docset:VisitsInformedConsentAssent>

               Informed Consent/Assent </docset:VisitsInformedConsentAssent></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 916.0; width: 250.0; height: 164.0; page: 12;}; "><docset:InformedConsentAssentScreening>

                   X </docset:InformedConsentAssentScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 916.0; width: 230.0; height: 164.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 916.0; width: 221.0; height: 164.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 916.0; width: 437.0; height: 164.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 916.0; width: 350.0; height: 164.0; page: 12;}; "><docset:InformedConsentAssentComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 916.0; width: 608.0; height: 164.0; page: 12;}; "><docset:InformedConsentAssent structure="p">

               Should be obtained before any <dgm:_testRef>study</dgm:_testRef>-related procedures are performed. </docset:InformedConsentAssent></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1081.0; width: 2696.0; height: 55.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1080.0; width: 600.0; height: 56.0; page: 12;}; "><docset:VisitsInclusionExclusionCriteria>

               Inclusion/Exclusion Criteria </docset:VisitsInclusionExclusionCriteria></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 1080.0; width: 250.0; height: 56.0; page: 12;}; "><docset:InclusionExclusionCriteriaScreening>

                   X </docset:InclusionExclusionCriteriaScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 1080.0; width: 230.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 1080.0; width: 221.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 1080.0; width: 437.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 1080.0; width: 350.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 1080.0; width: 608.0; height: 56.0; page: 12;}; "><docset:InclusionExclusionCriteriaComments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1137.0; width: 2696.0; height: 55.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1136.0; width: 600.0; height: 56.0; page: 12;}; "><docset:VisitsMedicalHistory>

               <dg:chunk>Medical History </dg:chunk></docset:VisitsMedicalHistory></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 1136.0; width: 250.0; height: 56.0; page: 12;}; "><docset:MedicalHistoryScreening>

                   X </docset:MedicalHistoryScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 1136.0; width: 230.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 1136.0; width: 221.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 1136.0; width: 437.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 1136.0; width: 350.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 1136.0; width: 608.0; height: 56.0; page: 12;}; "><docset:MedicalHistoryComments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1193.0; width: 2696.0; height: 55.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1192.0; width: 600.0; height: 56.0; page: 12;}; "><docset:VisitsPre-existingConditions>

               Pre-existing Conditions </docset:VisitsPre-existingConditions></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 1192.0; width: 250.0; height: 56.0; page: 12;}; "><docset:Pre-existingConditionsScreening>

                   X </docset:Pre-existingConditionsScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 1192.0; width: 230.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 1192.0; width: 221.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 1192.0; width: 437.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 1192.0; width: 350.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 1192.0; width: 608.0; height: 56.0; page: 12;}; "><docset:Pre-existingConditionsComments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1249.0; width: 2696.0; height: 55.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1248.0; width: 600.0; height: 56.0; page: 12;}; "><docset:VisitsAge>

               Age </docset:VisitsAge></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 1248.0; width: 250.0; height: 56.0; page: 12;}; "><docset:AgeScreening>

                   X </docset:AgeScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 1248.0; width: 230.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 1248.0; width: 221.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 1248.0; width: 437.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 1248.0; width: 350.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 1248.0; width: 608.0; height: 56.0; page: 12;}; "><docset:AgeComments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1305.0; width: 2696.0; height: 55.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1304.0; width: 600.0; height: 56.0; page: 12;}; "><docset:VisitsHeight>

               Height </docset:VisitsHeight></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 1304.0; width: 250.0; height: 56.0; page: 12;}; "><docset:HeightScreening>

                   X </docset:HeightScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 1304.0; width: 230.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 1304.0; width: 221.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 1304.0; width: 437.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 1304.0; width: 350.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 1304.0; width: 608.0; height: 56.0; page: 12;}; "><docset:HeightComments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1361.0; width: 2696.0; height: 55.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1360.0; width: 600.0; height: 56.0; page: 12;}; "><docset:VisitsWeight>

               Weight </docset:VisitsWeight></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 1360.0; width: 250.0; height: 56.0; page: 12;}; "><docset:WeightScreening>

                   X </docset:WeightScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 1360.0; width: 230.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 1360.0; width: 221.0; height: 56.0; page: 12;}; "><docset:WeightFollow-UpaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 1360.0; width: 437.0; height: 56.0; page: 12;}; "><docset:WeightComments>

                        X </docset:WeightComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 1360.0; width: 350.0; height: 56.0; page: 12;}; "><docset:Weight>

                      X </docset:Weight></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 1360.0; width: 608.0; height: 56.0; page: 12;}; "><docset:Weight /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1417.0; width: 2696.0; height: 217.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1416.0; width: 600.0; height: 218.0; page: 12;}; "><docset:VisitsPhysicalExamination>

               <dg:chunk>Physical <dgm:_testRef>Examination </dgm:_testRef></dg:chunk></docset:VisitsPhysicalExamination></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 1416.0; width: 250.0; height: 218.0; page: 12;}; "><docset:PhysicalExaminationScreening>

                   X </docset:PhysicalExaminationScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 1416.0; width: 230.0; height: 218.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 1416.0; width: 221.0; height: 218.0; page: 12;}; "><docset:PhysicalExaminationFollow-UpaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 1416.0; width: 437.0; height: 218.0; page: 12;}; "><docset:PhysicalExaminationComments>

                     Predose </docset:PhysicalExaminationComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 1416.0; width: 350.0; height: 218.0; page: 12;}; "><docset:PhysicalExamination>

                      X </docset:PhysicalExamination></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 1416.0; width: 608.0; height: 218.0; page: 12;}; "><docset:PhysicalExamination structure="p">

               Physical <dgm:_testRef>examination </dgm:_testRef>at <dgm:_testRef>screening</dgm:_testRef>. Thereafter, targeted medical assessment, as appropriate. </docset:PhysicalExamination></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1635.0; width: 2696.0; height: 55.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1634.0; width: 600.0; height: 56.0; page: 12;}; "><docset:VisitsAdmissiontoStudySite>

               Admission to <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Site </dg:chunk></docset:VisitsAdmissiontoStudySite></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 1634.0; width: 250.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 1634.0; width: 230.0; height: 56.0; page: 12;}; "><docset:AdmissiontoStudySiteStudyPeriodsPeriods1And2 /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 1634.0; width: 221.0; height: 56.0; page: 12;}; "><docset:AdmissiontoStudySiteFollow-UpaEarlyDiscontinuationb>

                   X </docset:AdmissiontoStudySiteFollow-UpaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 1634.0; width: 437.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 1634.0; width: 350.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 1634.0; width: 608.0; height: 56.0; page: 12;}; "><docset:AdmissiontoStudySiteComments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1691.0; width: 2696.0; height: 163.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1690.0; width: 600.0; height: 164.0; page: 12;}; "><docset:VisitsIWRSAndRandomisation>

               IWRS and Randomisation </docset:VisitsIWRSAndRandomisation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 1690.0; width: 250.0; height: 164.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 1690.0; width: 230.0; height: 164.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 1690.0; width: 221.0; height: 164.0; page: 12;}; "><docset:IWRSAndRandomisationFollow-UpaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 1690.0; width: 437.0; height: 164.0; page: 12;}; "><docset:IWRSAndRandomisationComments>

                        X </docset:IWRSAndRandomisationComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 1690.0; width: 350.0; height: 164.0; page: 12;}; "><docset:IWRSAndRandomisation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 1690.0; width: 608.0; height: 164.0; page: 12;}; "><docset:IWRSAndRandomisation structure="p">

               Randomisation in Period 1 only. Age group for randomisation will be based on initial <dgm:_testRef>screening</dgm:_testRef>. </docset:IWRSAndRandomisation></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1855.0; width: 2696.0; height: 163.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1854.0; width: 600.0; height: 164.0; page: 12;}; "><docset:VisitsPreviousDiabetesTherapyRecordPrandialAndBasalInsulinDose structure="h1">

               Previous <dgm:Condition>Diabetes </dgm:Condition>Therapy Record Prandial and Basal <dgm:Medication>Insulin </dgm:Medication>Dose </docset:VisitsPreviousDiabetesTherapyRecordPrandialAndBasalInsulinDose></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 1854.0; width: 250.0; height: 164.0; page: 12;}; "><docset:PreviousDiabetesTherapyRecordPrandialAndBasalInsulinDoseScreening>

                   X </docset:PreviousDiabetesTherapyRecordPrandialAndBasalInsulinDoseScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 1854.0; width: 230.0; height: 164.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 1854.0; width: 221.0; height: 164.0; page: 12;}; "><docset:PreviousDiabetesTherapyRecordPrandialAndBasalInsulinDoseFollow-UpaEar /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 1854.0; width: 437.0; height: 164.0; page: 12;}; "><docset:PreviousDiabetesTherapyRecordPrandialAndBasalInsulinDoseComments>

                       X* </docset:PreviousDiabetesTherapyRecordPrandialAndBasalInsulinDoseComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 1854.0; width: 350.0; height: 164.0; page: 12;}; "><docset:PreviousDiabetesTherapyRecordPrandialAndBasalInsulinDose /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 1854.0; width: 608.0; height: 164.0; page: 12;}; "><docset:PreviousDiabetesTherapyRecordPrandialAndBasalInsulinDose>

               *Period 1 only. </docset:PreviousDiabetesTherapyRecordPrandialAndBasalInsulinDose></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 2019.0; width: 2696.0; height: 109.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 2018.0; width: 600.0; height: 110.0; page: 12;}; "><docset:VisitsVitalSignsPulseSittingBP structure="h1">

               <dgm:MedicalTest>Vital Signs </dgm:MedicalTest>(Pulse, Sitting BP) </docset:VisitsVitalSignsPulseSittingBP></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 2018.0; width: 250.0; height: 110.0; page: 12;}; "><docset:VitalSignsPulseSittingBPScreening>

                   X </docset:VitalSignsPulseSittingBPScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 2018.0; width: 230.0; height: 110.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 2018.0; width: 221.0; height: 110.0; page: 12;}; "><docset:VitalSignsPulseSittingBPFollow-UpaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 2018.0; width: 437.0; height: 110.0; page: 12;}; "><docset:VitalSignsPulseSittingBPComments structure="h1">

                  Pre- and <docset:PostdoseTime>2 hours </docset:PostdoseTime>postdose </docset:VitalSignsPulseSittingBPComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 2018.0; width: 350.0; height: 110.0; page: 12;}; "><docset:VitalSignsPulseSittingBP>

                      X </docset:VitalSignsPulseSittingBP></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 2018.0; width: 608.0; height: 110.0; page: 12;}; "><docset:VitalSignsPulseSittingBP /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 2129.0; width: 2696.0; height: 55.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 2128.0; width: 600.0; height: 56.0; page: 12;}; "><docset:VisitsEligibilityAssessment>

               <dg:chunk>Eligibility Assessment </dg:chunk></docset:VisitsEligibilityAssessment></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 2128.0; width: 250.0; height: 56.0; page: 12;}; "><docset:EligibilityAssessmentScreening>

                   X </docset:EligibilityAssessmentScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 2128.0; width: 230.0; height: 56.0; page: 12;}; "><docset:EligibilityAssessmentStudyPeriodsPeriods1And2>

                   X </docset:EligibilityAssessmentStudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 2128.0; width: 221.0; height: 56.0; page: 12;}; "><docset:EligibilityAssessmentFollow-UpaEarlyDiscontinuationb>

                  X* </docset:EligibilityAssessmentFollow-UpaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 2128.0; width: 437.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 2128.0; width: 350.0; height: 56.0; page: 12;}; "><docset:EligibilityAssessmentComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 2128.0; width: 608.0; height: 56.0; page: 12;}; "><docset:EligibilityAssessment>

               *Period 1 only. </docset:EligibilityAssessment></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 2185.0; width: 2696.0; height: 55.0; page: 12;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 2184.0; width: 600.0; height: 56.0; page: 12;}; "><docset:VisitsHipAndWaistCircumference>

               Hip and <dg:chunk>Waist Circumference </dg:chunk></docset:VisitsHipAndWaistCircumference></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 2184.0; width: 250.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 2184.0; width: 230.0; height: 56.0; page: 12;}; "><docset:HipAndWaistCircumferenceStudyPeriodsPeriods1And2 /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 2184.0; width: 221.0; height: 56.0; page: 12;}; "><docset:HipAndWaistCircumferenceFollow-UpaEarlyDiscontinuationb>

                   X </docset:HipAndWaistCircumferenceFollow-UpaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 2184.0; width: 437.0; height: 56.0; page: 12;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 2184.0; width: 350.0; height: 56.0; page: 12;}; "><docset:HipAndWaistCircumferenceComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 2184.0; width: 608.0; height: 56.0; page: 12;}; "><docset:HipAndWaistCircumference structure="h1">

               Applicable only to adult patients. </docset:HipAndWaistCircumference></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 582; width: 2694; height: 165; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 581; width: 598; height: 166; page: 13;}; "><docset:VisitsDay>

                          Day </docset:VisitsDay></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 898; top: 581; width: 251; height: 166; page: 13;}; "><docset:DayScreening structure="h1">

                Within <docset:DaysPriortoDay-1>28 days </docset:DaysPriortoDay-1>Prior to Day <docset:DayBeforeEvent>-1 </docset:DayBeforeEvent></docset:DayScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 581; width: 231; height: 166; page: 13;}; "><docset:DayStudyPeriodsPeriods1And2>

               ≥Day -10c </docset:DayStudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 581; width: 220; height: 166; page: 13;}; "><docset:DayFollow-UpaEarlyDiscontinuationb>

                  -ld </docset:DayFollow-UpaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1600; top: 581; width: 437; height: 166; page: 13;}; "><docset:DayComments>

                        <dgc:Number>1 </dgc:Number></docset:DayComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 581; width: 351; height: 166; page: 13;}; "><docset:Day structure="h1">

                <docset:StudyDrugDuration>≥14 days </docset:StudyDrugDuration>After <dg:chunk>Last Dose </dg:chunk>of <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Drug </dg:chunk></docset:Day></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 581; width: 606; height: 166; page: 13;}; "><docset:Day /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 748; width: 2694; height: 269; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 747; width: 598; height: 270; page: 13;}; "><docset:VisitsClinicalLaboratoryTests>

               <dg:chunk>Clinical Laboratory Tests </dg:chunk></docset:VisitsClinicalLaboratoryTests></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 898; top: 747; width: 251; height: 270; page: 13;}; "><docset:ClinicalLaboratoryTestsScreening>

                   x </docset:ClinicalLaboratoryTestsScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 747; width: 231; height: 270; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 747; width: 220; height: 270; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1600; top: 747; width: 437; height: 270; page: 13;}; "><docset:ClinicalLaboratoryTestsComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 747; width: 351; height: 270; page: 13;}; "><docset:ClinicalLaboratoryTests>

                     x </docset:ClinicalLaboratoryTests></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 747; width: 606; height: 270; page: 13;}; "><docset:ClinicalLaboratoryTests structure="p">

               See Appendix <docset:AlcoholBreathTestResults>2 </docset:AlcoholBreathTestResults>for details. All patients of legal drinking age (according to local laws) will receive <dgm:MedicalTest>alcohol <dgm:MedicalTest>breath <dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest></dgm:MedicalTest>on Day <docset:AlcoholBreathTest>-1</docset:AlcoholBreathTest>. </docset:ClinicalLaboratoryTests></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1018; width: 2694; height: 109; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1017; width: 598; height: 110; page: 13;}; "><docset:VisitsGlycatedHaemoglobinHbAlcAssessment>

               <dg:chunk>Glycated Haemoglobin </dg:chunk>(<dg:chunk><docset:GlycatedHaemoglobinAssessment>HbAlc</docset:GlycatedHaemoglobinAssessment>) Assessment </dg:chunk></docset:VisitsGlycatedHaemoglobinHbAlcAssessment></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 898; top: 1017; width: 251; height: 110; page: 13;}; "><docset:GlycatedHaemoglobinHbAlcAssessmentScreening>

                   X </docset:GlycatedHaemoglobinHbAlcAssessmentScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 1017; width: 231; height: 110; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 1017; width: 220; height: 110; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1600; top: 1017; width: 437; height: 110; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 1017; width: 351; height: 110; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 1017; width: 606; height: 110; page: 13;}; "><docset:GlycatedHaemoglobinHbAlcAssessmentComments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1128; width: 2694; height: 57; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1127; width: 598; height: 58; page: 13;}; "><docset:VisitsUrinalysis>

               <dgm:MedicalTest>Urinalysis </dgm:MedicalTest></docset:VisitsUrinalysis></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 898; top: 1127; width: 251; height: 58; page: 13;}; "><docset:UrinalysisScreening>

                   X </docset:UrinalysisScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 1127; width: 231; height: 58; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 1127; width: 220; height: 58; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1600; top: 1127; width: 437; height: 58; page: 13;}; "><docset:UrinalysisComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 1127; width: 351; height: 58; page: 13;}; "><docset:Urinalysis>

                     x </docset:Urinalysis></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 1127; width: 606; height: 58; page: 13;}; "><docset:Urinalysis /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1186; width: 2694; height: 53; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1185; width: 598; height: 54; page: 13;}; "><docset:Visits12-LeadECG>

               <docset:ECGLeads>12</docset:ECGLeads>-Lead <dgm:MedicalTest>ECG </dgm:MedicalTest></docset:Visits12-LeadECG></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 898; top: 1185; width: 251; height: 54; page: 13;}; "><docset:_12-LeadECGScreening>

                   x </docset:_12-LeadECGScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 1185; width: 231; height: 54; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 1185; width: 220; height: 54; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1600; top: 1185; width: 437; height: 54; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 1185; width: 351; height: 54; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 1185; width: 606; height: 54; page: 13;}; "><docset:_12-LeadECGComments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1240; width: 2694; height: 649; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1239; width: 598; height: 650; page: 13;}; "><docset:VisitsPregnancyTest>

               <dgm:MedicalTest><dgm:Condition>Pregnancy </dgm:Condition><dgm:_testRef>Test </dgm:_testRef></dgm:MedicalTest></docset:VisitsPregnancyTest></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 898; top: 1239; width: 251; height: 650; page: 13;}; "><docset:PregnancyTestScreening>

                   A </docset:PregnancyTestScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 1239; width: 231; height: 650; page: 13;}; "><docset:PregnancyTestStudyPeriodsPeriods1And2 /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 1239; width: 220; height: 650; page: 13;}; "><docset:PregnancyTestFollow-UpaEarlyDiscontinuationb>

                  X </docset:PregnancyTestFollow-UpaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1600; top: 1239; width: 437; height: 650; page: 13;}; "><docset:PregnancyTestComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 1239; width: 351; height: 650; page: 13;}; "><docset:PregnancyTest>

                     x </docset:PregnancyTest></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 1239; width: 606; height: 650; page: 13;}; "><docset:PregnancyTest structure="p">

               <dgm:Condition>Pregnancy </dgm:Condition>tests will be performed for all females <docset:PregnancyTestingAgeLimit>≥12 years </docset:PregnancyTestingAgeLimit>of age or &lt;<docset:PregnancyTestAgeLimit>12 years </docset:PregnancyTestAgeLimit>of age with onset of menses. Serum <dgm:Condition>pregnancy </dgm:Condition>tests will be performed at <dgm:_testRef>screening</dgm:_testRef>, and urine <dgm:MedicalTest><dgm:Condition>pregnancy </dgm:Condition><dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest>on Day <docset:PregnancyTesting>-1 </docset:PregnancyTesting>of Periods 1 and <docset:PregnancyTesting>2 </docset:PregnancyTesting>(or when clinically indicated), and at the follow-up of ED visit. Urine <dgm:Condition>pregnancy </dgm:Condition>tests at other visits accepted per local regulations. </docset:PregnancyTest></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1890; width: 2694; height: 57; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1889; width: 598; height: 58; page: 13;}; "><docset:VisitsProvideEveningMeal>

               Provide <dg:chunk>Evening Meal </dg:chunk></docset:VisitsProvideEveningMeal></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 898; top: 1889; width: 251; height: 58; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 1889; width: 231; height: 58; page: 13;}; "><docset:ProvideEveningMealStudyPeriodsPeriods1And2 /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 1889; width: 220; height: 58; page: 13;}; "><docset:ProvideEveningMealFollow-UpaEarlyDiscontinuationb>

                  X </docset:ProvideEveningMealFollow-UpaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1600; top: 1889; width: 437; height: 58; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 1889; width: 351; height: 58; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 1889; width: 606; height: 58; page: 13;}; "><docset:ProvideEveningMealComments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1948; width: 2694; height: 161; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1947; width: 598; height: 162; page: 13;}; "><docset:VisitsBeginOvernightFast>

               Begin Overnight Fast </docset:VisitsBeginOvernightFast></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 898; top: 1947; width: 251; height: 162; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 1947; width: 231; height: 162; page: 13;}; "><docset:BeginOvernightFastStudyPeriodsPeriods1And2 /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 1947; width: 220; height: 162; page: 13;}; "><docset:BeginOvernightFastFollow-UpaEarlyDiscontinuationb>

                  x </docset:BeginOvernightFastFollow-UpaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1600; top: 1947; width: 437; height: 162; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 1947; width: 351; height: 162; page: 13;}; "><docset:BeginOvernightFastComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 1947; width: 606; height: 162; page: 13;}; "><docset:BeginOvernightFast structure="p">

               Patients will be fasted (except for water) for at least <docset:FastingPeriod>10 hours </docset:FastingPeriod>before each <dgm:_testRef>test </dgm:_testRef>meal. </docset:BeginOvernightFast></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 2110; width: 2694; height: 109; page: 13;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 2109; width: 598; height: 110; page: 13;}; "><docset:VisitsStopCSII>

               Stop CSII </docset:VisitsStopCSII></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 898; top: 2109; width: 251; height: 110; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 2109; width: 231; height: 110; page: 13;}; "><docset:StopCSIIStudyPeriodsPeriods1And2 /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 2109; width: 220; height: 110; page: 13;}; "><docset:StopCSIIFollow-UpaEarlyDiscontinuationb>

                  X </docset:StopCSIIFollow-UpaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1600; top: 2109; width: 437; height: 110; page: 13;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 2109; width: 351; height: 110; page: 13;}; "><docset:StopCSIIComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 2109; width: 606; height: 110; page: 13;}; "><docset:StopCSII structure="p">

               Prior to start of run-in. Applicable only to patients on </docset:StopCSII></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 586; width: 2694; height: 165; page: 14;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 585; width: 599; height: 166; page: 14;}; "><docset:VisitsDay>

                          Day </docset:VisitsDay></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 899; top: 585; width: 250; height: 166; page: 14;}; "><docset:DayScreening structure="h1">

                Within <docset:DaysPriortoDay-1>28 days </docset:DaysPriortoDay-1>Prior to Day <docset:DayBeforeEvent>-1 </docset:DayBeforeEvent></docset:DayScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 585; width: 231; height: 166; page: 14;}; "><docset:DayStudyPeriodsPeriods1And2>

               ≥Day -10e </docset:DayStudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 585; width: 221; height: 166; page: 14;}; "><docset:DayFollow-UpaEarlyDiscontinuationb>

                  -ld </docset:DayFollow-UpaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601; top: 585; width: 436; height: 166; page: 14;}; "><docset:DayComments>

                        <dgc:Number>1 </dgc:Number></docset:DayComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 585; width: 351; height: 166; page: 14;}; "><docset:Day structure="h1">

                <docset:StudyDrugDuration>≥14 days </docset:StudyDrugDuration>After <dg:chunk>Last Dose </dg:chunk>of <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Drug </dg:chunk></docset:Day></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 585; width: 606; height: 166; page: 14;}; "><docset:Comments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 752; width: 2694; height: 49; page: 14;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 751; width: 599; height: 50; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 899; top: 751; width: 250; height: 50; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 751; width: 231; height: 50; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 751; width: 221; height: 50; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1601; top: 751; width: 436; height: 50; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 751; width: 351; height: 50; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 751; width: 606; height: 50; page: 14;}; ">

               <docset:CSII>CSII</docset:CSII>. </xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 802; width: 2694; height: 479; page: 14;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 801; width: 599; height: 480; page: 14;}; "><docset:VisitsRun-inStabilisationofGlucose>

               Run-in/Stabilisation of Glucose </docset:VisitsRun-inStabilisationofGlucose></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 899; top: 801; width: 250; height: 480; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 801; width: 231; height: 480; page: 14;}; "><docset:Run-inStabilisationofGlucoseStudyPeriodsPeriods1And2 /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 801; width: 221; height: 480; page: 14;}; "><docset:Run-inStabilisationofGlucoseFollow-UpaEarlyDiscontinuationb>

                  X (following 

                evening meal) </docset:Run-inStabilisationofGlucoseFollow-UpaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601; top: 801; width: 436; height: 480; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 801; width: 351; height: 480; page: 14;}; "><docset:Run-inStabilisationofGlucoseComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 801; width: 606; height: 480; page: 14;}; "><docset:Run-inStabilisationofGlucose structure="p">

               Approximately at <docset:GlucoseInfusionStartTime>09:00 </docset:GlucoseInfusionStartTime>to <docset:BloodGlucoseMonitoringSchedule>10:00 PM </docset:BloodGlucoseMonitoringSchedule>infusion of glucose (<dgm:Medication>dextrose </dgm:Medication>solution) or CCI <dgm:Medication>insulin </dgm:Medication>to target a blood glucose concentration of <docset:TargetBloodGlucoseConcentration>135</docset:TargetBloodGlucoseConcentration>+<docset:BloodGlucoseMonitoringSchedule>25 </docset:BloodGlucoseMonitoringSchedule>mg/dL (<docset:TargetBloodGlucoseConcentration>7.5</docset:TargetBloodGlucoseConcentration>+<docset:BloodGlucoseMonitoringSchedule>1.4 </docset:BloodGlucoseMonitoringSchedule>mmol/L). Blood glucose concentrations will be monitored at a minimum of <docset:BloodGlucoseMonitoringSchedule>30- </docset:BloodGlucoseMonitoringSchedule>to <docset:BloodGlucoseMonitoringInterval>60-minute </docset:BloodGlucoseMonitoringInterval>intervals. </docset:Run-inStabilisationofGlucose></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1282; width: 2694; height: 285; page: 14;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1281; width: 599; height: 286; page: 14;}; "><docset:VisitsStudyDrugAdministrationSingleSCInjection structure="h1">

               <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Drug Administration </dg:chunk>(Single SC injection) </docset:VisitsStudyDrugAdministrationSingleSCInjection></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 899; top: 1281; width: 250; height: 286; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 1281; width: 231; height: 286; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 1281; width: 221; height: 286; page: 14;}; "><docset:StudyDrugAdministrationSingleSCInjectionFollow-UpaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601; top: 1281; width: 436; height: 286; page: 14;}; "><docset:StudyDrugAdministrationSingleSCInjectionComments>

                       x </docset:StudyDrugAdministrationSingleSCInjectionComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 1281; width: 351; height: 286; page: 14;}; "><docset:StudyDrugAdministrationSingleSCInjection /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 1281; width: 606; height: 286; page: 14;}; "><docset:StudyDrugAdministrationSingleSCInjection structure="p">

               Time of <dgm:_testRef>study </dgm:_testRef>drug administration = <docset:TimeofStudyDrugAdministration>0 hour</docset:TimeofStudyDrugAdministration>. <dgm:_testRef>Study </dgm:_testRef>drug will be administered at approximately the same times on Day <docset:StudyDrugAdministrationTime>1 </docset:StudyDrugAdministrationTime>of each <dgm:_testRef>study </dgm:_testRef>period. </docset:StudyDrugAdministrationSingleSCInjection></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1568; width: 2694; height: 47; page: 14;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1567; width: 599; height: 48; page: 14;}; "><docset:VisitsImmunogenicitySample>

               <dg:chunk>Immunogenicity Sample </dg:chunk></docset:VisitsImmunogenicitySample></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 899; top: 1567; width: 250; height: 48; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 1567; width: 231; height: 48; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 1567; width: 221; height: 48; page: 14;}; "><docset:ImmunogenicitySampleFollow-UpaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601; top: 1567; width: 436; height: 48; page: 14;}; "><docset:ImmunogenicitySampleComments>

                     Predose </docset:ImmunogenicitySampleComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 1567; width: 351; height: 48; page: 14;}; "><docset:ImmunogenicitySample>

                     X </docset:ImmunogenicitySample></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 1567; width: 606; height: 48; page: 14;}; "><docset:ImmunogenicitySample /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1616; width: 2694; height: 217; page: 14;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1615; width: 599; height: 218; page: 14;}; "><docset:VisitsInjection-SiteEvaluation>

               <dg:chunk>Injection-Site Evaluation </dg:chunk></docset:VisitsInjection-SiteEvaluation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 899; top: 1615; width: 250; height: 218; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 1615; width: 231; height: 218; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 1615; width: 221; height: 218; page: 14;}; "><docset:Injection-SiteEvaluationFollow-UpaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601; top: 1615; width: 436; height: 218; page: 14;}; "><docset:Injection-SiteEvaluationComments structure="h1">

               <docset:PostdoseTime>0</docset:PostdoseTime>, <docset:PostdoseTime>60</docset:PostdoseTime>, and <docset:PostdoseTime>240 </docset:PostdoseTime>minutes postdose </docset:Injection-SiteEvaluationComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 1615; width: 351; height: 218; page: 14;}; "><docset:Injection-SiteEvaluation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 1615; width: 606; height: 218; page: 14;}; "><docset:Injection-SiteEvaluation structure="p">

               Time <docset:AssessmentTime>0</docset:AssessmentTime>: Assessments of injection-site local tolerability will occur immediately following the injection. </docset:Injection-SiteEvaluation></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1834; width: 2694; height: 223; page: 14;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1833; width: 599; height: 224; page: 14;}; "><docset:VisitsDirectionsforPreparingforPKAndMMTTVisits structure="p">

               Directions for Preparing for PK and MMTT Visits </docset:VisitsDirectionsforPreparingforPKAndMMTTVisits></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 899; top: 1833; width: 250; height: 224; page: 14;}; "><docset:DirectionsforPreparingforPKAndMMTTVisitsScreening /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 1833; width: 231; height: 224; page: 14;}; "><docset:DirectionsforPreparingforPKAndMMTTVisitsStudyPeriodsPeriods1And2>

                  X </docset:DirectionsforPreparingforPKAndMMTTVisitsStudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 1833; width: 221; height: 224; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1601; top: 1833; width: 436; height: 224; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 1833; width: 351; height: 224; page: 14;}; "><docset:DirectionsforPreparingforPKAndMMTTVisitsComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 1833; width: 606; height: 224; page: 14;}; "><docset:DirectionsforPreparingforPKAndMMTTVisits structure="p">

               Patients will receive preparatory instructions as part of their pre- <dgm:_testRef>study </dgm:_testRef>telephone consultation (see Section 6.3, for details) </docset:DirectionsforPreparingforPKAndMMTTVisits></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 2058; width: 2694; height: 159; page: 14;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 2057; width: 599; height: 160; page: 14;}; "><docset:VisitsMixedMealToleranceTestMMTT structure="h1">

               <dg:chunk>Mixed Meal <dgm:MedicalTest>Tolerance <dgm:_testRef>Test </dgm:_testRef></dgm:MedicalTest></dg:chunk>(MMTT) </docset:VisitsMixedMealToleranceTestMMTT></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 899; top: 2057; width: 250; height: 160; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1149; top: 2057; width: 231; height: 160; page: 14;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380; top: 2057; width: 221; height: 160; page: 14;}; "><docset:MixedMealToleranceTestMMTTFollow-UpaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601; top: 2057; width: 436; height: 160; page: 14;}; "><docset:MixedMealToleranceTestMMTTComments>

                       x </docset:MixedMealToleranceTestMMTTComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2037; top: 2057; width: 351; height: 160; page: 14;}; "><docset:MixedMealToleranceTestMMTT /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388; top: 2057; width: 606; height: 160; page: 14;}; "><docset:MixedMealToleranceTestMMTT structure="p">

               A standard liquid meal will be administered at the <docset:MealTime>MMTT </docset:MealTime>time "<docset:Comments>0</docset:Comments>" (as soon as possible after </docset:MixedMealToleranceTestMMTT></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 745.0; width: 2696.0; height: 163.0; page: 15;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 744.0; width: 600.0; height: 164.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 744.0; width: 250.0; height: 164.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 744.0; width: 230.0; height: 164.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 744.0; width: 221.0; height: 164.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 744.0; width: 437.0; height: 164.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 744.0; width: 350.0; height: 164.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 744.0; width: 608.0; height: 164.0; page: 15;}; "><dg:chunk structure="p">

               administration of <dgm:_testRef>study </dgm:_testRef>drug) and should be consumed within <docset:StudyDrugAdministrationTime>15 minutes</docset:StudyDrugAdministrationTime>. </dg:chunk></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 909.0; width: 2696.0; height: 379.0; page: 15;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 908.0; width: 600.0; height: 380.0; page: 15;}; "><docset:VisitsBloodGlucoseSamplingMMTT>

               <dg:chunk><docset:BloodGlucoseSampling>Blood Glucose </docset:BloodGlucoseSampling>Sampling </dg:chunk>(<docset:BloodGlucoseSampling>MMTT</docset:BloodGlucoseSampling>) </docset:VisitsBloodGlucoseSamplingMMTT></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 908.0; width: 250.0; height: 380.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 908.0; width: 230.0; height: 380.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 908.0; width: 221.0; height: 380.0; page: 15;}; "><docset:BloodGlucoseSamplingMMTTFollow-UpaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 908.0; width: 437.0; height: 380.0; page: 15;}; "><docset:BloodGlucoseSamplingMMTTComments structure="p">

                <docset:Premeal>-30</docset:Premeal>, <docset:PremealBloodGlucose>-15</docset:PremealBloodGlucose>, <docset:PostmealTime>0 </docset:PostmealTime>(premeal), <docset:PostmealTime>10</docset:PostmealTime>, <docset:PostmealTime>20</docset:PostmealTime>, <docset:PostmealTime>30</docset:PostmealTime>, <docset:PostmealTime>40</docset:PostmealTime>, <docset:PostmealTime>50</docset:PostmealTime>, <docset:PostmealTime>60</docset:PostmealTime>, <docset:PostmealTime>70</docset:PostmealTime>, <docset:PostmealTime>80</docset:PostmealTime>, <docset:PostmealTime>90</docset:PostmealTime>, <docset:PostmealTime>100</docset:PostmealTime>, <docset:PostmealTime>110</docset:PostmealTime>, <docset:PostmealTime>120</docset:PostmealTime>, <docset:PostmealTime>135</docset:PostmealTime>, <docset:PostmealTime>150</docset:PostmealTime>, <docset:PostmealTime>165</docset:PostmealTime>, <docset:PostmealTime>180</docset:PostmealTime>, <docset:PostmealTime>195</docset:PostmealTime>, <docset:PostmealTime>210</docset:PostmealTime>, <docset:PostmealTime>225</docset:PostmealTime>, <docset:PostmealTime>240</docset:PostmealTime>, <docset:PostmealTime>300 </docset:PostmealTime>minutes postmeal </docset:BloodGlucoseSamplingMMTTComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 908.0; width: 350.0; height: 380.0; page: 15;}; "><docset:BloodGlucoseSamplingMMTT /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 908.0; width: 608.0; height: 380.0; page: 15;}; "><docset:BloodGlucoseSamplingMMTT structure="p">

               Time is referenced to meal start time, i.e., time <docset:MealStartTime>0</docset:MealStartTime>. Time <dgc:Number>0 </dgc:Number>is collected immediately prior to start of meal consumption. </docset:BloodGlucoseSamplingMMTT></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1289.0; width: 2696.0; height: 271.0; page: 15;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1288.0; width: 600.0; height: 272.0; page: 15;}; "><docset:VisitsInsulinLisproPKSampling>

               <dg:chunk><dgm:Medication><dgm:Medication>Insulin </dgm:Medication><docset:InsulinLispro>Lispro </docset:InsulinLispro></dgm:Medication>PK Sampling </dg:chunk></docset:VisitsInsulinLisproPKSampling></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 1288.0; width: 250.0; height: 272.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 1288.0; width: 230.0; height: 272.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 1288.0; width: 221.0; height: 272.0; page: 15;}; "><docset:InsulinLisproPKSamplingFollow-UpaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 1288.0; width: 437.0; height: 272.0; page: 15;}; "><docset:InsulinLisproPKSamplingComments structure="p">

               <docset:PostdoseTime>0</docset:PostdoseTime>, <docset:PostdoseTimePoints>5</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>10</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>15</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>20</docset:PostdoseTimePoints>, <docset:PostdoseTimepoints>25</docset:PostdoseTimepoints>, <docset:PostdoseTimepoints>30</docset:PostdoseTimepoints>, <docset:PostdoseTimepoints>35</docset:PostdoseTimepoints>, <docset:MaximumDuration>40</docset:MaximumDuration>, <docset:MaximumDuration>45</docset:MaximumDuration>, <docset:MaximumDuration>50</docset:MaximumDuration>, <docset:MaximumDuration>60</docset:MaximumDuration>, <docset:MaximumDuration>70</docset:MaximumDuration>, <docset:MaximumDuration>90</docset:MaximumDuration>, <docset:MaximumDuration>120</docset:MaximumDuration>, <docset:MaximumDuration>150</docset:MaximumDuration>, <docset:MaximumDuration>180</docset:MaximumDuration>, <docset:MaximumDuration>240</docset:MaximumDuration>, <docset:MaximumDuration>300</docset:MaximumDuration>, <docset:MaximumDuration>360</docset:MaximumDuration>, and <docset:MaximumDuration>420 </docset:MaximumDuration>minutes postdose </docset:InsulinLisproPKSamplingComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 1288.0; width: 350.0; height: 272.0; page: 15;}; "><docset:InsulinLisproPKSampling /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 1288.0; width: 608.0; height: 272.0; page: 15;}; "><docset:InsulinLisproPKSampling structure="p">

               Sampling times are relative to the time of <dgm:_testRef>study </dgm:_testRef>drug treatment administration (t = <docset:SamplingTimes>0</docset:SamplingTimes>) in each period </docset:InsulinLisproPKSampling></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1561.0; width: 2696.0; height: 433.0; page: 15;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1560.0; width: 600.0; height: 434.0; page: 15;}; "><docset:VisitsTransitiontoNPHTwiceDailyTherapy7-3DaysPriortoDay-1 structure="h1">

               Transition to <dgm:Medication>NPH </dgm:Medication><dg:chunk>Twice <dgc:Frequency>Daily </dgc:Frequency>Therapy </dg:chunk><docset:DaysPriortoDay-1>7</docset:DaysPriortoDay-1><docset:TransitiontoNPHTwiceDailyTherapy>-</docset:TransitiontoNPHTwiceDailyTherapy><docset:TransitionPeriod>3 days </docset:TransitionPeriod>Prior to Day <docset:Day-1>-1 </docset:Day-1></docset:VisitsTransitiontoNPHTwiceDailyTherapy7-3DaysPriortoDay-1></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 1560.0; width: 250.0; height: 434.0; page: 15;}; "><docset:TransitiontoNPHTwiceDailyTherapy7-3DaysPriortoDay-1Screening /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 1560.0; width: 230.0; height: 434.0; page: 15;}; "><docset:TransitiontoNPHTwiceDailyTherapy7-3DaysPriortoDay-1StudyPeriodsPer>

                   X </docset:TransitiontoNPHTwiceDailyTherapy7-3DaysPriortoDay-1StudyPeriodsPer></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 1560.0; width: 221.0; height: 434.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 1560.0; width: 437.0; height: 434.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 1560.0; width: 350.0; height: 434.0; page: 15;}; "><docset:TransitiontoNPHTwiceDailyTherapy7-3DaysPriortoDay-1Comments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 1560.0; width: 608.0; height: 434.0; page: 15;}; "><docset:TransitiontoNPHTwiceDailyTherapy7-3DaysPriortoDay-1 structure="p">

               Applicable only to patients using multiple <dgc:Frequency>daily </dgc:Frequency>injection therapy. Patient can return to pre-<dgm:_testRef>study </dgm:_testRef>basal <dgm:Medication>insulin </dgm:Medication>following completion of MMTT sampling period per investigator’s decision and allowing for transition to <dgm:Medication>NPH </dgm:Medication>prior to next dosing. </docset:TransitiontoNPHTwiceDailyTherapy7-3DaysPriortoDay-1></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1995.0; width: 2696.0; height: 217.0; page: 15;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1994.0; width: 600.0; height: 218.0; page: 15;}; "><docset:VisitsResumePrestudyCSIIRate>

               Resume <dg:chunk>Prestudy CSII Rate </dg:chunk></docset:VisitsResumePrestudyCSIIRate></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 1994.0; width: 250.0; height: 218.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 1994.0; width: 230.0; height: 218.0; page: 15;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 1994.0; width: 221.0; height: 218.0; page: 15;}; "><docset:ResumePrestudyCSIIRateFollow-UpaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 1994.0; width: 437.0; height: 218.0; page: 15;}; "><docset:ResumePrestudyCSIIRateComments>

                        X </docset:ResumePrestudyCSIIRateComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 1994.0; width: 350.0; height: 218.0; page: 15;}; "><docset:ResumePrestudyCSIIRate /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 1994.0; width: 608.0; height: 218.0; page: 15;}; "><docset:ResumePrestudyCSIIRate structure="p">

               Applicable only to patients on <docset:ContinuousSubcutaneousInsulinInfusion>CSII</docset:ContinuousSubcutaneousInsulinInfusion>. 

               CSII with the patient’s prestudy <docset:Comments>insulin </docset:Comments>will be restarted after </docset:ResumePrestudyCSIIRate></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 745.0; width: 2696.0; height: 163.0; page: 16;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 744.0; width: 600.0; height: 164.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 744.0; width: 250.0; height: 164.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 744.0; width: 230.0; height: 164.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 744.0; width: 221.0; height: 164.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 744.0; width: 437.0; height: 164.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 744.0; width: 350.0; height: 164.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 744.0; width: 608.0; height: 164.0; page: 16;}; "><dg:chunk structure="p">

               completion of assessment period (approximately <docset:AssessmentPeriodCompletionTime>420 minutes </docset:AssessmentPeriodCompletionTime>postdose). </dg:chunk></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 909.0; width: 2696.0; height: 55.0; page: 16;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 908.0; width: 600.0; height: 56.0; page: 16;}; "><docset:VisitsAdverseEventsHypoglycaemia>

               Adverse Events/Hypoglycaemia </docset:VisitsAdverseEventsHypoglycaemia></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 908.0; width: 250.0; height: 56.0; page: 16;}; "><docset:AdverseEventsHypoglycaemiaScreening>

                   X </docset:AdverseEventsHypoglycaemiaScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 908.0; width: 230.0; height: 56.0; page: 16;}; "><docset:AdverseEventsHypoglycaemiaStudyPeriodsPeriods1And2>

                   X </docset:AdverseEventsHypoglycaemiaStudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 908.0; width: 221.0; height: 56.0; page: 16;}; "><docset:AdverseEventsHypoglycaemiaFollow-UpaEarlyDiscontinuationb>

                   X </docset:AdverseEventsHypoglycaemiaFollow-UpaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 908.0; width: 437.0; height: 56.0; page: 16;}; "><docset:AdverseEventsHypoglycaemiaComments>

                        X </docset:AdverseEventsHypoglycaemiaComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 908.0; width: 350.0; height: 56.0; page: 16;}; "><docset:AdverseEventsHypoglycaemia>

                      X </docset:AdverseEventsHypoglycaemia></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 908.0; width: 608.0; height: 56.0; page: 16;}; "><docset:AdverseEventsHypoglycaemia /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 965.0; width: 2696.0; height: 56.0; page: 16;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 964.0; width: 600.0; height: 57.0; page: 16;}; "><docset:VisitsConcomitantMedications>

               <dg:chunk>Concomitant Medications </dg:chunk></docset:VisitsConcomitantMedications></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 964.0; width: 250.0; height: 57.0; page: 16;}; "><docset:ConcomitantMedicationsScreening>

                   X </docset:ConcomitantMedicationsScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 964.0; width: 230.0; height: 57.0; page: 16;}; "><docset:ConcomitantMedicationsStudyPeriodsPeriods1And2>

                   X </docset:ConcomitantMedicationsStudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 964.0; width: 221.0; height: 57.0; page: 16;}; "><docset:ConcomitantMedicationsFollow-UpaEarlyDiscontinuationb>

                   X </docset:ConcomitantMedicationsFollow-UpaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 964.0; width: 437.0; height: 57.0; page: 16;}; "><docset:ConcomitantMedicationsComments>

                        X </docset:ConcomitantMedicationsComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 964.0; width: 350.0; height: 57.0; page: 16;}; "><docset:ConcomitantMedications>

                      X </docset:ConcomitantMedications></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 964.0; width: 608.0; height: 57.0; page: 16;}; "><docset:ConcomitantMedications /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1022.0; width: 2696.0; height: 217.0; page: 16;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1021.0; width: 600.0; height: 218.0; page: 16;}; "><docset:VisitsPatientDischargeFromStudySite structure="h1">

               <dg:chunk>Patient Discharge </dg:chunk>from <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Site </dg:chunk></docset:VisitsPatientDischargeFromStudySite></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 900.0; top: 1021.0; width: 250.0; height: 218.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1150.0; top: 1021.0; width: 230.0; height: 218.0; page: 16;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1380.0; top: 1021.0; width: 221.0; height: 218.0; page: 16;}; "><docset:PatientDischargeFromStudySiteFollow-UpaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1601.0; top: 1021.0; width: 437.0; height: 218.0; page: 16;}; "><docset:PatientDischargeFromStudySiteComments>

                        X </docset:PatientDischargeFromStudySiteComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2038.0; top: 1021.0; width: 350.0; height: 218.0; page: 16;}; "><docset:PatientDischargeFromStudySite /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2388.0; top: 1021.0; width: 608.0; height: 218.0; page: 16;}; "><docset:PatientDischargeFromStudySite structure="p">

               If the next MMTT (Period 2) is scheduled on the next day, the patient may be discharged after the second MMTT (Period <docset:DischargeCriteria>2</docset:DischargeCriteria>). </docset:PatientDischargeFromStudySite></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:ScheduleofActivities></dg:chunk><dg:chunk><dg:chunk><dg:chunk structure="h1">

              Abbreviations: </dg:chunk><dg:chunk structure="div">BP = blood pressure; CSII = continuous subcutaneous <dgm:Medication>insulin </dgm:Medication>infusion; <dgm:MedicalTest>ECG </dgm:MedicalTest>= electrocardiogram; ED = early discontinuation; IWRS = <dg:chunk>Interactive Web Response System</dg:chunk>; MMTT = mixed meal <dgm:MedicalTest>tolerance <dgm:_testRef>test</dgm:_testRef></dgm:MedicalTest>; <dgm:Medication>NPH </dgm:Medication>= neutral <dgm:Medication>protamine </dgm:Medication>Hagedorn; PK = pharmacokinetics; SC = subcutaneous. </dg:chunk></dg:chunk><dg:chunk><dg:chunk><dg:chunk structure="p">

              a </dg:chunk><dg:chunk structure="p">

                     Safety follow-up visit should occur at least <docset:Follow-upVisit>14 days </docset:Follow-upVisit>after the last dose. </dg:chunk></dg:chunk><dg:chunk><docset:EarlyDiscontinuationProcedures structure="p">

              b Early discontinuation procedures will be performed at least <docset:EarlyDiscontinuationProcedures>14 days </docset:EarlyDiscontinuationProcedures>after a patient stops the <dgm:_testRef>study </dgm:_testRef>after receiving <dgm:_testRef>study </dgm:_testRef>drug on Day 1 of Period 1 and </docset:EarlyDiscontinuationProcedures><dg:chunk structure="p">

                     before Day <docset:TelephoneVisit>1 </docset:TelephoneVisit>of Period 2. c This is a telephone visit. </dg:chunk></dg:chunk><dg:chunk><dg:chunk structure="p">

              d </dg:chunk><docset:StudyProcedures structure="p">

                     In case of dosing on consecutive days, the medical assessments to be conducted on Day <docset:MedicalAssessmentSchedule>-1 </docset:MedicalAssessmentSchedule>of Period <docset:MedicalAssessmentSchedule>2 </docset:MedicalAssessmentSchedule>may be done on Day <docset:MedicalAssessmentSchedule>1 </docset:MedicalAssessmentSchedule>of Period 1. Note: The <dgm:_testRef>study </dgm:_testRef>site should schedule activities as appropriate. In cases where several <dgm:_testRef>study </dgm:_testRef>procedures are scheduled at the same time, the order of priority will be as follows: pharmacokinetic samples including <dgm:MedicalTest>blood sampling </dgm:MedicalTest>for blood glucose and laboratory samples per protocol nominal times. Electrocardiograms and vital sign measurements should be scheduled before but as close as possible to the PK sampling times. Injection-site assessments can be done after PK sampling. </docset:StudyProcedures></dg:chunk></dg:chunk></dg:chunk></dg:chunk></docset:Glucodynamic></docset:Glucodynamic-section><dg:chunk><docset:StudyScheduleProtocolI8B-MC-ITSAPartB-section><dg:chunk structure="h1">

              <dgm:_testRef>Study </dgm:_testRef>Schedule Protocol I8B-MC-ITSA (<dg:chunk>Part B</dg:chunk>) </dg:chunk><docset:StudyScheduleProtocolI8B-MC-ITSAPartB structure="div"><docset:StudySchedule><xhtml:table structure="table" style="boundingBox:{left: 300.0; top: 355.0; width: 2700.0; height: 1811.0; page: 17;}; boundingBox:{left: 300; top: 307; width: 2700; height: 1638; page: 18;}; boundingBox:{left: 300.0; top: 301.0; width: 2700.0; height: 1799.0; page: 19;}; boundingBox:{left: 300; top: 307; width: 2700; height: 1844; page: 20;}; boundingBox:{left: 300; top: 307; width: 2700; height: 1740; page: 21;}; boundingBox:{left: 300.0; top: 301.0; width: 2700.0; height: 1857.0; page: 22;}; boundingBox:{left: 299.9; top: 301.0; width: 2700.0; height: 769.0; page: 23;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 300.0; top: 355.0; width: 2700.0; height: 1811.0; page: 17;}; boundingBox:{left: 300; top: 307; width: 2700; height: 1638; page: 18;}; boundingBox:{left: 300.0; top: 301.0; width: 2700.0; height: 1799.0; page: 19;}; boundingBox:{left: 300; top: 307; width: 2700; height: 1844; page: 20;}; boundingBox:{left: 300; top: 307; width: 2700; height: 1740; page: 21;}; boundingBox:{left: 300.0; top: 301.0; width: 2700.0; height: 1857.0; page: 22;}; boundingBox:{left: 299.9; top: 301.0; width: 2700.0; height: 769.0; page: 23;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 355.0; width: 2700.0; height: 114.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 355.0; width: 638.0; height: 226.0; page: 17;}; " rowspan="2">

                           Visits </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 355.0; width: 492.0; height: 115.0; page: 17;}; " colspan="2"><dg:chunk structure="h1">

                     <dgm:_testRef>Screening </dgm:_testRef></dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 355.0; width: 662.0; height: 115.0; page: 17;}; " colspan="2"><dg:chunk structure="h1">

                        <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Periods </dg:chunk>(Periods <docset:StudyPeriods>1 </docset:StudyPeriods>and <docset:StudyPeriods>2</docset:StudyPeriods>) </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 355.0; width: 436.0; height: 115.0; page: 17;}; "><dg:chunk structure="h1">

                 Follow-upa/Early Discontinuationb </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 355.0; width: 472.0; height: 115.0; page: 17;}; "><dg:chunk structure="h1">

                     Comments </dg:chunk></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 470.0; width: 2700.0; height: 111.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 470.0; width: 248.0; height: 111.0; page: 17;}; "><docset:Visits102>

                                                <dgc:Number>102 </dgc:Number></docset:Visits102></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 470.0; width: 244.0; height: 111.0; page: 17;}; "><docset:_102Screening structure="h1">

                                             <dg:chunk>Telephone Visit </dg:chunk></docset:_102Screening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 470.0; width: 662.0; height: 111.0; page: 17;}; " colspan="2"><docset:_102StudyPeriodsPeriods1And2>

                                                         <docset:NumberofChildren>3 </docset:NumberofChildren>and <docset:Field4>4 </docset:Field4></docset:_102StudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 470.0; width: 436.0; height: 111.0; page: 17;}; "><docset:_102Follow-upaEarlyDiscontinuationb>

                                                     <dgc:Number>802 </dgc:Number></docset:_102Follow-upaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 470.0; width: 472.0; height: 111.0; page: 17;}; "><docset:_102Comments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 582.0; width: 2700.0; height: 162.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 581.0; width: 638.0; height: 163.0; page: 17;}; "><docset:VisitsDay structure="h1">

                           Day </docset:VisitsDay></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 581.0; width: 248.0; height: 163.0; page: 17;}; "><docset:DayScreening structure="h1">

                Within <docset:DaysPriortoDay-1>28 days </docset:DaysPriortoDay-1>Prior to Day <docset:DayBeforeEvent>-1 </docset:DayBeforeEvent></docset:DayScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 581.0; width: 244.0; height: 163.0; page: 17;}; "><docset:DayStudyPeriodsPeriods1And2>

               ≥ Day -10c </docset:DayStudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 581.0; width: 228.0; height: 163.0; page: 17;}; "><docset:DayFollow-upaEarlyDiscontinuationb>

                  -1d </docset:DayFollow-upaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 581.0; width: 434.0; height: 163.0; page: 17;}; "><docset:DayComments>

                        <dgc:Number>1 </dgc:Number></docset:DayComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 581.0; width: 436.0; height: 163.0; page: 17;}; "><docset:Day>

                  <docset:DischargeDate>≥14 days </docset:DischargeDate>After Discharge </docset:Day></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 581.0; width: 472.0; height: 163.0; page: 17;}; "><docset:Day /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 745.0; width: 2700.0; height: 217.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 744.0; width: 638.0; height: 218.0; page: 17;}; "><docset:VisitsInformedConsentAssent>

               Informed Consent/Assent </docset:VisitsInformedConsentAssent></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 744.0; width: 248.0; height: 218.0; page: 17;}; "><docset:InformedConsentAssentScreening>

                   Xe </docset:InformedConsentAssentScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 744.0; width: 244.0; height: 218.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 744.0; width: 228.0; height: 218.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 744.0; width: 434.0; height: 218.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 744.0; width: 436.0; height: 218.0; page: 17;}; "><docset:InformedConsentAssentComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 744.0; width: 472.0; height: 218.0; page: 17;}; "><docset:InformedConsentAssent structure="p">

               Should be obtained before any <dgm:_testRef>study</dgm:_testRef>-related procedures are performed. </docset:InformedConsentAssent></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 963.0; width: 2700.0; height: 55.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 962.0; width: 638.0; height: 56.0; page: 17;}; "><docset:VisitsInclusionExclusionCriteria>

               Inclusion/Exclusion Criteria </docset:VisitsInclusionExclusionCriteria></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 962.0; width: 248.0; height: 56.0; page: 17;}; "><docset:InclusionExclusionCriteriaScreening>

                   X </docset:InclusionExclusionCriteriaScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 962.0; width: 244.0; height: 56.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 962.0; width: 228.0; height: 56.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 962.0; width: 434.0; height: 56.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 962.0; width: 436.0; height: 56.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 962.0; width: 472.0; height: 56.0; page: 17;}; "><docset:InclusionExclusionCriteriaComments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1019.0; width: 2700.0; height: 55.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1018.0; width: 638.0; height: 56.0; page: 17;}; "><docset:VisitsMedicalHistory>

               <dg:chunk>Medical History </dg:chunk></docset:VisitsMedicalHistory></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 1018.0; width: 248.0; height: 56.0; page: 17;}; "><docset:MedicalHistoryScreening>

                   X </docset:MedicalHistoryScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 1018.0; width: 244.0; height: 56.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 1018.0; width: 228.0; height: 56.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 1018.0; width: 434.0; height: 56.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 1018.0; width: 436.0; height: 56.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 1018.0; width: 472.0; height: 56.0; page: 17;}; "><docset:MedicalHistoryComments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1075.0; width: 2700.0; height: 271.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1074.0; width: 638.0; height: 272.0; page: 17;}; "><docset:VisitsPre-existingConditions>

               Pre-existing Conditions </docset:VisitsPre-existingConditions></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 1074.0; width: 248.0; height: 272.0; page: 17;}; "><docset:Pre-existingConditionsScreening>

                   X </docset:Pre-existingConditionsScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 1074.0; width: 244.0; height: 272.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 1074.0; width: 228.0; height: 272.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 1074.0; width: 434.0; height: 272.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 1074.0; width: 436.0; height: 272.0; page: 17;}; "><docset:Pre-existingConditionsComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 1074.0; width: 472.0; height: 272.0; page: 17;}; "><docset:Pre-existingConditions structure="p">

               For patients continuing from <dg:chunk>Part A</dg:chunk>, a review will be performed to record any changes from the previous <dgm:_testRef>screening</dgm:_testRef>. </docset:Pre-existingConditions></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1347.0; width: 2700.0; height: 379.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1346.0; width: 638.0; height: 380.0; page: 17;}; "><docset:VisitsAge>

               Age </docset:VisitsAge></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 1346.0; width: 248.0; height: 380.0; page: 17;}; "><docset:AgeScreening>

                   X </docset:AgeScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 1346.0; width: 244.0; height: 380.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 1346.0; width: 228.0; height: 380.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 1346.0; width: 434.0; height: 380.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 1346.0; width: 436.0; height: 380.0; page: 17;}; "><docset:AgeComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 1346.0; width: 472.0; height: 380.0; page: 17;}; "><docset:Age structure="p">

               Applicable only to newly enrolled patients. For patients participating from <dg:chunk>Part A</dg:chunk>, age at initial <dgm:_testRef>screening </dgm:_testRef>(<dg:chunk>Part A</dg:chunk>) will be used for reporting purposes. </docset:Age></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1727.0; width: 2700.0; height: 55.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1726.0; width: 638.0; height: 56.0; page: 17;}; "><docset:VisitsHeight>

               Height </docset:VisitsHeight></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 1726.0; width: 248.0; height: 56.0; page: 17;}; "><docset:HeightScreening>

                   X </docset:HeightScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 1726.0; width: 244.0; height: 56.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 1726.0; width: 228.0; height: 56.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 1726.0; width: 434.0; height: 56.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 1726.0; width: 436.0; height: 56.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 1726.0; width: 472.0; height: 56.0; page: 17;}; "><docset:HeightComments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1783.0; width: 2700.0; height: 55.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1782.0; width: 638.0; height: 56.0; page: 17;}; "><docset:VisitsWeight>

               Weight </docset:VisitsWeight></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 1782.0; width: 248.0; height: 56.0; page: 17;}; "><docset:WeightScreening>

                   X </docset:WeightScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 1782.0; width: 244.0; height: 56.0; page: 17;}; "><docset:WeightStudyPeriodsPeriods1And2 /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 1782.0; width: 228.0; height: 56.0; page: 17;}; "><docset:WeightFollow-upaEarlyDiscontinuationb>

                   X </docset:WeightFollow-upaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 1782.0; width: 434.0; height: 56.0; page: 17;}; "><docset:WeightComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 1782.0; width: 436.0; height: 56.0; page: 17;}; "><docset:Weight>

                        X </docset:Weight></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 1782.0; width: 472.0; height: 56.0; page: 17;}; "><docset:Weight /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1839.0; width: 2700.0; height: 271.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1838.0; width: 638.0; height: 272.0; page: 17;}; "><docset:VisitsPhysicalExamination>

               <dg:chunk>Physical <dgm:_testRef>Examination </dgm:_testRef></dg:chunk></docset:VisitsPhysicalExamination></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 1838.0; width: 248.0; height: 272.0; page: 17;}; "><docset:PhysicalExaminationScreening>

                   X </docset:PhysicalExaminationScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 1838.0; width: 244.0; height: 272.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 1838.0; width: 228.0; height: 272.0; page: 17;}; "><docset:PhysicalExaminationFollow-upaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 1838.0; width: 434.0; height: 272.0; page: 17;}; "><docset:PhysicalExaminationComments>

                     Predose </docset:PhysicalExaminationComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 1838.0; width: 436.0; height: 272.0; page: 17;}; "><docset:PhysicalExamination>

                        X </docset:PhysicalExamination></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 1838.0; width: 472.0; height: 272.0; page: 17;}; "><docset:PhysicalExamination structure="p">

               Physical <dgm:_testRef>examination </dgm:_testRef>at <dgm:_testRef>screening</dgm:_testRef>. Thereafter, targeted medical assessment, as appropriate. </docset:PhysicalExamination></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 2111.0; width: 2700.0; height: 55.0; page: 17;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 2110.0; width: 638.0; height: 56.0; page: 17;}; "><docset:VisitsAdmissiontoStudySite>

               Admission to <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Site </dg:chunk></docset:VisitsAdmissiontoStudySite></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 2110.0; width: 248.0; height: 56.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 2110.0; width: 244.0; height: 56.0; page: 17;}; "><docset:AdmissiontoStudySiteStudyPeriodsPeriods1And2 /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 2110.0; width: 228.0; height: 56.0; page: 17;}; "><docset:AdmissiontoStudySiteFollow-upaEarlyDiscontinuationb>

                   X </docset:AdmissiontoStudySiteFollow-upaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 2110.0; width: 434.0; height: 56.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 2110.0; width: 436.0; height: 56.0; page: 17;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 2110.0; width: 472.0; height: 56.0; page: 17;}; "><docset:AdmissiontoStudySiteComments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 532; width: 2700; height: 163; page: 18;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 531; width: 636; height: 164; page: 18;}; "><docset:VisitsDay>

                           Day </docset:VisitsDay></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 531; width: 249; height: 164; page: 18;}; "><docset:DayScreening structure="h1">

                Within <docset:DaysPriortoDay-1>28 days </docset:DaysPriortoDay-1>Prior to Day <docset:DayBeforeEvent>-1 </docset:DayBeforeEvent></docset:DayScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1185; top: 531; width: 244; height: 164; page: 18;}; "><docset:DayStudyPeriodsPeriods1And2>

               ≥Day -10c </docset:DayStudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 531; width: 228; height: 164; page: 18;}; "><docset:DayFollow-upaEarlyDiscontinuationb>

                  -ld </docset:DayFollow-upaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 531; width: 434; height: 164; page: 18;}; "><docset:DayComments>

                        <dgc:Number>1 </dgc:Number></docset:DayComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 531; width: 435; height: 164; page: 18;}; "><docset:Day>

                  <docset:DischargeDate>≥14 days </docset:DischargeDate>After Discharge </docset:Day></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 531; width: 474; height: 164; page: 18;}; "><docset:Day /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 696; width: 2700; height: 271; page: 18;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 695; width: 636; height: 272; page: 18;}; "><docset:VisitsIWRSAndRandomisation>

               IWRS and Randomisation </docset:VisitsIWRSAndRandomisation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 695; width: 249; height: 272; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1185; top: 695; width: 244; height: 272; page: 18;}; "><docset:IWRSAndRandomisationStudyPeriodsPeriods1And2 /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 695; width: 228; height: 272; page: 18;}; "><docset:IWRSAndRandomisationFollow-upaEarlyDiscontinuationb>

                   X </docset:IWRSAndRandomisationFollow-upaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 695; width: 434; height: 272; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 695; width: 435; height: 272; page: 18;}; "><docset:IWRSAndRandomisationComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 695; width: 474; height: 272; page: 18;}; "><docset:IWRSAndRandomisation structure="p">

               Randomisation at Period <docset:AgeGroup>1 </docset:AgeGroup>only. Age group for randomisation will be based on initial <dgm:_testRef>screening</dgm:_testRef>. </docset:IWRSAndRandomisation></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 968; width: 2700; height: 163; page: 18;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 967; width: 636; height: 164; page: 18;}; "><docset:VisitsPreviousDiabetesTherapyRecordPrandialAndBasalInsulinDose structure="h1">

               Previous <dgm:Condition>Diabetes </dgm:Condition>Therapy Record Prandial and Basal <dgm:Medication>Insulin </dgm:Medication>Dose </docset:VisitsPreviousDiabetesTherapyRecordPrandialAndBasalInsulinDose></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 967; width: 249; height: 164; page: 18;}; "><docset:PreviousDiabetesTherapyRecordPrandialAndBasalInsulinDoseScreening>

                   X </docset:PreviousDiabetesTherapyRecordPrandialAndBasalInsulinDoseScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1185; top: 967; width: 244; height: 164; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 967; width: 228; height: 164; page: 18;}; "><docset:PreviousDiabetesTherapyRecordPrandialAndBasalInsulinDoseFollow-upaEarl /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 967; width: 434; height: 164; page: 18;}; "><docset:PreviousDiabetesTherapyRecordPrandialAndBasalInsulinDoseComments>

                       X* </docset:PreviousDiabetesTherapyRecordPrandialAndBasalInsulinDoseComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 967; width: 435; height: 164; page: 18;}; "><docset:PreviousDiabetesTherapyRecordPrandialAndBasalInsulinDose /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 967; width: 474; height: 164; page: 18;}; "><docset:PreviousDiabetesTherapyRecordPrandialAndBasalInsulinDose>

               *Period 1 only. </docset:PreviousDiabetesTherapyRecordPrandialAndBasalInsulinDose></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1132; width: 2700; height: 104; page: 18;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1131; width: 636; height: 105; page: 18;}; "><docset:VisitsVitalSignsPulseSittingBP structure="h1">

               <dgm:MedicalTest>Vital Signs </dgm:MedicalTest>(Pulse, Sitting BP) </docset:VisitsVitalSignsPulseSittingBP></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 1131; width: 249; height: 105; page: 18;}; "><docset:VitalSignsPulseSittingBPScreening>

                   X </docset:VitalSignsPulseSittingBPScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1185; top: 1131; width: 244; height: 105; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 1131; width: 228; height: 105; page: 18;}; "><docset:VitalSignsPulseSittingBPFollow-upaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 1131; width: 434; height: 105; page: 18;}; "><docset:VitalSignsPulseSittingBPComments structure="h1">

                 Pre- and <docset:PostdoseTime>2 hours </docset:PostdoseTime>postdose </docset:VitalSignsPulseSittingBPComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 1131; width: 435; height: 105; page: 18;}; "><docset:VitalSignsPulseSittingBP>

                       x </docset:VitalSignsPulseSittingBP></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 1131; width: 474; height: 105; page: 18;}; "><docset:VitalSignsPulseSittingBP /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1237; width: 2700; height: 114; page: 18;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1236; width: 636; height: 115; page: 18;}; "><docset:VisitsHipAndWaistCircumference structure="h1">

               Hip and <dg:chunk>Waist Circumference </dg:chunk></docset:VisitsHipAndWaistCircumference></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 1236; width: 249; height: 115; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1185; top: 1236; width: 244; height: 115; page: 18;}; "><docset:HipAndWaistCircumferenceStudyPeriodsPeriods1And2 /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 1236; width: 228; height: 115; page: 18;}; "><docset:HipAndWaistCircumferenceFollow-upaEarlyDiscontinuationb>

                  X </docset:HipAndWaistCircumferenceFollow-upaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 1236; width: 434; height: 115; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 1236; width: 435; height: 115; page: 18;}; "><docset:HipAndWaistCircumferenceComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 1236; width: 474; height: 115; page: 18;}; "><docset:HipAndWaistCircumference structure="h1">

               Applicable only to adult patients. </docset:HipAndWaistCircumference></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1352; width: 2700; height: 49; page: 18;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1351; width: 636; height: 50; page: 18;}; "><docset:VisitsEligibilityAssessment>

               <dg:chunk>Eligibility Assessment </dg:chunk></docset:VisitsEligibilityAssessment></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 1351; width: 249; height: 50; page: 18;}; "><docset:EligibilityAssessmentScreening>

                   X </docset:EligibilityAssessmentScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1185; top: 1351; width: 244; height: 50; page: 18;}; "><docset:EligibilityAssessmentStudyPeriodsPeriods1And2>

                   X </docset:EligibilityAssessmentStudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 1351; width: 228; height: 50; page: 18;}; "><docset:EligibilityAssessmentFollow-upaEarlyDiscontinuationb>

                  x* </docset:EligibilityAssessmentFollow-upaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 1351; width: 434; height: 50; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 1351; width: 435; height: 50; page: 18;}; "><docset:EligibilityAssessmentComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 1351; width: 474; height: 50; page: 18;}; "><docset:EligibilityAssessment>

               *Period 1 only. </docset:EligibilityAssessment></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1402; width: 2700; height: 325; page: 18;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1401; width: 636; height: 326; page: 18;}; "><docset:VisitsClinicalLaboratoryTests>

               <dg:chunk>Clinical Laboratory Tests </dg:chunk></docset:VisitsClinicalLaboratoryTests></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 1401; width: 249; height: 326; page: 18;}; "><docset:ClinicalLaboratoryTestsScreening>

                   x </docset:ClinicalLaboratoryTestsScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1185; top: 1401; width: 244; height: 326; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 1401; width: 228; height: 326; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 1401; width: 434; height: 326; page: 18;}; "><docset:ClinicalLaboratoryTestsComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 1401; width: 435; height: 326; page: 18;}; "><docset:ClinicalLaboratoryTests>

                       X </docset:ClinicalLaboratoryTests></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 1401; width: 474; height: 326; page: 18;}; "><docset:ClinicalLaboratoryTests structure="p">

               See Appendix <docset:AlcoholBreathTestResults>2 </docset:AlcoholBreathTestResults>for details. All patients of legal drinking age (according to local laws) will receive <dgm:MedicalTest>alcohol <dgm:MedicalTest>breath <dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest></dgm:MedicalTest>on Day <docset:AlcoholBreathTest>-1</docset:AlcoholBreathTest>. </docset:ClinicalLaboratoryTests></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1728; width: 2700; height: 115; page: 18;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1727; width: 636; height: 116; page: 18;}; "><docset:VisitsGlycatedHaemoglobinHbAlcAssessment>

               <dg:chunk>Glycated Haemoglobin </dg:chunk>(<dg:chunk><docset:GlycatedHaemoglobinAssessment>HbAlc</docset:GlycatedHaemoglobinAssessment>) Assessment </dg:chunk></docset:VisitsGlycatedHaemoglobinHbAlcAssessment></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 1727; width: 249; height: 116; page: 18;}; "><docset:GlycatedHaemoglobinHbAlcAssessmentScreening>

                   x </docset:GlycatedHaemoglobinHbAlcAssessmentScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1185; top: 1727; width: 244; height: 116; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 1727; width: 228; height: 116; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 1727; width: 434; height: 116; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 1727; width: 435; height: 116; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 1727; width: 474; height: 116; page: 18;}; "><docset:GlycatedHaemoglobinHbAlcAssessmentComments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1844; width: 2700; height: 49; page: 18;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1843; width: 636; height: 50; page: 18;}; "><docset:VisitsUrinalysis>

               <dgm:MedicalTest>Urinalysis </dgm:MedicalTest></docset:VisitsUrinalysis></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 1843; width: 249; height: 50; page: 18;}; "><docset:UrinalysisScreening>

                   X </docset:UrinalysisScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1185; top: 1843; width: 244; height: 50; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 1843; width: 228; height: 50; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 1843; width: 434; height: 50; page: 18;}; "><docset:UrinalysisComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 1843; width: 435; height: 50; page: 18;}; "><docset:Urinalysis>

                       X </docset:Urinalysis></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 1843; width: 474; height: 50; page: 18;}; "><docset:Urinalysis /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1894; width: 2700; height: 51; page: 18;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1893; width: 636; height: 52; page: 18;}; "><docset:Visits12-LeadECG>

               <docset:ECGLeads>12</docset:ECGLeads>-Lead <dgm:MedicalTest>ECG </dgm:MedicalTest></docset:Visits12-LeadECG></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 1893; width: 249; height: 52; page: 18;}; "><docset:_12-LeadECGScreening>

                   x </docset:_12-LeadECGScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1185; top: 1893; width: 244; height: 52; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 1893; width: 228; height: 52; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 1893; width: 434; height: 52; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 1893; width: 435; height: 52; page: 18;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 1893; width: 474; height: 52; page: 18;}; "><docset:_12-LeadECGComments /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 692.0; width: 2700.0; height: 810.0; page: 19;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 691.0; width: 638.0; height: 811.0; page: 19;}; "><docset:VisitsPregnancyTest>

               <dgm:MedicalTest><dgm:Condition>Pregnancy </dgm:Condition><dgm:_testRef>Test </dgm:_testRef></dgm:MedicalTest></docset:VisitsPregnancyTest></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 691.0; width: 248.0; height: 811.0; page: 19;}; "><docset:PregnancyTestScreening>

                   X </docset:PregnancyTestScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 691.0; width: 244.0; height: 811.0; page: 19;}; "><docset:PregnancyTestStudyPeriodsPeriods1And2 /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 691.0; width: 228.0; height: 811.0; page: 19;}; "><docset:PregnancyTestFollow-upaEarlyDiscontinuationb>

                   X </docset:PregnancyTestFollow-upaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 691.0; width: 434.0; height: 811.0; page: 19;}; "><docset:PregnancyTestComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 691.0; width: 436.0; height: 811.0; page: 19;}; "><docset:PregnancyTest>

                        X </docset:PregnancyTest></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 691.0; width: 472.0; height: 811.0; page: 19;}; "><docset:PregnancyTest structure="p">

               <dgm:Condition>Pregnancy </dgm:Condition>tests will be performed for all females <docset:PregnancyTestAgeLimit>≥12 years </docset:PregnancyTestAgeLimit>of age or &lt; <docset:PregnancyTestAgeLimit>12 years </docset:PregnancyTestAgeLimit>of age with onset of menses. Serum <dgm:Condition>pregnancy </dgm:Condition>tests will be performed at <dgm:_testRef>screening</dgm:_testRef>, and urine <dgm:MedicalTest><dgm:Condition>pregnancy </dgm:Condition><dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest>on Day <docset:PregnancyTesting>-1 </docset:PregnancyTesting>of Periods 1 and <docset:PregnancyTesting>2 </docset:PregnancyTesting>(or when clinically indicated), and at the follow-up or ED visit. Urine <dgm:Condition>pregnancy </dgm:Condition>tests at other visits accepted per local regulations. </docset:PregnancyTest></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1503.0; width: 2700.0; height: 379.0; page: 19;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1502.0; width: 638.0; height: 380.0; page: 19;}; "><docset:VisitsProvideEveningMealAndAdministerBolusInsulinInfusion structure="h1">

               Provide <dg:chunk>Evening Meal </dg:chunk>and <dg:chunk>Administer Bolus <dgm:Medication>Insulin </dgm:Medication>Infusion </dg:chunk></docset:VisitsProvideEveningMealAndAdministerBolusInsulinInfusion></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 1502.0; width: 248.0; height: 380.0; page: 19;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 1502.0; width: 244.0; height: 380.0; page: 19;}; "><docset:ProvideEveningMealAndAdministerBolusInsulinInfusionStudyPeriodsPeriods /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 1502.0; width: 228.0; height: 380.0; page: 19;}; "><docset:ProvideEveningMealAndAdministerBolusInsulinInfusionFollow-upaEarlyDisc>

                   X </docset:ProvideEveningMealAndAdministerBolusInsulinInfusionFollow-upaEarlyDisc></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 1502.0; width: 434.0; height: 380.0; page: 19;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 1502.0; width: 436.0; height: 380.0; page: 19;}; "><docset:ProvideEveningMealAndAdministerBolusInsulinInfusionComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 1502.0; width: 472.0; height: 380.0; page: 19;}; "><docset:ProvideEveningMealAndAdministerBolusInsulinInfusion structure="p">

               Provide instructions for replacement of pump reservoir/tubing/infusion set containing IP to occur following evening meal. Prandial <dgm:Medication>insulin </dgm:Medication>to be patient’s usual <dgm:Medication>insulin</dgm:Medication>. </docset:ProvideEveningMealAndAdministerBolusInsulinInfusion></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1883.0; width: 2700.0; height: 217.0; page: 19;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1882.0; width: 638.0; height: 218.0; page: 19;}; "><docset:VisitsBeginOvernightFast>

               Begin Overnight Fast </docset:VisitsBeginOvernightFast></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 1882.0; width: 248.0; height: 218.0; page: 19;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 1882.0; width: 244.0; height: 218.0; page: 19;}; "><docset:BeginOvernightFastStudyPeriodsPeriods1And2 /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 1882.0; width: 228.0; height: 218.0; page: 19;}; "><docset:BeginOvernightFastFollow-upaEarlyDiscontinuationb>

                   X </docset:BeginOvernightFastFollow-upaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 1882.0; width: 434.0; height: 218.0; page: 19;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 1882.0; width: 436.0; height: 218.0; page: 19;}; "><docset:BeginOvernightFastComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 1882.0; width: 472.0; height: 218.0; page: 19;}; "><docset:BeginOvernightFast structure="p">

               Patients will be fasted (except for water) for at least <docset:FastingPeriod>10 hours </docset:FastingPeriod>before each <dgm:_testRef>test </dgm:_testRef>meal. </docset:BeginOvernightFast></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 532; width: 2700; height: 163; page: 20;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 531; width: 636; height: 164; page: 20;}; "><docset:VisitsDay>

                           Day </docset:VisitsDay></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 531; width: 249; height: 164; page: 20;}; "><docset:DayScreening structure="h1">

                Within <docset:DaysPriortoDay-1>28 days </docset:DaysPriortoDay-1>Prior to Day <docset:DayBeforeEvent>-1 </docset:DayBeforeEvent></docset:DayScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1185; top: 531; width: 244; height: 164; page: 20;}; "><docset:DayStudyPeriodsPeriods1And2>

               ≥ Day -10c </docset:DayStudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 531; width: 228; height: 164; page: 20;}; "><docset:DayFollow-upaEarlyDiscontinuationb>

                  -ld </docset:DayFollow-upaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 531; width: 434; height: 164; page: 20;}; "><docset:DayComments>

                        <dgc:Number>1 </dgc:Number></docset:DayComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 531; width: 435; height: 164; page: 20;}; "><docset:Day>

                  <docset:DischargeDate>≥14 days </docset:DischargeDate>After Discharge </docset:Day></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 531; width: 474; height: 164; page: 20;}; "><docset:Day /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 696; width: 2700; height: 271; page: 20;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 695; width: 636; height: 272; page: 20;}; "><docset:VisitsReduceCSIIBasalRate>

               Reduce CSII basal rate </docset:VisitsReduceCSIIBasalRate></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 695; width: 249; height: 272; page: 20;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1185; top: 695; width: 244; height: 272; page: 20;}; "><docset:ReduceCSIIBasalRateStudyPeriodsPeriods1And2 /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 695; width: 228; height: 272; page: 20;}; "><docset:ReduceCSIIBasalRateFollow-upaEarlyDiscontinuationb>

                   X </docset:ReduceCSIIBasalRateFollow-upaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 695; width: 434; height: 272; page: 20;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 695; width: 435; height: 272; page: 20;}; "><docset:ReduceCSIIBasalRateComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 695; width: 474; height: 272; page: 20;}; "><docset:ReduceCSIIBasalRate><docset:BasalRateReduction structure="p">

               Prior to start of run-in. Applicable only to patients on CSII. Basal rate to be reduced to </docset:BasalRateReduction><dg:chunk structure="h1">

               <docset:DoseRate>0.1 </docset:DoseRate>U/hour. </dg:chunk></docset:ReduceCSIIBasalRate></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 968; width: 2700; height: 745; page: 20;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 967; width: 636; height: 746; page: 20;}; "><docset:VisitsRun-inStabilisationofGlucose>

               Run-in/Stabilisation of Glucose </docset:VisitsRun-inStabilisationofGlucose></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 967; width: 249; height: 746; page: 20;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1185; top: 967; width: 244; height: 746; page: 20;}; "><docset:Run-inStabilisationofGlucoseStudyPeriodsPeriods1And2 /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 967; width: 228; height: 746; page: 20;}; "><docset:Run-inStabilisationofGlucoseFollow-upaEarlyDiscontinuationb>

                   X following 

                evening meal) </docset:Run-inStabilisationofGlucoseFollow-upaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 967; width: 434; height: 746; page: 20;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 967; width: 435; height: 746; page: 20;}; "><docset:Run-inStabilisationofGlucoseComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 967; width: 474; height: 746; page: 20;}; "><docset:Run-inStabilisationofGlucose><dg:chunk structure="p">

               Approximately at <docset:StartTime>09:00 </docset:StartTime></dg:chunk><docset:GlucoseInfusion structure="p">

               to <docset:InfusionEndTime>10:00 PM </docset:InfusionEndTime>infusion of 

               glucose (<dgm:Medication>dextrose </dgm:Medication>solution) or CCI 

                     <dgm:Medication>insulin </dgm:Medication>to target a blood glucose concentration of <docset:TargetBloodGlucose>135</docset:TargetBloodGlucose>+<docset:BloodGlucoseTarget>25 </docset:BloodGlucoseTarget>mg/dL (<docset:TargetBloodGlucoseConcentration>7.5</docset:TargetBloodGlucoseConcentration>+<docset:BloodGlucoseMonitoring>1.4 </docset:BloodGlucoseMonitoring>mmol/L). Blood glucose concentrations will be monitored at a minimum of <docset:BloodGlucoseMonitoringFrequency>30- to </docset:BloodGlucoseMonitoringFrequency><docset:BloodGlucoseMonitoringInterval>60-minute </docset:BloodGlucoseMonitoringInterval>intervals. </docset:GlucoseInfusion></docset:Run-inStabilisationofGlucose></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1714; width: 2700; height: 386; page: 20;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1713; width: 636; height: 387; page: 20;}; "><docset:VisitsStudyDrugAdministrationSingleBolusViaCSII structure="h1">

               <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Drug Administration </dg:chunk>(<dg:chunk>Single Bolus </dg:chunk>via CSII) </docset:VisitsStudyDrugAdministrationSingleBolusViaCSII></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 1713; width: 249; height: 387; page: 20;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1185; top: 1713; width: 244; height: 387; page: 20;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 1713; width: 228; height: 387; page: 20;}; "><docset:StudyDrugAdministrationSingleBolusViaCSIIFollow-upaEarlyDiscontinuation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 1713; width: 434; height: 387; page: 20;}; "><docset:StudyDrugAdministrationSingleBolusViaCSIIComments>

                       x </docset:StudyDrugAdministrationSingleBolusViaCSIIComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 1713; width: 435; height: 387; page: 20;}; "><docset:StudyDrugAdministrationSingleBolusViaCSII /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 1713; width: 474; height: 387; page: 20;}; "><docset:StudyDrugAdministrationSingleBolusViaCSII structure="p">

               Time of <dgm:_testRef>study </dgm:_testRef>drug administration = <docset:TimeofStudyDrugAdministration>0 hour</docset:TimeofStudyDrugAdministration>. <dgm:_testRef>Study </dgm:_testRef>drug will be administered at approximately the same times on Day <docset:StudyDrugAdministrationTime>1 </docset:StudyDrugAdministrationTime>of each <dgm:_testRef>study </dgm:_testRef>period. </docset:StudyDrugAdministrationSingleBolusViaCSII></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 2101; width: 2700; height: 50; page: 20;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 2100; width: 636; height: 51; page: 20;}; "><docset:VisitsImmunogenicitySample>

               <dg:chunk>Immunogenicity Sample </dg:chunk></docset:VisitsImmunogenicitySample></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 2100; width: 249; height: 51; page: 20;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1185; top: 2100; width: 244; height: 51; page: 20;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 2100; width: 228; height: 51; page: 20;}; "><docset:ImmunogenicitySampleFollow-upaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 2100; width: 434; height: 51; page: 20;}; "><docset:ImmunogenicitySampleComments>

                     Predose </docset:ImmunogenicitySampleComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 2100; width: 435; height: 51; page: 20;}; "><docset:ImmunogenicitySample>

                       X </docset:ImmunogenicitySample></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 2100; width: 474; height: 51; page: 20;}; "><docset:ImmunogenicitySample /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 532; width: 2700; height: 158; page: 21;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 531; width: 636; height: 159; page: 21;}; "><docset:VisitsDay>

                           Day </docset:VisitsDay></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 531; width: 255; height: 159; page: 21;}; "><docset:DayScreening structure="h1">

                Within <docset:DaysPriortoDay-1>28 days </docset:DaysPriortoDay-1>Prior to Day <docset:DayBeforeEvent>-1 </docset:DayBeforeEvent></docset:DayScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1191; top: 531; width: 238; height: 159; page: 21;}; "><docset:DayStudyPeriodsPeriods1And2>

               ≥ Day -10c </docset:DayStudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 531; width: 228; height: 159; page: 21;}; "><docset:DayFollow-upaEarlyDiscontinuationb>

                  -ld </docset:DayFollow-upaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 531; width: 434; height: 159; page: 21;}; "><docset:DayComments>

                        <dgc:Number>1 </dgc:Number></docset:DayComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 531; width: 435; height: 159; page: 21;}; "><docset:Day>

                  <docset:DischargeDate>≥14 days </docset:DischargeDate>After Discharge </docset:Day></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 531; width: 474; height: 159; page: 21;}; "><docset:Day /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 691; width: 2700; height: 220; page: 21;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 690; width: 636; height: 221; page: 21;}; "><docset:VisitsCatheter-SiteEvaluation>

               <dg:chunk>Catheter-Site Evaluation </dg:chunk></docset:VisitsCatheter-SiteEvaluation></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 690; width: 255; height: 221; page: 21;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1191; top: 690; width: 238; height: 221; page: 21;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 690; width: 228; height: 221; page: 21;}; "><docset:Catheter-SiteEvaluationFollow-upaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 690; width: 434; height: 221; page: 21;}; "><docset:Catheter-SiteEvaluationComments structure="h1">

               <docset:PostdoseTime>0</docset:PostdoseTime>, <docset:PostdoseTimepoints>20</docset:PostdoseTimepoints>, <docset:PostdoseTime>40</docset:PostdoseTime>, <docset:PostdoseTime>60</docset:PostdoseTime>, and <docset:PostdoseTime>240 </docset:PostdoseTime>minutes postdose </docset:Catheter-SiteEvaluationComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 690; width: 435; height: 221; page: 21;}; "><docset:Catheter-SiteEvaluation /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 690; width: 474; height: 221; page: 21;}; "><docset:Catheter-SiteEvaluation structure="p">

               Time <docset:AssessmentTime>0</docset:AssessmentTime>: Assessments will occur immediately following the <dgm:_testRef>study </dgm:_testRef>drug administration </docset:Catheter-SiteEvaluation></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 912; width: 2700; height: 327; page: 21;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 911; width: 636; height: 328; page: 21;}; "><docset:VisitsDirectionsforPreparingforPKAndMMTTVisits structure="p">

               Directions for Preparing for PK and MMTT Visits </docset:VisitsDirectionsforPreparingforPKAndMMTTVisits></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 911; width: 255; height: 328; page: 21;}; "><docset:DirectionsforPreparingforPKAndMMTTVisitsScreening /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1191; top: 911; width: 238; height: 328; page: 21;}; "><docset:DirectionsforPreparingforPKAndMMTTVisitsStudyPeriodsPeriods1And2>

                   X </docset:DirectionsforPreparingforPKAndMMTTVisitsStudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 911; width: 228; height: 328; page: 21;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 911; width: 434; height: 328; page: 21;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 911; width: 435; height: 328; page: 21;}; "><docset:DirectionsforPreparingforPKAndMMTTVisitsComments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 911; width: 474; height: 328; page: 21;}; "><docset:DirectionsforPreparingforPKAndMMTTVisits structure="p">

               Patients will receive preparatory instructions as part of their pre-<dgm:_testRef>study </dgm:_testRef>telephone consultation (see Section 6.3, for details). </docset:DirectionsforPreparingforPKAndMMTTVisits></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1240; width: 2700; height: 433; page: 21;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1239; width: 636; height: 434; page: 21;}; "><docset:VisitsMixedMealToleranceTest>

               <dg:chunk>Mixed Meal <dgm:MedicalTest>Tolerance <dgm:_testRef>Test </dgm:_testRef></dgm:MedicalTest></dg:chunk></docset:VisitsMixedMealToleranceTest></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 1239; width: 255; height: 434; page: 21;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1191; top: 1239; width: 238; height: 434; page: 21;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 1239; width: 228; height: 434; page: 21;}; "><docset:MixedMealToleranceTestFollow-upaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 1239; width: 434; height: 434; page: 21;}; "><docset:MixedMealToleranceTestComments>

                       X </docset:MixedMealToleranceTestComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 1239; width: 435; height: 434; page: 21;}; "><docset:MixedMealToleranceTest /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 1239; width: 474; height: 434; page: 21;}; "><docset:MixedMealToleranceTest structure="p">

               A standard liquid meal will be administered at the <docset:MealAdministration>MMTT </docset:MealAdministration>time "<docset:MealAdministration>0</docset:MealAdministration>" (as soon as possible after administration of <dgm:_testRef>study </dgm:_testRef>drug) and should be consumed within <docset:MealConsumptionTime>15 minutes</docset:MealConsumptionTime>. </docset:MixedMealToleranceTest></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1674; width: 2700; height: 373; page: 21;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1673; width: 636; height: 374; page: 21;}; "><docset:VisitsBloodGlucoseSamplingMMTT>

               <dg:chunk><docset:BloodGlucoseSampling>Blood Glucose </docset:BloodGlucoseSampling>Sampling </dg:chunk>(<docset:BloodGlucoseSampling>MMTT</docset:BloodGlucoseSampling>) </docset:VisitsBloodGlucoseSamplingMMTT></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 936; top: 1673; width: 255; height: 374; page: 21;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1191; top: 1673; width: 238; height: 374; page: 21;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1429; top: 1673; width: 228; height: 374; page: 21;}; "><docset:BloodGlucoseSamplingMMTTFollow-upaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1657; top: 1673; width: 434; height: 374; page: 21;}; "><docset:BloodGlucoseSamplingMMTTComments structure="p">

                <docset:PremealBloodGlucose>-30</docset:PremealBloodGlucose>, - <docset:PostmealTime>15</docset:PostmealTime>, <docset:PostmealTime>0 </docset:PostmealTime>(premeal). <docset:PostmealTime>10</docset:PostmealTime>, <docset:PostmealTime>20</docset:PostmealTime>, <docset:PostmealTimeIntervals>30</docset:PostmealTimeIntervals>, <docset:PostmealTimeIntervals>40</docset:PostmealTimeIntervals>, <docset:PostmealTimeIntervals>50</docset:PostmealTimeIntervals>, <docset:PostmealTimeInterval>60</docset:PostmealTimeInterval>, <docset:PostmealTime>70</docset:PostmealTime>, <docset:PostmealTimeIntervals>80</docset:PostmealTimeIntervals>, <docset:PostmealTime>90</docset:PostmealTime>, <docset:PostmealTime>100</docset:PostmealTime>, <docset:PostmealTime>110</docset:PostmealTime>, <docset:PostmealTime>120</docset:PostmealTime>, <docset:PostmealTime>135</docset:PostmealTime>, <docset:PostmealBloodGlucoseTarget>150</docset:PostmealBloodGlucoseTarget>, <docset:PostmealTime>165</docset:PostmealTime>, <docset:PostmealTime>180</docset:PostmealTime>, <docset:PostmealTime>195</docset:PostmealTime>, <docset:PostmealTime>210</docset:PostmealTime>, <docset:PostmealTime>225 </docset:PostmealTime><docset:PostmealTimeIntervals>240</docset:PostmealTimeIntervals>, <docset:PostmealTimeIntervals>300 </docset:PostmealTimeIntervals>minutes (postmeal) </docset:BloodGlucoseSamplingMMTTComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2091; top: 1673; width: 435; height: 374; page: 21;}; "><docset:BloodGlucoseSamplingMMTT /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2526; top: 1673; width: 474; height: 374; page: 21;}; "><docset:BloodGlucoseSamplingMMTT structure="p">

               Time is referenced to meal start time. Time 0 is collected immediately prior to start of meal consumption. </docset:BloodGlucoseSamplingMMTT></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 692.0; width: 2700.0; height: 270.0; page: 22;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 691.0; width: 638.0; height: 271.0; page: 22;}; "><docset:VisitsInsulinLisproPKSampling>

               <dg:chunk><dgm:Medication><dgm:Medication>Insulin </dgm:Medication><docset:InsulinLispro>Lispro </docset:InsulinLispro></dgm:Medication>PK Sampling </dg:chunk></docset:VisitsInsulinLisproPKSampling></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 691.0; width: 248.0; height: 271.0; page: 22;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 691.0; width: 244.0; height: 271.0; page: 22;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 691.0; width: 228.0; height: 271.0; page: 22;}; "><docset:InsulinLisproPKSamplingFollow-upaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 691.0; width: 434.0; height: 271.0; page: 22;}; "><docset:InsulinLisproPKSamplingComments structure="p">

               <docset:PostdoseTime>0</docset:PostdoseTime>, <docset:PostdoseTimePoints>5</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>10</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>15</docset:PostdoseTimePoints>, <docset:PostdoseTimePoints>20</docset:PostdoseTimePoints>, <docset:PostdoseTimepoints>25</docset:PostdoseTimepoints>, <docset:PostdoseTimepoints>30</docset:PostdoseTimepoints>, <docset:PostdoseTimepoints>35</docset:PostdoseTimepoints>, <docset:MaximumDuration>40</docset:MaximumDuration>, <docset:MaximumDuration>45</docset:MaximumDuration>, <docset:MaximumDuration>50</docset:MaximumDuration>, <docset:MaximumDuration>60</docset:MaximumDuration>, <docset:MaximumDuration>70</docset:MaximumDuration>, <docset:MaximumDuration>90</docset:MaximumDuration>, <docset:MaximumDuration>120</docset:MaximumDuration>, <docset:MaximumDuration>150</docset:MaximumDuration>, <docset:MaximumDuration>180</docset:MaximumDuration>, <docset:MaximumDuration>240</docset:MaximumDuration>, <docset:MaximumDuration>300</docset:MaximumDuration>, <docset:MaximumDuration>360</docset:MaximumDuration>, and <docset:MaximumDuration>420 </docset:MaximumDuration>minutes postdose </docset:InsulinLisproPKSamplingComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 691.0; width: 436.0; height: 271.0; page: 22;}; "><docset:InsulinLisproPKSampling /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 691.0; width: 472.0; height: 271.0; page: 22;}; "><docset:InsulinLisproPKSampling structure="p">

               Sampling times are relative to the time of <dgm:_testRef>study </dgm:_testRef>drug treatment administration (t = <docset:SamplingTimes>0</docset:SamplingTimes>) in each period. </docset:InsulinLisproPKSampling></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 963.0; width: 2700.0; height: 595.0; page: 22;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 962.0; width: 638.0; height: 596.0; page: 22;}; "><docset:VisitsTransitiontoNPHTwiceDailyTherapy7-3DaysPriortoDay-1 structure="h1">

               Transition to <dgm:Medication>NPH </dgm:Medication><dg:chunk>Twice <dgc:Frequency>Daily </dgc:Frequency>Therapy </dg:chunk><docset:DaysPriortoDay-1>7</docset:DaysPriortoDay-1><docset:TransitiontoNPHTwiceDailyTherapy>-</docset:TransitiontoNPHTwiceDailyTherapy><docset:TransitionPeriod>3 days </docset:TransitionPeriod>Prior to Day <docset:Day-1>-1 </docset:Day-1></docset:VisitsTransitiontoNPHTwiceDailyTherapy7-3DaysPriortoDay-1></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 962.0; width: 248.0; height: 596.0; page: 22;}; "><docset:TransitiontoNPHTwiceDailyTherapy7-3DaysPriortoDay-1Screening /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 962.0; width: 244.0; height: 596.0; page: 22;}; "><docset:TransitiontoNPHTwiceDailyTherapy7-3DaysPriortoDay-1StudyPeriodsPer>

                   X </docset:TransitiontoNPHTwiceDailyTherapy7-3DaysPriortoDay-1StudyPeriodsPer></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 962.0; width: 228.0; height: 596.0; page: 22;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 962.0; width: 434.0; height: 596.0; page: 22;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 962.0; width: 436.0; height: 596.0; page: 22;}; "><docset:TransitiontoNPHTwiceDailyTherapy7-3DaysPriortoDay-1Comments /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 962.0; width: 472.0; height: 596.0; page: 22;}; "><docset:TransitiontoNPHTwiceDailyTherapy7-3DaysPriortoDay-1 structure="p">

               Applicable only to patients using multiple <dgc:Frequency>daily </dgc:Frequency>injection therapy. Patient can return to pre- <dgm:_testRef>study </dgm:_testRef>basal <dgm:Medication>insulin </dgm:Medication>following completion of MMTT sampling period per investigator’s decision and allowing for transition to <dgm:Medication>NPH </dgm:Medication>prior to next dosing. </docset:TransitiontoNPHTwiceDailyTherapy7-3DaysPriortoDay-1></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 1559.0; width: 2700.0; height: 487.0; page: 22;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 1558.0; width: 638.0; height: 488.0; page: 22;}; "><docset:VisitsResumePrestudyCSIIRate>

               Resume <dg:chunk>Prestudy CSII Rate </dg:chunk></docset:VisitsResumePrestudyCSIIRate></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 1558.0; width: 248.0; height: 488.0; page: 22;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 1558.0; width: 244.0; height: 488.0; page: 22;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 1558.0; width: 228.0; height: 488.0; page: 22;}; "><docset:ResumePrestudyCSIIRateFollow-upaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 1558.0; width: 434.0; height: 488.0; page: 22;}; "><docset:ResumePrestudyCSIIRateComments>

                        X </docset:ResumePrestudyCSIIRateComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 1558.0; width: 436.0; height: 488.0; page: 22;}; "><docset:ResumePrestudyCSIIRate /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 1558.0; width: 472.0; height: 488.0; page: 22;}; "><docset:ResumePrestudyCSIIRate structure="p">

               Applicable only to patients on <docset:RestartCSII>CSII</docset:RestartCSII>. CSII with the patient’s prestudy <dgm:Medication>insulin </dgm:Medication>will be restarted after completion of assessment period (approximately <docset:AssessmentPeriod>420 minutes </docset:AssessmentPeriod>postdose). </docset:ResumePrestudyCSIIRate></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 2047.0; width: 2700.0; height: 55.0; page: 22;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 2046.0; width: 638.0; height: 56.0; page: 22;}; "><docset:VisitsAdverseEventsHypoglycaemia>

               Adverse Events/Hypoglycaemia </docset:VisitsAdverseEventsHypoglycaemia></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 2046.0; width: 248.0; height: 56.0; page: 22;}; "><docset:AdverseEventsHypoglycaemiaScreening>

                   X </docset:AdverseEventsHypoglycaemiaScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 2046.0; width: 244.0; height: 56.0; page: 22;}; "><docset:AdverseEventsHypoglycaemiaStudyPeriodsPeriods1And2>

                   X </docset:AdverseEventsHypoglycaemiaStudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 2046.0; width: 228.0; height: 56.0; page: 22;}; "><docset:AdverseEventsHypoglycaemiaFollow-upaEarlyDiscontinuationb>

                   X </docset:AdverseEventsHypoglycaemiaFollow-upaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 2046.0; width: 434.0; height: 56.0; page: 22;}; "><docset:AdverseEventsHypoglycaemiaComments>

                        X </docset:AdverseEventsHypoglycaemiaComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 2046.0; width: 436.0; height: 56.0; page: 22;}; "><docset:AdverseEventsHypoglycaemia>

                        X </docset:AdverseEventsHypoglycaemia></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 2046.0; width: 472.0; height: 56.0; page: 22;}; "><docset:AdverseEventsHypoglycaemia /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300.0; top: 2103.0; width: 2700.0; height: 55.0; page: 22;}; "><xhtml:td structure="td" style="boundingBox:{left: 300.0; top: 2102.0; width: 638.0; height: 56.0; page: 22;}; "><docset:VisitsConcomitantMedications>

               <dg:chunk>Concomitant Medications </dg:chunk></docset:VisitsConcomitantMedications></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 938.0; top: 2102.0; width: 248.0; height: 56.0; page: 22;}; "><docset:ConcomitantMedicationsScreening>

                   X </docset:ConcomitantMedicationsScreening></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1186.0; top: 2102.0; width: 244.0; height: 56.0; page: 22;}; "><docset:ConcomitantMedicationsStudyPeriodsPeriods1And2>

                   X </docset:ConcomitantMedicationsStudyPeriodsPeriods1And2></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1430.0; top: 2102.0; width: 228.0; height: 56.0; page: 22;}; "><docset:ConcomitantMedicationsFollow-upaEarlyDiscontinuationb>

                   X </docset:ConcomitantMedicationsFollow-upaEarlyDiscontinuationb></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1658.0; top: 2102.0; width: 434.0; height: 56.0; page: 22;}; "><docset:ConcomitantMedicationsComments>

                        X </docset:ConcomitantMedicationsComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2092.0; top: 2102.0; width: 436.0; height: 56.0; page: 22;}; "><docset:ConcomitantMedications>

                        X </docset:ConcomitantMedications></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2528.0; top: 2102.0; width: 472.0; height: 56.0; page: 22;}; "><docset:ConcomitantMedications /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 299.9; top: 692.0; width: 2700.0; height: 378.0; page: 23;}; "><xhtml:td structure="td" style="boundingBox:{left: 299.9; top: 691.0; width: 638.0; height: 379.0; page: 23;}; "><docset:VisitsPatientDischargeFromStudySite structure="h1">

               <dg:chunk>Patient Discharge </dg:chunk>from <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Site </dg:chunk></docset:VisitsPatientDischargeFromStudySite></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 937.9; top: 691.0; width: 248.0; height: 379.0; page: 23;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1185.9; top: 691.0; width: 244.0; height: 379.0; page: 23;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1429.9; top: 691.0; width: 228.0; height: 379.0; page: 23;}; "><docset:PatientDischargeFromStudySiteFollow-upaEarlyDiscontinuationb /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1657.9; top: 691.0; width: 434.0; height: 379.0; page: 23;}; "><docset:PatientDischargeFromStudySiteComments>

                        X </docset:PatientDischargeFromStudySiteComments></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2091.9; top: 691.0; width: 436.0; height: 379.0; page: 23;}; "><docset:PatientDischargeFromStudySite /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2527.9; top: 691.0; width: 472.0; height: 379.0; page: 23;}; "><docset:PatientDischargeFromStudySite structure="p">

               If the next MMTT (Period 2) is scheduled on the next day, the patient may be discharged after the second MMTT (Period <docset:DischargeCriteria>2</docset:DischargeCriteria>). </docset:PatientDischargeFromStudySite></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:StudySchedule><dg:chunk><dg:chunk><dg:chunk structure="h1">

              Abbreviations: </dg:chunk><dg:chunk structure="div">BP = blood pressure; CSII = continuous subcutaneous <dgm:Medication>insulin </dgm:Medication>infusion; <dgm:MedicalTest>ECG </dgm:MedicalTest>= electrocardiogram; ED = early discontinuation; IWRS = <dg:chunk>Interactive Web Response System</dg:chunk>; MMTT = mixed meal <dgm:MedicalTest>tolerance <dgm:_testRef>test</dgm:_testRef></dgm:MedicalTest>; <dgm:Medication>NPH </dgm:Medication>= neutral <dgm:Medication>protamine </dgm:Medication>Hagedorn; PK = pharmacokinetics; SC = subcutaneous. </dg:chunk></dg:chunk><dg:chunk><dg:chunk><dg:chunk structure="p">

              a </dg:chunk><docset:SafetyFollow-upVisit structure="p">

                     Safety follow-up visit should occur at least <docset:Follow-upVisit>14 days </docset:Follow-upVisit>after the completion of Period 2. </docset:SafetyFollow-upVisit></dg:chunk><dg:chunk><docset:EarlyDiscontinuationProcedures structure="p">

              b Early discontinuation procedures will be performed at least <docset:EarlyDiscontinuationProcedures>14 days </docset:EarlyDiscontinuationProcedures>after a patient stops the <dgm:_testRef>study </dgm:_testRef>after receiving <dgm:_testRef>study </dgm:_testRef>drug on Day 1 of Period 1 and </docset:EarlyDiscontinuationProcedures><dg:chunk structure="p">

                     before Day <docset:Period2StartDate>1 </docset:Period2StartDate>of Period <docset:Period2StartDate>2</docset:Period2StartDate>. </dg:chunk></dg:chunk><dg:chunk structure="p">

              c This is a telephonic visit. </dg:chunk><dg:chunk><dg:chunk structure="p">

              d </dg:chunk><docset:MedicalAssessments structure="p">

                     In case of dosing on consecutive days, the medical assessments to be conducted on Day <docset:Day-1MedicalAssessments>-1 </docset:Day-1MedicalAssessments>of Period <docset:MedicalAssessmentSchedule>2 </docset:MedicalAssessmentSchedule>may be done on Day <docset:MedicalAssessmentSchedule>1 </docset:MedicalAssessmentSchedule>of Period 1. </docset:MedicalAssessments></dg:chunk></dg:chunk></dg:chunk></docset:StudyScheduleProtocolI8B-MC-ITSAPartB></docset:StudyScheduleProtocolI8B-MC-ITSAPartB-section><dg:chunk structure="h1">

              e Not applicable for patients continuing from Part A. </dg:chunk></dg:chunk><dg:chunk><dg:chunk structure="h1">

              Note: </dg:chunk><dg:chunk structure="div"><docset:StudyProcedures structure="p">The <dgm:_testRef>study </dgm:_testRef>site should schedule activities as appropriate. In cases where several <dgm:_testRef>study </dgm:_testRef>procedures are scheduled at the same time, the order of priority will be as follows: pharmacokinetic samples including <dgm:MedicalTest>blood sampling </dgm:MedicalTest>for blood glucose and laboratory samples per protocol nominal times. Vital sign and measurements should be scheduled before but as close as possible to the PK sampling times. Catheter-site assessments can be performed after PK sampling. </docset:StudyProcedures><dg:chunk><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 1041.7; top: 308.3; width: 462.5; height: 66.7; page: 24;}; "><dg:chunk structure="li" style="boundingBox:{left: 1041.7; top: 308.3; width: 462.5; height: 66.7; page: 24;}; "><dg:chunk structure="lim" style="boundingBox:{left: 1041.7; top: 308.3; width: 54.2; height: 66.7; page: 24;}; ">

                                                 3. </dg:chunk><dg:chunk structure="h1">Introduction </dg:chunk></dg:chunk></dg:chunk><dg:chunk><docset:StudyObjectives structure="ol" style="list-style-type: decimal; boundingBox:{left: 295.8; top: 441.7; width: 591.7; height: 1087.5; page: 24;}; "><dg:chunk structure="li" style="boundingBox:{left: 295.8; top: 441.7; width: 1950.0; height: 961.3; page: 24;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 441.7; width: 95.8; height: 58.3; page: 24;}; ">

              3.1. </dg:chunk><dg:chunk><docset:StudyRationale structure="h1"><dgm:_testRef>Study </dgm:_testRef>Rationale </docset:StudyRationale><dg:chunk structure="div">              A prandial <dgm:Medication>insulin </dgm:Medication>with faster-on and/or faster-off characteristics might reduce glycaemic excursions and the incidence of postprandial hypoglycaemia compared to currently available fast-acting <dgm:Medication>insulin </dgm:Medication>analogues. LY900014 is an ultra-rapid-acting <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>formulation with increased early absorption compared to commercially available <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>formulation (<docset:InsulinLispro><dgm:Medication>Humalog</dgm:Medication>®</docset:InsulinLispro>; <docset:StudyDescription><dg:chunk>Eli Lilly </dg:chunk>and Company)</docset:StudyDescription>. <dg:chunk>LY900014 </dg:chunk>aims to mimic the physiological prandial <dgm:Medication>insulin </dgm:Medication>secretion pattern, which may more effectively control postprandial glucose excursions. This faster profile may help to overcome commonly observed difficulties in <dgm:Medication>insulin </dgm:Medication>therapy in paediatric patients such as increasing weight, height, and caloric needs as well as unpredictable eating behaviour of young children and peripheral resistance of puberty.               The aim of the <dgm:_testRef>study </dgm:_testRef>is to evaluate <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>pharmacokinetics (PK), glucodynamics (GD), safety, and tolerability of LY900014 in comparison with <dgm:Medication>Humalog </dgm:Medication>following a single subcutaneous (SC) dose administration immediately prior to a standardised liquid meal in paediatric and adult patients with type 1 <dgm:Condition><dgm:Condition>diabetes </dgm:Condition>mellitus </dgm:Condition>(<dg:chunk>T1DM</dg:chunk>). This will be the first <dgm:_testRef>study </dgm:_testRef>to evaluate LY900014 in paediatric patients with <dg:chunk>T1DM</dg:chunk>. </dg:chunk></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 295.8; top: 1470.8; width: 1950.0; height: 1525.0; page: 24;}; "><dg:chunk structure="lim" style="boundingBox:{left: 295.8; top: 1470.8; width: 100.0; height: 58.3; page: 24;}; ">

              3.2. </dg:chunk><docset:Background-section><dg:chunk structure="h1">Background </dg:chunk><docset:Background structure="div">              The <dgm:Medication>insulin </dgm:Medication>analogue, <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>(<dgm:Medication>Humalog</dgm:Medication>), has shown to be absorbed more quickly than regular human <dgm:Medication>insulin </dgm:Medication>(RHI) (<dgm:Medication>Humalog </dgm:Medication>package insert, <docset:InsulinAbsorption>2015</docset:InsulinAbsorption>). In healthy volunteers given SC doses of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>ranging from <docset:InsulinAbsorption>0.1 </docset:InsulinAbsorption>to <docset:InsulinAbsorption>0.4 </docset:InsulinAbsorption>units (U)/kg, peak serum levels were seen <docset:InsulinAbsorption>30 </docset:InsulinAbsorption>to <docset:InsulinAbsorptionTime>90 minutes </docset:InsulinAbsorptionTime>after dosing (<dgm:Medication>Humalog </dgm:Medication>package insert, <dg:chunk xsi:type="date">2015</dg:chunk>). The persistent delays in absorption and variability in the duration of action of currently available rapid-acting <dgm:Medication>insulin </dgm:Medication>analogues contribute to commonly observed difficulties of <dgm:Medication>insulin </dgm:Medication>therapy in youths (due to increasing weight, height, peripheral resistance of puberty, changes in caloric needs, and unpredictable eating behaviour of younger youths; Cengiz <docset:InsulinAbsorption>2012</docset:InsulinAbsorption>). An ultra-rapid-acting prandial <dgm:Medication>insulin </dgm:Medication>would shift the PK/GD of <dgm:Medication>insulin </dgm:Medication>analogues so that they have an even faster onset to better match carbohydrate absorption and lead to improved postprandial glucose that also allows greater flexibility in the time of dosing relative to meals.               Regional evidence suggests that the incidence of <dg:chunk>T1DM </dg:chunk>in youths is increasing in the US (<docset:InsulinAbsorption>Lipman </docset:InsulinAbsorption>et al. <docset:InsulinAbsorption>2013</docset:InsulinAbsorption>) and Europe (<dg:chunk>EURODIAB ACE <dgm:_testRef>Study </dgm:_testRef>Group </dg:chunk>2000). Estimates of T1DM prevalence in the paediatric population in the US come from the Centers for <dg:chunk>Disease Control </dg:chunk>and Prevention-sponsored SEARCH for <dgm:Condition>Diabetes </dgm:Condition>in <dg:chunk>Youth (SEARCH) <dgm:_testRef>Study </dgm:_testRef></dg:chunk>(SEARCH for <dgm:Condition>Diabetes </dgm:Condition>in <dg:chunk>Youth <dgm:_testRef>Study </dgm:_testRef>Group </dg:chunk><docset:InsulinAbsorption>2009</docset:InsulinAbsorption>), which collects <dgm:Condition>diabetes </dgm:Condition>diagnosis information from multiple centres throughout the US. This <dgm:_testRef>study </dgm:_testRef>estimated the 2001 prevalence of <dg:chunk>T1DM </dg:chunk>among children under <docset:InsulinAbsorption>10 years </docset:InsulinAbsorption>of age to be <docset:InsulinAbsorption>0.76 </docset:InsulinAbsorption>per <dgc:Number>1000</dgc:Number>; amongst adolescents <docset:InsulinAbsorption>10 </docset:InsulinAbsorption>to 19 <docset:DurationofStudy>years </docset:DurationofStudy>of age, the risk more than doubled to <docset:InsulinAbsorption>2.28 </docset:InsulinAbsorption>cases per <docset:InsulinAbsorption>1000</docset:InsulinAbsorption>. More recently, the SEARCH <dgm:_testRef>study </dgm:_testRef>estimated that in <docset:InsulinAbsorption>2011 </docset:InsulinAbsorption>the total number of youth in the US &lt;<docset:InsulinAbsorption>20 </docset:InsulinAbsorption>years of age with <dg:chunk>T1DM </dg:chunk>was <docset:InsulinAbsorption>166,984 </docset:InsulinAbsorption>(Pettit et al. <docset:InsulinAbsorption>2014</docset:InsulinAbsorption>). As with adults, intensive <dgm:Condition>diabetes </dgm:Condition>management through maintenance of tight glycaemic control helps to delay onset and slow the progression of complications of the disease in youths (DCCT 1993). Tight glycaemic control is achieved via intensive <dgm:Medication>insulin </dgm:Medication>therapy, which requires </docset:Background></docset:Background-section></dg:chunk></docset:StudyObjectives><dg:chunk><docset:IntensiveInsulinTreatment structure="p">

              dietary discipline, frequent blood glucose monitoring, and multiple injections of <dgm:Medication>insulin </dgm:Medication>(both rapid- and long-acting <dgm:Medication>insulin</dgm:Medication>) to mimic the natural pattern of <dgm:Medication>insulin </dgm:Medication>release, the combination of which represents a major burden on the patient, especially youths. Intensive <dgm:Medication>insulin </dgm:Medication>treatment in <dg:chunk>T1DM </dg:chunk>should be initiated early in disease progression and the improved glycaemic control may have a lasting impact on reducing the onset of diabetic complications. </docset:IntensiveInsulinTreatment><dg:chunk><docset:NewFormulation structure="p">

              <docset:FormulationDescription>LY900014 </docset:FormulationDescription>represents a new formulation that contains <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro</dgm:Medication>, <dgm:Medication>treprostinil</dgm:Medication>, citrate, and other excipients. This formulation involves the novel use of a microdose of <dgm:Medication>treprostinil </dgm:Medication></docset:NewFormulation><dg:chunk><docset:LY900014Formulation structure="p">

                             ; an excipient to enhance the absorption of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>by local vasodilatation rather than as an active pharmaceutical ingredient to to elicit a Si Si fect. <dgm:Medication>Treprostinil </dgm:Medication>is a prostacyclin analogue, administered either through inhalati CCI ,as an intravenous (IV) infusion, or as a continuous SC administration for the treatment of symptomatic pulmonary arterial <dgm:Condition>hypertension </dgm:Condition>(PAH) and has been approved in the US since <docset:Formulation>2002 </docset:Formulation>and for SC administration in Germany since <docset:Excipients>200</docset:Excipients>: In adults dosed with <docset:Excipients>LY900014</docset:Excipients>, systemic <dgm:Medication>treprostinil </dgm:Medication>was unmeasurable and no haemodynamic effects were noted with a <dgm:Medication>treprostinil </dgm:Medication>dose equivalent that contained in of LY900014. <dgm:Medication>Sodium </dgm:Medication>citrate, an excipient that speeds up <dgm:Medication>insulin </dgm:Medication>absorption (at least in part by enhancing vascular permeability), is also included in the formulation to further enhance the absorption of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro</dgm:Medication>. Each of the other excipients (such as <dgm:Medication><dgm:Medication>magnesium </dgm:Medication>chloride</dgm:Medication>) in the LY900014 formulation is listed in the US <docset:Excipients>Food and Drug Administration (FDA</docset:Excipients>)'s Generally Recognized as Safe Food Additives database and in the FDA's Inactive Ingredients in Approved Drugs database. Furthermore, concentration of the excipients in LY900014 is within the limits identified for approved drug products in the <dg:chunk>FDA Inactive Ingredients </dg:chunk>in Approved Drugs database. </docset:LY900014Formulation><docset:StudyDesign structure="p">

              To date, LY900014 has been administered to approximately <docset:StudyPopulation>89 </docset:StudyPopulation>adult patients with <dgm:Condition>diabetes </dgm:Condition>(<dgc:Number>60 </dgc:Number><dg:chunk>T1DM </dg:chunk>and <docset:StudyResults>29 </docset:StudyResults>type 2 <dgm:Condition><dgm:Condition>diabetes </dgm:Condition>mellitus </dgm:Condition>[T2DM]). The total <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>exposure was similar between LY900014 and <dgm:Medication>Humalog</dgm:Medication>; however, LY900014 demonstrated a faster and earlier <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>absorption compared to <dgm:Medication>Humalog</dgm:Medication>. LY900014 displayed proportional increases in <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>exposure (area under the concentration versus time curve [AUC] and maximum observed drug concentration (Cmax) with dose. The faster early <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>absorption was maintained across the dose range studied (7.5 to 15 U). Additionally, through the use of multiple <dgc:Frequency>daily </dgc:Frequency>injections of <docset:ClinicalTrialResults>LY900014 </docset:ClinicalTrialResults>for up to <docset:TreatmentDuration>2 weeks </docset:TreatmentDuration>in patients with either <dg:chunk>T1DM </dg:chunk>or T2DM, it was found that LY900014 was well tolerated. Data from these Phase 1b studies show there was only 1 sample with quantifiable plasma <dgm:Medication>treprostinil </dgm:Medication>concentrations from approximately <docset:NumberofSamples>472 </docset:NumberofSamples>samples taken from a total of <docset:NumberofPatients>60 </docset:NumberofPatients>patients with <dg:chunk>T1DM </dg:chunk>and T2DM following administration of <dgc:Number>LY900014 </dgc:Number>using doses up to <docset:StudyDesign>50 </docset:StudyDesign>U per SC bolus injection. In addition, no quantifiable plasma <dgm:Medication>treprostinil </dgm:Medication>concentrations were observed with continuous subcutaneous <dgm:Medication>insulin </dgm:Medication>infusion (CSII) therapy during the basal infusion or after the bolus dose in <docset:StudyDesign>30 </docset:StudyDesign>patients. There were no serious adverse events (SAEs) related to <dgm:_testRef>study </dgm:_testRef>treatment or discontinuations from the studies because of a drug- related adverse event (AE). Small numbers of treatment-emergent adverse events were reported, and there were no notable increases in these events in relation to any of the <dg:chunk>LY900014 </dg:chunk>formulations compared to those in relation to <dgm:Medication>Humalog</dgm:Medication>. There were no reported cases of severe hypoglycaemia. Additionally, there were no reported incidences of local or systemic allergic reactions. </docset:StudyDesign></dg:chunk></dg:chunk></dg:chunk></dg:chunk><dg:chunk><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 294; top: 314.6; width: 855.9; height: 60.4; page: 26;}; "><dg:chunk structure="li" style="boundingBox:{left: 294; top: 314.6; width: 855.9; height: 60.4; page: 26;}; "><dg:chunk structure="lim" style="boundingBox:{left: 294; top: 310; width: 112; height: 65; page: 26;}; ">

              3.3. </dg:chunk><dg:chunk structure="h1">Benefit/Risk Assessment </dg:chunk></dg:chunk></dg:chunk><dg:chunk><docset:StudyBenefits structure="p">

              This <dgm:_testRef>study </dgm:_testRef>will not offer any direct benefits to the patients participating in the <dgm:_testRef>study</dgm:_testRef>. The data from previous adult studies in healthy subjects and patients with <dg:chunk>T1DM </dg:chunk>and T2DM have shown that LY900014 was well tolerated and the adverse drug reactions are in keeping with those reported for <dgm:Medication>Humalog</dgm:Medication>. </docset:StudyBenefits><dg:chunk><docset:PotentialRisks structure="p">

              Potential risks associated with <docset:Risks>LY900014</docset:Risks>, derived from the known risks of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>(<dgm:Medication>Humalog</dgm:Medication>), are hypoglycaemia, hypersensitivity reactions (localised <dgm:Condition>allergy </dgm:Condition>and/or systemic <dgm:Condition>allergy</dgm:Condition>), undesirable effects at the injection site (injection-site reactions and <dgm:Condition>lipodystrophy</dgm:Condition>), and peripheral oedema (<dgm:Medication>Humalog </dgm:Medication>package insert, <docset:PotentialRisks>2015</docset:PotentialRisks>). </docset:PotentialRisks><docset:TreprostinilExposure structure="p">

              Notably, across all doses in the adult studies that have evaluated <dgm:Medication>treprostinil </dgm:Medication>as a local vasodilator with or without <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro</dgm:Medication>, there was no clinically significant increase in those AEs associated with systemic absorption of <dgm:Medication>treprostinil</dgm:Medication>, as described in the The exposures of <dgm:Medication>treprostinil </dgm:Medication>in <docset:TreprostinilExposure>LY900014 </docset:TreprostinilExposure>in this <dgm:_testRef>study </dgm:_testRef>are compared to those observed in the dose ranges previously explored with SC bolus administration of <dgm:Medication>treprostinil </dgm:Medication>and are expected to be substantially lower than those observed in the treatment of PAH </docset:TreprostinilExposure></dg:chunk><dg:chunk><docset:TreprostinilUseinChildren structure="p">

              There are limited data on the use of <dgm:Medication>treprostinil </dgm:Medication>in paediatric patients. Paediatric assessments </docset:TreprostinilUseinChildren><dg:chunk><docset:TreprostinilSafety structure="p">

              have not been required for <dgm:Medication>treprostinil </dgm:Medication>because of its orphan drug designation; thus, the safety </docset:TreprostinilSafety><dg:chunk><docset:TreprostinilSafetyandEffectiveness structure="p">

              and effectiveness of <dgm:Medication>treprostinil </dgm:Medication>in paediatric patients have not been established CCI </docset:TreprostinilSafetyandEffectiveness><docset:TreprostinilExposure structure="p">

                                 Subcutaneous <dgm:Medication>treprostinil </dgm:Medication>has been evaluated in children with <docset:TreprostinilDose>PAH </docset:TreprostinilDose>in an observational <dgm:_testRef>study </dgm:_testRef>(n=8). Patients initially received a fixed <dgm:Medication>treprostinil </dgm:Medication>dose of <docset:InitialDose>1.25 </docset:InitialDose>ng/kg/min, which was gradually increased according to general and local tolerance, reaching a median of <docset:TreprostinilExposure>40 </docset:TreprostinilExposure>ng/kg/min (range, <docset:TreprostinilExposure>37 </docset:TreprostinilExposure>to 60 ng/kg/min) over the duration of follow-up (<docset:TreatmentDuration>6- to 18-month time </docset:TreatmentDuration>period) after initiation of <dgm:Medication>treprostinil </dgm:Medication>therapy. <docset:NumberofChildren>Six </docset:NumberofChildren>children had symptomatic and haemodynamic response to the addition of SC <dgm:Medication>treprostinil</dgm:Medication>, with manageable control of local injection-site discomfort (<docset:TreprostinilDose>Levy </docset:TreprostinilDose>et al. <docset:TreprostinilDose>2011</docset:TreprostinilDose>). The amount of <dgm:Medication>treprostinil </dgm:Medication>will vary based upon the <docset:TreprostinilExposure>LY900014 </docset:TreprostinilExposure>dose administered CCI and <dgm:Medication>treprostinil </dgm:Medication>exposure has not been detected in adults a 1b multiple <dgc:Frequency>daily </dgc:Frequency>injection (MDI) studies or with CSII therapy during the basal infusion (up to <docset:TreprostinilExposure>1.6 </docset:TreprostinilExposure>U/h containing <docset:TreprostinilExposure>16 </docset:TreprostinilExposure>ng/h of <dgm:Medication>treprostinil</dgm:Medication>) or after the bolus dose CCI On average, the paediatric population will use a lower preprandial <dgm:Medication>insulin </dgm:Medication>dose, further lowering exposure to <dgm:Medication>treprostinil </dgm:Medication>in this population. </docset:TreprostinilExposure></dg:chunk></dg:chunk></dg:chunk><dg:chunk><docset:SafetyInformation structure="p">

              In preclinical safety pharmacology and toxicity studies, or clinical pharmacology studies involving <docset:DrugName>LY900014 </docset:DrugName>or <dgm:Medication>treprostinil </dgm:Medication>alone, other than known risks associated with <dgm:Medication>Humalog </dgm:Medication>and </docset:SafetyInformation><dg:chunk><docset:TreprostinilSafetyProfile structure="p">

                         , no additional risks were identified. <dg:chunk>Repeat SC </dg:chunk>dosing with <dgm:Medication><dgm:Medication>treprostinil </dgm:Medication><dgm:Medication>sodium </dgm:Medication></dgm:Medication>for up to <docset:RepeatDoseToxicity>26 weeks </docset:RepeatDoseToxicity>was well tolerated in rats and dogs. Survival was not affected in rats at doses up to <docset:RepeatDoseToxicity>0.1 </docset:RepeatDoseToxicity>mg/kg/day and in dogs at doses up to <docset:MaximumDose><docset:RepeatDoseToxicity>0.07 </docset:RepeatDoseToxicity>mg</docset:MaximumDose>/kg/day. Clinical signs were limited to transient, dose-related flushing of the extremities secondary to the vasodilatory pharmacology of <dgm:Medication>treprostinil </dgm:Medication>in rats only. No evidence of injection-site reactions to <dgm:Medication>treprostinil </dgm:Medication>occurred either when <dgm:Medication>treprostinil </dgm:Medication>was injected alone in <docset:RepeatDoseToxicity>13- </docset:RepeatDoseToxicity>or <docset:RepeatDoseToxicity>26</docset:RepeatDoseToxicity>-<docset:RepeatDoseToxicity>week </docset:RepeatDoseToxicity>repeat-dose toxicity studies in rats and dogs or when <dgm:Medication>treprostinil </dgm:Medication>was injected in combination with <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>in a <docset:LocalToleranceStudy>2-week </docset:LocalToleranceStudy>local tolerance <dgm:_testRef>study </dgm:_testRef>in rats. Furthermore, there was no indication of systemic target organ toxicity in either rats or dogs. No evidence of genotoxicity was demonstrated with <dgm:Medication>treprostinil </dgm:Medication>in a standard </docset:TreprostinilSafetyProfile><dg:chunk><docset:GeneticToxicityTests structure="p">

              battery of genetic toxicity tests. There was no evidence of reproductive toxicity or teratogenicity </docset:GeneticToxicityTests><dg:chunk><docset:SafetyInformation structure="p">

              in rats and no evidence of teratogenicity in rabbits 

                                   hus, there are no known potential risks associated with the use of small amounts of <dgm:Medication>treprostinil </dgm:Medication>CCI in the <docset:SafetyProfile>LY900014 </docset:SafetyProfile>formulation. </docset:SafetyInformation><docset:SafetyProfile structure="p">

              Additionally, local and systemic toxicity profiles of <dgm:Medication>Humalog </dgm:Medication>and do not suggest the potential for additive or synergistic toxicity. </docset:SafetyProfile></dg:chunk></dg:chunk></dg:chunk></dg:chunk><docset:HypoglycaemiaManagement structure="p">

              The <dgm:_testRef>study </dgm:_testRef>includes inpatient procedures during which participants will be continuously monitored. Patients will be without further oral food intake following consumption of liquid <dgm:_testRef>test </dgm:_testRef>meal to completion of blood glucose collection (approximately <docset:StudyProcedure>300 minutes</docset:StudyProcedure>) unless required to treat hypoglycaemia, as defined by the plasma glucose (PG) level <docset:HypoglycemiaTreatment>≤70 </docset:HypoglycemiaTreatment>mg/dL (<docset:BloodGlucoseLevel>3.9 mM</docset:BloodGlucoseLevel>) with symptoms or any PG &lt;<docset:BloodGlucoseManagement>60 </docset:BloodGlucoseManagement>mg/dL (<docset:HypoglycemiaTreatment>3.0 mM</docset:HypoglycemiaTreatment>) during the inpatient period, i.e ., reversed with either rapidly absorbable oral carbohydrates or IV glucose. If a patient's blood glucose concentration rises above <docset:BloodGlucoseManagement>300 </docset:BloodGlucoseManagement>mg/dL (<docset:BloodGlucoseLevel>16.7 </docset:BloodGlucoseLevel>mM) for more than <docset:HyperglycaemiaTreatment>1 hour</docset:HyperglycaemiaTreatment>, RHI will be administered IV. Appropriate measures will be taken to minimise the risk of hyperglycaemia (see Section 9.4.6). </docset:HypoglycaemiaManagement><docset:KnownandExpectedBenefitsandRisks structure="p">

              More detailed information about the known and expected benefits and risks of <dgm:Medication>Humalog </dgm:Medication>may be found in the following: Summary of Product Characteristics (SPC) (<dg:chunk><dgm:Medication>Humalog </dgm:Medication>SPC [EPAR</dg:chunk>] [WWW]); known and expected benefits and risks of <dgm:Medication>treprostinil </dgm:Medication>may be found in the package insert for <dgm:Medication>treprostinil </dgm:Medication>(C More information about the known and expected benefits, risks, SAEs, and reasonably anticipated AEs of <docset:InvestigatorsBrochure>LY900014 </docset:InvestigatorsBrochure>is to be found in the Investigator's Brochure (IB). </docset:KnownandExpectedBenefitsandRisks></dg:chunk></dg:chunk><dg:chunk><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 819; top: 294; width: 907; height: 78; page: 28;}; "><dg:chunk structure="li" style="boundingBox:{left: 819; top: 294; width: 907; height: 78; page: 28;}; "><dg:chunk structure="lim" style="boundingBox:{left: 819; top: 297; width: 60; height: 71; page: 28;}; ">

                                       4. </dg:chunk><dg:chunk structure="h1">Objectives and Endpoints </dg:chunk></dg:chunk></dg:chunk><dg:chunk structure="p">

              <dg:chunk>Table ITSA </dg:chunk><docset:StudyObjectives>1 </docset:StudyObjectives>shows the objectives and endpoints of the <dgm:_testRef>study</dgm:_testRef>. </dg:chunk></dg:chunk></dg:chunk></dg:chunk></dg:chunk><docset:TableITSA1-section><dg:chunk structure="h1">

              Table <docset:ITSA>ITSA.1</docset:ITSA>. </dg:chunk><docset:ObjectivesAndEndpoints-section structure="div"><dg:chunk structure="h1">

                                     Objectives and Endpoints </dg:chunk><docset:ObjectivesAndEndpoints structure="div"><dg:chunk><docset:ObjectivesAndEndpoints><xhtml:table structure="table" style="boundingBox:{left: 276; top: 616; width: 1974; height: 1354; page: 28;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 276; top: 616; width: 1974; height: 1354; page: 28;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 276; top: 616; width: 1974; height: 44; page: 28;}; "><xhtml:td structure="td" style="boundingBox:{left: 276; top: 616; width: 999; height: 44; page: 28;}; "><dg:chunk structure="h1">

              Objectives </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1275; top: 616; width: 975; height: 44; page: 28;}; "><docset:Objectives>

              Endpoints </docset:Objectives></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 276; top: 661; width: 1974; height: 362; page: 28;}; "><xhtml:td structure="td" style="boundingBox:{left: 276; top: 660; width: 999; height: 363; page: 28;}; "><docset:Primary-cell><dg:chunk structure="h1">

              Primary </dg:chunk><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 300; top: 738.4; width: 911; height: 293.6; page: 28;}; "><docset:StudyObjectives structure="li" style="boundingBox:{left: 300; top: 738.4; width: 911; height: 293.6; page: 28;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300; top: 737; width: 43; height: 49; page: 28;}; ">

              1. </dg:chunk><docset:StudyObjective structure="p">Part A: To evaluate the PK of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>following a single SC bolus dose administered through injection of <docset:StudyDrug>LY900014 </docset:StudyDrug>compared to <dgm:Medication>Humalog </dgm:Medication>in children, adolescents, and adults with <dg:chunk>T1DM </dg:chunk></docset:StudyObjective></docset:StudyObjectives></dg:chunk></docset:Primary-cell></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1276; top: 660; width: 974; height: 363; page: 28;}; "><docset:EndpointsPrimary1PartAToEvaluatethePKofInsulinLisproFollowingaSing structure="h1">

              <docset:EarlyAUC>1</docset:EarlyAUC>. Early <docset:EarlyTmax>50% </docset:EarlyTmax>tmax and <docset:AUC0-30min>AUC(0</docset:AUC0-30min><docset:EarlyAUC>-<dg:chunk>30min</dg:chunk></docset:EarlyAUC>) </docset:EndpointsPrimary1PartAToEvaluatethePKofInsulinLisproFollowingaSing></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 276; top: 1024; width: 1974; height: 330; page: 28;}; "><xhtml:td structure="td" style="boundingBox:{left: 276; top: 1023; width: 999; height: 331; page: 28;}; "><docset:Objectives2PartBToEvaluatethePKofInsulinLisproFollowingaSingleSCB><dg:chunk structure="h1">

              <docset:PartB>2</docset:PartB>. <dg:chunk>Part B</dg:chunk>: </dg:chunk><dg:chunk structure="div">To evaluate the PK of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>following a single SC bolus dose administered through CSII of <docset:StudyDrug>LY900014 </docset:StudyDrug>compared to <dgm:Medication>Humalog </dgm:Medication>in children, adolescents, and adults with <dg:chunk>T1DM </dg:chunk></dg:chunk></docset:Objectives2PartBToEvaluatethePKofInsulinLisproFollowingaSingleSCB></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1276; top: 1023; width: 974; height: 331; page: 28;}; "><docset:Endpoints2PartBToEvaluatethePKofInsulinLisproFollowingaSingleSCBo structure="h1">

              <docset:EarlyAUC>2</docset:EarlyAUC>. Early <docset:EarlyAUC>50% </docset:EarlyAUC>tmax and <docset:AUC0-30min>AUC(0</docset:AUC0-30min><docset:EarlyAUC>-<dg:chunk>30min</dg:chunk></docset:EarlyAUC>) </docset:Endpoints2PartBToEvaluatethePKofInsulinLisproFollowingaSingleSCBo></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 276; top: 1355; width: 1974; height: 381; page: 28;}; "><xhtml:td structure="td" style="boundingBox:{left: 276; top: 1354; width: 999; height: 382; page: 28;}; "><docset:Secondary-cell><dg:chunk structure="h1">

              Secondary </dg:chunk><docset:StudyObjectives structure="p">

              1. Part A and Part B: To evaluate the difference in GD response to <docset:StudyDrug>LY900014 </docset:StudyDrug>and <dgm:Medication>Humalog </dgm:Medication>administered through SC bolus injection or CSII, as assessed using the liquid MMTT in children, adolescents, and adults with <dg:chunk>T1DM </dg:chunk></docset:StudyObjectives></docset:Secondary-cell></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1276; top: 1354; width: 974; height: 382; page: 28;}; "><docset:EndpointsSecondary1PartAAndPartBToEvaluatetheDifferenceinGDRespons>

              <docset:AAUC>1</docset:AAUC>. <dgc:Number>AAUC(0</dgc:Number>-<docset:AAUC0-2h>2h</docset:AAUC0-2h>), <docset:AAUC0>AAUC(0</docset:AAUC0>-<docset:AAUC0-5h>5h</docset:AAUC0-5h>) </docset:EndpointsSecondary1PartAAndPartBToEvaluatetheDifferenceinGDRespons></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 276; top: 1737; width: 1974; height: 233; page: 28;}; "><xhtml:td structure="td" style="boundingBox:{left: 276; top: 1736; width: 999; height: 234; page: 28;}; "><docset:Objectives2PartAAndPartBToEvaluatetheTolerabilityofLY900014Followin structure="p">

              <docset:EvaluationofTolerability>2</docset:EvaluationofTolerability>. Part A and Part B: To evaluate the tolerability of <docset:StudyDrug>LY900014 </docset:StudyDrug>following SC injection or CSII in children, adolescents, and adults with <dg:chunk>T1DM </dg:chunk></docset:Objectives2PartAAndPartBToEvaluatetheTolerabilityofLY900014Followin></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1276; top: 1736; width: 974; height: 234; page: 28;}; "><docset:Endpoints2PartAAndPartBToEvaluatetheTolerabilityofLY900014Following structure="p">

              <docset:AdverseEvents>2</docset:AdverseEvents>. AEs including injection/catheter insertion site reactions/pain, hypoglycaemia, and anti-<dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>antibodies </docset:Endpoints2PartAAndPartBToEvaluatetheTolerabilityofLY900014Following></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:ObjectivesAndEndpoints><docset:Abbreviations-section><dg:chunk structure="h1">

              Abbreviations: </dg:chunk><docset:Abbreviations structure="div">AE = adverse event; AUC = area under the concentration versus time curve; AUC(0-<dg:chunk>30min</dg:chunk>) = AUC 

                 from time zero to <docset:TimeFrame>30 minutes</docset:TimeFrame>; AAUC = area under the baseline subtracted glucose concentration versus time curve; AAUC(0-2h) = area under the baseline subtracted glucose concentration versus from time <docset:GlucodynamicsStudyEndpoints>0 </docset:GlucodynamicsStudyEndpoints>to <docset:PostmealGlucoseAreaUndertheCurve>2 hours </docset:PostmealGlucoseAreaUndertheCurve>postmeal; AAUC(0-5h) = area under the baseline subtracted glucose concentration versus from time <dgc:TimeDuration>0 </dgc:TimeDuration>to <docset:MaximumTime>5 hours </docset:MaximumTime>postmeal; CSII = continuous subcutaneous <dgm:Medication>insulin </dgm:Medication>infusion; early <docset:Percentage>50% </docset:Percentage>tmax = time to early half-maximal drug concentration; GD = glucodynamics; MMTT = mixed meal <dgm:MedicalTest>tolerance <dgm:_testRef>test</dgm:_testRef></dgm:MedicalTest>; PK = pharmacokinetic(s); SC = subcutaneous; <dg:chunk>T1DM </dg:chunk>= type 1 <dgm:Condition><dgm:Condition>diabetes </dgm:Condition>mellitus</dgm:Condition>. </docset:Abbreviations></docset:Abbreviations-section></dg:chunk><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 1016; top: 292; width: 508; height: 80; page: 29;}; "><dg:chunk structure="li" style="boundingBox:{left: 1016; top: 292; width: 508; height: 80; page: 29;}; "><dg:chunk structure="lim" style="boundingBox:{left: 1016; top: 292; width: 59; height: 76; page: 29;}; ">

                                                5. </dg:chunk><dg:chunk structure="h1"><dgm:_testRef>Study </dgm:_testRef>Design </dg:chunk></dg:chunk></dg:chunk><dg:chunk><docset:StudyDesign structure="ol" style="list-style-type: decimal; boundingBox:{left: 293; top: 426; width: 1951; height: 387; page: 29;}; boundingBox:{left: 299; top: 761; width: 347; height: 61; page: 30;}; "><dg:chunk structure="li" style="boundingBox:{left: 288; top: 426; width: 1959.0; height: 2473.0; page: 29;}; boundingBox:{left: 291; top: 459; width: 1916; height: 248.0; page: 30;}; "><dg:chunk structure="lim" style="boundingBox:{left: 294; top: 426; width: 113; height: 67; page: 29;}; ">

              5.1. </dg:chunk><docset:StudyDesign structure="p">Overall Design This is a Phase 1, randomised, 2-part, patient- and investigator-blind, 2-period crossover <dgm:_testRef>study </dgm:_testRef>in children (age <docset:StudyDesign>6 </docset:StudyDesign>to &lt;<docset:AgeRange>12 years</docset:AgeRange>), adolescents (age <docset:StudyDesign>12 </docset:StudyDesign>to &lt;<docset:AgeRange>18 years</docset:AgeRange>), and adults (age <docset:StudyDesign>18 </docset:StudyDesign>to &lt;<docset:MaximumAge>65 years</docset:MaximumAge>) with <dg:chunk>T1DM </dg:chunk>currently using a CSII pump or MDIs. The aim is to evaluate <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>PK, GD, and tolerability of LY900014 in comparison with <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>(reference) following a single dose SC administration immediately prior to a standardised liquid meal.               During the <dgm:_testRef>screening </dgm:_testRef>visit, patients will receive a diary to document any AEs and/or hypoglycaemic events. Transition instructions pertinent to those patients receiving MDI who will transition their basal <dgm:Medication>insulin </dgm:Medication>to twice <dgc:Frequency>daily </dgc:Frequency>neutral <dgm:Medication>protamine </dgm:Medication>Hagedorn (<dgm:Medication>NPH</dgm:Medication>) will be provided and reviewed during the telephone call (on or before Day-10) discussed below. All patients who are currently using either a <docset:InsulinDeliveryMethod>CSII </docset:InsulinDeliveryMethod>pump or receiving MDI and are eligible to participate in the <dgm:_testRef>study </dgm:_testRef>based on the results of the <dgm:_testRef>screening </dgm:_testRef>procedures (within <docset:ScreeningPeriod>28 days </docset:ScreeningPeriod>of Day -1 of Period 1) will be contacted via a telephone call on or before Day -10. This telephone call will confirm their eligibility and address any questions participants and parents/guardians may have about the upcoming <dgm:_testRef>test </dgm:_testRef>meal visits. Patients entering the <dgm:_testRef>study </dgm:_testRef>on CSII therapy will remain on their current basal rate and bolus settings during the lead-in period and will be instructed to bring additional pump supplies when they arrive at the <dgm:_testRef>study </dgm:_testRef>site.               Those patients receiving MDI and who will transition from their basal <dgm:Medication>insulin </dgm:Medication>to twice <dgc:Frequency>daily </dgc:Frequency><dgm:Medication><dgm:Medication>NPH </dgm:Medication><dgm:Medication>insulin </dgm:Medication></dgm:Medication>will review the site-provided instructions during this call. The investigator will ensure the patients are provided with <dgm:Medication>NPH </dgm:Medication>as required. Patients or their parents/guardians may call the site at any time to address questions or concerns as they arise (including, but not limited to the transition phase). In lieu of a telephone call on or before Day -10 to review <dgm:Medication>insulin </dgm:Medication>transition instructions, a site visit may be scheduled at the investigator's discretion.               This <dgm:_testRef>study </dgm:_testRef>comprises of 2 parts: <dg:chunk>Part A </dg:chunk>and Part B. During <dg:chunk>Part A</dg:chunk>, patients will receive a single dose of LY900014 and <dgm:Medication>Humalog </dgm:Medication>on 1 occasion each as SC bolus injection and in <dg:chunk>Part B </dg:chunk>a single dose of LY900014 and <dgm:Medication>Humalog </dgm:Medication>on 1 occasion each as SC bolus via CSII.               Patients will be randomised on Day 1 of Period 1 in <dg:chunk>Part A </dg:chunk>and Day -1 of Period 1 in Part B. For each age group, patients will be randomised to 1 of the 2 treatment sequences (first double-blind <dg:chunk>LY900014 </dg:chunk>then double-blind <dgm:Medication>Humalog</dgm:Medication>, and first double-blind <dgm:Medication>Humalog </dgm:Medication>then double-blind <dg:chunk>LY900014</dg:chunk>) in 1:1 ratio. In both parts, dosing in Period 1 and Period 2 can occur on consecutive days but not more than 22 days apart. For patients available for dosing on consecutive days, the medical assessments scheduled for Day -1 of Period 2 may be done on Day 1 of Period 1. Patients will undergo a rescreening visit if dosing visit between <dg:chunk>Part A </dg:chunk>and <dg:chunk>Part B </dg:chunk>is more than 28 days apart. Patients who participate in <dg:chunk>Part A </dg:chunk>may continue to <dg:chunk>Part B</dg:chunk>; however, patients who complete <dg:chunk>Part A </dg:chunk>but discontinue prior to <dg:chunk>Part B </dg:chunk>may be replaced by newly enrolled patients in Part B. Newly enrolled patients will be randomised to 1 of 2 treatment sequences after completing the <dgm:_testRef>screening </dgm:_testRef>per the Schedule of Activities (Section 2) and are expected to complete only Part B activities. Before each MMTT, a run-in period to stabilise blood glucose will occur. Details of run-in activities are described in Section 5.1.1.1, 5.1.2.1, and in Section 2.               A formal interim analysis is planned when all patients complete <dg:chunk>Part A </dg:chunk>(Section 10.3.5). Lilly intends to complete <dg:chunk>Part A </dg:chunk>to inform <dgm:_testRef>study </dgm:_testRef>design of the paediatric Phase 3 <dgm:_testRef>study</dgm:_testRef>. Initiation of <dg:chunk>Part B </dg:chunk>of the <dgm:_testRef>study </dgm:_testRef>may begin pending review of the PK, GD, safety, and tolerability data from <dg:chunk>Part A </dg:chunk>and ongoing or planned adult CSII Phase 1b studies. </docset:StudyDesign></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 299; top: 761; width: 347; height: 61; page: 30;}; "><dg:chunk structure="lim" style="boundingBox:{left: 299; top: 761; width: 158; height: 59; page: 30;}; ">

              5.1.1. </dg:chunk><dg:chunk>Part A </dg:chunk></dg:chunk></docset:StudyDesign><dg:chunk><docset:InsulinDose structure="p">

              In each period, patients will undergo an overnight run-in period followed by an MMTT (see Section 5.1.1.1). Each patient will receive single <docset:InsulinDose>0.2 </docset:InsulinDose>U/kg of body weight SC injections of <docset:StudyDrugDose>LY900014 </docset:StudyDrugDose>and <dgm:Medication>Humalog</dgm:Medication>. The <dgm:_testRef>study </dgm:_testRef>drug will be administered immediately before the start of a <dgm:_testRef>test </dgm:_testRef>meal (see Section 6.3.1) per the assigned treatment sequence. This dose of <dgm:Medication>insulin </dgm:Medication>before the MMTTs for each patient will be the same for each <dgm:_testRef>test </dgm:_testRef>meal throughout the crossover periods; this dose will also be maintained for the patient in Part B. </docset:InsulinDose><dg:chunk structure="p">

              Figure <docset:StudyDesign>ITSA.1 </docset:StudyDesign>illustrates the <dgm:_testRef>study </dgm:_testRef>design for Part A. </dg:chunk></dg:chunk></dg:chunk></docset:ObjectivesAndEndpoints></docset:ObjectivesAndEndpoints-section></docset:TableITSA1-section></dg:chunk></dg:chunk></dg:chunk></docset:ListofAppendices></docset:ListofAppendices-section><dg:chunk><dg:chunk structure="h1">

                                                 Period <docset:Period1>1 </docset:Period1></dg:chunk><docset:Period2-section structure="div"><dg:chunk structure="h1">

                                                                              Period <docset:Period2>2 </docset:Period2></dg:chunk><docset:Period2 structure="div"><dg:chunk><dg:chunk><dg:chunk structure="p">

               Du </dg:chunk><docset:Abbreviations-section><dg:chunk structure="h1">

                        Abbreviations: </dg:chunk><docset:Abbreviations structure="div">MDI = multiple <dgc:Frequency>daily </dgc:Frequency>injection; MMTT = mixed meal <dgm:MedicalTest>tolerance <dgm:_testRef>test</dgm:_testRef></dgm:MedicalTest>; <dgm:Medication>NPH </dgm:Medication>= neutral <dgm:Medication>protamine </dgm:Medication>Hagedorn; SC = subcutaneous; T = telephone visit; <dg:chunk>T1DM </dg:chunk>= type 1 <dgm:Condition><dgm:Condition>diabetes </dgm:Condition>mellitus</dgm:Condition>. a At <dgm:_testRef>study </dgm:_testRef>entry, patients on MDI therapy with any basal <dgm:Medication>insulin </dgm:Medication>other than <dgm:Medication>NPH </dgm:Medication>twice <dgc:Frequency>daily </dgc:Frequency>will transition to <dgm:Medication>NPH </dgm:Medication>twice <dgc:Frequency>daily </dgc:Frequency>therapy approximately <docset:InsulinTransitionPeriod>7 to 3 days </docset:InsulinTransitionPeriod>prior to Day -1 of Period 1. b <dgm:Medication>Insulin </dgm:Medication>transition is applicable if Period <docset:InsulinTransition>2 </docset:InsulinTransition>occurs &gt;<docset:InsulinTransition>3 </docset:InsulinTransition>to <docset:InsulinTransitionPeriod>7 days </docset:InsulinTransitionPeriod>after Period 1. The second MMTT assessment may occur on consecutive days but no more than <docset:MaximumMMTTAssessmentInterval>22 days </docset:MaximumMMTTAssessmentInterval>after the first MMTT. </docset:Abbreviations></docset:Abbreviations-section></dg:chunk><dg:chunk structure="p">

              Figure <docset:ITSAFigure>ITSA.1</docset:ITSAFigure>. </dg:chunk></dg:chunk><dg:chunk><docset:IllustrationofStudyDesignforPartA-section><dg:chunk structure="h1">

                                    Illustration of <dgm:_testRef>study </dgm:_testRef>design for Part A. </dg:chunk><docset:IllustrationofStudyDesignforPartA structure="div"><dg:chunk><dg:chunk><docset:StudyVisits structure="p">

              Patients will be required to attend the <dgm:_testRef>study </dgm:_testRef>site on <docset:NumberofStudyVisits>3 </docset:NumberofStudyVisits>or <docset:StudyVisits>4 </docset:StudyVisits>occasions for <dg:chunk>Part A </dg:chunk>as described below: </docset:StudyVisits><docset:StudyVisits structure="ul" style="list-style-type: circle; boundingBox:{left: 446.2; top: 2258.1; width: 1646.8; height: 665.9; page: 31;}; "><dg:chunk structure="li" style="boundingBox:{left: 446.2; top: 2258.1; width: 1641.8; height: 350.9; page: 31;}; "><dg:chunk structure="lim" style="boundingBox:{left: 444; top: 2262; width: 30; height: 53; page: 31;}; ">

                     • </dg:chunk><docset:ScreeningVisit structure="p">A <dgm:_testRef>screening </dgm:_testRef>visit (up to <docset:ScreeningVisitDuration>28 days </docset:ScreeningVisitDuration>prior to Day <docset:ScreeningVisit>-1 </docset:ScreeningVisit>of Period 1). The informed consent/assent will be obtained during this visit and patients will be provided a diary to document any AEs and/or hypoglycaemic events. A telephone visit is planned after <dgm:_testRef>screening </dgm:_testRef>and on or prior to <docset:ScreeningVisitDate>Day </docset:ScreeningVisitDate><docset:TelephoneVisit>-10 </docset:TelephoneVisit>to inform patients of their eligibility, provide instructions and address any questions participants and parents may have about the upcoming <dgm:_testRef>test </dgm:_testRef>meal visits. </docset:ScreeningVisit></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 2641.7; width: 1630.0; height: 122.3; page: 31;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 2641.7; width: 370.8; height: 50.0; page: 31;}; ">

                     • </dg:chunk><docset:InpatientStayRequirements structure="p"><docset:NumberofInpatientOvernightStays>Two </docset:NumberofInpatientOvernightStays>separate inpatient overnight stays from <docset:InpatientStayDates>Day </docset:InpatientStayDates><docset:Pre-StudyInpatientStay>-1 </docset:Pre-StudyInpatientStay>to Day <dgc:Number>1 </dgc:Number>(<docset:InpatientStayDuration>1 </docset:InpatientStayDuration>in each <dgm:_testRef>study </dgm:_testRef>period for MMTTs). These inpatient stays may occur on consecutive nights. </docset:InpatientStayRequirements></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 2800.0; width: 1643.0; height: 124.0; page: 31;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 2800.0; width: 341.7; height: 50.0; page: 31;}; ">

                     • </dg:chunk><docset:Follow-upVisit structure="p">A follow-up visit at least <docset:Follow-upVisit>14 days </docset:Follow-upVisit>after the last dose or early discontinuation if the patient discontinues after Part A. Patients will be discharged from the <dgm:_testRef>study </dgm:_testRef>site on Day 1 (at least <docset:Follow-upVisit>7 hours </docset:Follow-upVisit>after the <dgm:_testRef>test </dgm:_testRef>meal) or later, if deemed necessary for safety monitoring as determined by the investigator. </docset:Follow-upVisit></dg:chunk></docset:StudyVisits></dg:chunk><docset:InsulinTransitionGuidelines structure="p">

              Patients entering the <dgm:_testRef>study </dgm:_testRef>on MDI therapy with any basal <dgm:Medication>insulin </dgm:Medication>other than <dgm:Medication>NPH </dgm:Medication>twice <dgc:Frequency>daily </dgc:Frequency>will transition to <dgm:Medication>NPH </dgm:Medication>twice <dgc:Frequency>daily </dgc:Frequency>therapy approximately <docset:TransitionPeriod>7 to </docset:TransitionPeriod><docset:TransitionPeriod>3 days </docset:TransitionPeriod>prior to Day <docset:TransitiontoNPHInsulin>-1 </docset:TransitiontoNPHInsulin>of Period 1. Transition guidelines, including dosages and timing, will be determined by the investigator and will be based on the needs of individual patient. </docset:InsulinTransitionGuidelines><docset:InsulinAdministration structure="p">

              On Day -1, the last injection of <dgm:Medication>NPH </dgm:Medication>prior to the MMTT will occur in the morning and will resume only after the completion of the MMTT assessment (<docset:ResumeNPHInjection><dg:chunk>~7 </dg:chunk>hours </docset:ResumeNPHInjection>postdose on Day <docset:LastNPHInjection>1</docset:LastNPHInjection>). </docset:InsulinAdministration></dg:chunk><docset:_5121InpatientProceduresforPart-section><dg:chunk structure="h1">

              <docset:InpatientProcedures>5.1.1.1</docset:InpatientProcedures>. <dg:chunk>Inpatient Procedures </dg:chunk>for <dg:chunk>Part A </dg:chunk></dg:chunk><docset:_5121InpatientProceduresforPart structure="div"><dg:chunk><docset:InsulinAdministration structure="p">

              On the day before each MMTT day (i.e ., <docset:Run-inPeriodStart>Day-1 </docset:Run-inPeriodStart>in each of the <docset:Run-inPeriod>2 </docset:Run-inPeriod>periods), patients will arrive at the <dgm:_testRef>study </dgm:_testRef>site in the early <docset:EveningDinner>evening </docset:EveningDinner>(approximately <docset:DinnerTime>05:00 PM)</docset:DinnerTime>. The patient's short-acting <dgm:Medication>insulin </dgm:Medication>will be administered before the start of a standardised dinner. Before the start of a run-in period, the cannulation of the vein will be performed. At the start of the run-in period, patients entering the <dgm:_testRef>study </dgm:_testRef>on CSII therapy will suspend all <dgm:Medication>insulin </dgm:Medication>delivery and disconnect tubing from the infusion site. </docset:InsulinAdministration><docset:Run-InPeriod structure="p">

              Start of the run-in period will occur following the evening meal (approximately at <docset:Run-inPeriodStartTime>09:00 </docset:Run-inPeriodStartTime>or <docset:Run-InPeriodStartTime>10:00 PM)</docset:Run-InPeriodStartTime>. The run-in period will start with a variable IV infusion of glucose (<docset:Run-inPeriodGlucoseTarget>5% </docset:Run-inPeriodGlucoseTarget><dgm:Medication>dextrose </dgm:Medication>solution) or RHI to reach a target glucose level of <docset:GlucoseTargetLevel>135</docset:GlucoseTargetLevel><docset:Run-InPeriodTargetGlucoseLevel>+25 </docset:Run-InPeriodTargetGlucoseLevel>mg/dL (<docset:Run-InPeriod>7.5</docset:Run-InPeriod>+<docset:Run-InPeriod>1.4 </docset:Run-InPeriod>mmol/L). If this target glucose level is not attained before <docset:Run-InPeriodEndTime>11:00 AM </docset:Run-InPeriodEndTime>on Day 1, MMTT will be halted and may be performed on a separate visit; an MMTT can only be rescheduled (up to <docset:Run-inPeriod>7 days</docset:Run-inPeriod>) once for each <dgm:_testRef>study </dgm:_testRef>period. During the run-in period, blood glucose concentrations will be monitored at a minimum of <docset:Run-InPeriod>30- </docset:Run-InPeriod>to <docset:Run-inPeriodMonitoringInterval>60-minute </docset:Run-inPeriodMonitoringInterval>intervals (see Sections 7.4.1 and 9.6.1). </docset:Run-InPeriod><dg:chunk><docset:TestMeal structure="p">

              The run-in period will end once the target blood glucose level is attained and remains stable without intervention for at least <docset:Run-inPeriodEndTime>20 minutes </docset:Run-inPeriodEndTime>before the scheduled start time of MMTT on Day 1. The MMTT will start in the early morning at approximately <docset:StartTime>08:00 AM </docset:StartTime>with allowance up to <docset:EndofRun-InPeriod>11:00 AM</docset:EndofRun-InPeriod>, if required, to ensure the patient's blood glucose is stable and on target, with the premeal activities as specified in the Schedule of Activities (Section 2). <dg:chunk>LY900014 </dg:chunk>or <dgm:Medication>Humalog </dgm:Medication>SC bolus injection will be administered immediately before the start of MMTT using an <dgm:Medication>insulin </dgm:Medication>syringe. The liquid <dgm:_testRef>test </dgm:_testRef>meal will be administered on Day 1 for each of the <dgc:Number>2 </dgc:Number>treatment periods. A detailed description of the <dgm:_testRef>test </dgm:_testRef>meal is presented in Section 6.3.1. Patients are expected to complete each <dgm:_testRef>test </dgm:_testRef>meal within <docset:MealCompletionTime>15 minutes </docset:MealCompletionTime>of starting the meal. Patients will be without further oral food intake following consumption of liquid <dgm:_testRef>test </dgm:_testRef>meal to completion of blood glucose collection (approximately <docset:TestMealDuration>300 minutes</docset:TestMealDuration>) unless required to treat hypoglycaemia, as defined by the PG level ≤70 mg/dL (<docset:Run-InPeriodEndCriteria>3.9 </docset:Run-InPeriodEndCriteria>mM) with symptoms or any PG &lt;60 mg/dL (<docset:Run-InPeriod>3.0 </docset:Run-InPeriod>mM) during the inpatient period, i.e ., reversed with either rapidly absorbable oral carbohydrates or IV glucose. If a patient's blood glucose concentration rises above 300 mg/dL (<docset:Run-InPeriodEnd>16.7 </docset:Run-InPeriodEnd>mM) for more than <docset:Run-InPeriodEndTime>1 hour</docset:Run-InPeriodEndTime>, RHI will be administered IV. In both cases, blood samples for blood glucose (for safety) will be taken and PK samples will be collected as planned. For each MMTT, the patient should stay in a sitting or semisupine position for <docset:Run-inPeriod>2 hours </docset:Run-inPeriod>postdose and the patient will not be allowed to consume water for <docset:Run-InPeriodEndCriteria>2 </docset:Run-InPeriodEndCriteria>hours after dosing (see Figure ITSA.2). If necessary, patients may be given </docset:TestMeal><docset:InsulinAdministration structure="p">

              a low carbohydrate snack (&lt;20 g carbohydrate), which does not require an <dgm:Medication>insulin </dgm:Medication>dose, after GD assessments (approximately <docset:AssessmentPeriod>300 minutes </docset:AssessmentPeriod>postdose). Following completion of the assessment period and sample collection (approximately <docset:EndofAssessmentPeriod>420 minutes</docset:EndofAssessmentPeriod>), patients will be offered a meal. For patients who were using MDI therapy, the investigator shall provide guidance on whether they should resume their prestudy basal <dgm:Medication>insulin </dgm:Medication>at the end of Period 1 or continue with <dgm:Medication>NPH </dgm:Medication>depending on the length of time between Period 1 and Period <docset:InsulinDoseAdjustment>2</docset:InsulinDoseAdjustment>. Patients may return to pre-<dgm:_testRef>study </dgm:_testRef>basal <dgm:Medication>insulin </dgm:Medication>following completion of Period <dgc:Number>2 </dgc:Number>MMTT sampling period with investigator’s guidance. For CSII patients, the <dgm:Medication>insulin </dgm:Medication>pump may be resumed at the usual rates and settings with prestudy <dgm:Medication>insulin </dgm:Medication>and bolus mealtime <dgm:Medication>insulin </dgm:Medication>will be administered. A new infusion set may be required. </docset:InsulinAdministration></dg:chunk><docset:PatientDischarge structure="p">

              Patients will be observed following administration of the meal and discharged at the investigator’s discretion. </docset:PatientDischarge></dg:chunk><docset:_18B-MC-ITSADClinicalPharmacologyProtocol-section><dg:chunk structure="h1">

              <docset:ClinicalPharmacologyProtocol>18B</docset:ClinicalPharmacologyProtocol>-MC-ITSA(d) Clinical Pharmacology Protocol </dg:chunk><docset:_18B-MC-ITSADClinicalPharmacologyProtocol structure="div"><docset:Page33-section><dg:chunk structure="h1">

                                                                                                                                    Page <docset:PageNumber>33 </docset:PageNumber></dg:chunk><docset:Page33 structure="div"><dg:chunk structure="p">

                                Admission to <dgm:_testRef>study </dgm:_testRef>site </dg:chunk><docset:AdmissiontoStudySite><xhtml:table structure="table" style="boundingBox:{left: 386; top: 469.7; width: 2562; height: 865.3; page: 34;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 386; top: 469.7; width: 2562; height: 865.3; page: 34;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 386; top: 469.7; width: 2562; height: 183.3; page: 34;}; "><xhtml:td structure="td" style="boundingBox:{left: 386; top: 469.7; width: 360.5; height: 183.3; page: 34;}; "><dg:chunk structure="h1">

                        MDI patients: Last dose of <dgm:Medication><dgm:Medication>NPH </dgm:Medication><dgm:Medication>insulin </dgm:Medication></dgm:Medication></dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 746.5; top: 469.7; width: 241.0; height: 183.3; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 987.5; top: 469.7; width: 723.0; height: 183.3; page: 34;}; "><dg:chunk structure="h1">

                     CSII patients: Stop basal <dgm:Medication>insulin </dgm:Medication></dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1710.5; top: 469.7; width: 479.9; height: 183.3; page: 34;}; " colspan="2"><dg:chunk structure="p">

                     SC bolus of <dgm:_testRef>study </dgm:_testRef>drug via injection followed by MMTT </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2190.4; top: 469.7; width: 494.6; height: 183.3; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2685; top: 469.7; width: 263; height: 183.3; page: 34;}; ">

                  Restart prestudy <docset:MDIPatientsLastDoseofNPHInsulin>insulin </docset:MDIPatientsLastDoseofNPHInsulin></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 386; top: 653.0; width: 2562; height: 142.5; page: 34;}; "><xhtml:td structure="td" style="boundingBox:{left: 386; top: 653.0; width: 360.5; height: 142.5; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 746.5; top: 653.0; width: 241.0; height: 142.5; page: 34;}; ">

                     Dinner </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 987.5; top: 653.0; width: 723.0; height: 142.5; page: 34;}; "><docset:CSIIPatientsStopBasalInsulin>

                                        <docset:RomanEmpire>Rım</docset:RomanEmpire>-in </docset:CSIIPatientsStopBasalInsulin></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1710.5; top: 653.0; width: 234.5; height: 142.5; page: 34;}; "><docset:SCBolusofStudyDrugViaInjectionFollowedbyMMTT structure="h1">

                    <dg:chunk>Stable BG </dg:chunk><docset:BGStability>≥20 </docset:BGStability><docset:StableBGTime>mins </docset:StableBGTime>before MMTT </docset:SCBolusofStudyDrugViaInjectionFollowedbyMMTT></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1945; top: 653.0; width: 245.4; height: 142.5; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2190.4; top: 653.0; width: 494.6; height: 142.5; page: 34;}; "><docset:RestartPrestudyInsulin>

                        <docset:MMTT>MMTT </docset:MMTT></docset:RestartPrestudyInsulin></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2685; top: 653.0; width: 263; height: 142.5; page: 34;}; "><docset:MDIPatientsLastDoseofNPHInsulin /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 386; top: 795.5; width: 2562; height: 41.5; page: 34;}; "><xhtml:td structure="td" style="boundingBox:{left: 386; top: 795.5; width: 360.5; height: 41.5; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 746.5; top: 795.5; width: 241.0; height: 41.5; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 987.5; top: 795.5; width: 723.0; height: 41.5; page: 34;}; "><docset:CSIIPatientsStopBasalInsulin>

                           <docset:FieldName>1F </docset:FieldName></docset:CSIIPatientsStopBasalInsulin></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1710.5; top: 795.5; width: 234.5; height: 41.5; page: 34;}; "><docset:SCBolusofStudyDrugViaInjectionFollowedbyMMTT>

                       coh oh </docset:SCBolusofStudyDrugViaInjectionFollowedbyMMTT></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1945; top: 795.5; width: 245.4; height: 41.5; page: 34;}; ">

                   We </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2190.4; top: 795.5; width: 494.6; height: 41.5; page: 34;}; "><docset:RestartPrestudyInsulin /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2685; top: 795.5; width: 263; height: 41.5; page: 34;}; ">

                        cr </xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 386; top: 837.0; width: 2562; height: 80.5; page: 34;}; "><xhtml:td structure="td" style="boundingBox:{left: 386; top: 837.0; width: 360.5; height: 80.5; page: 34;}; "><docset:MDIPatientsLastDoseofNPHInsulinCr>

                              cr </docset:MDIPatientsLastDoseofNPHInsulinCr></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 746.5; top: 837.0; width: 241.0; height: 80.5; page: 34;}; "><docset:Cr>

                    <dg:chunk><docset:FrenchLoanwords>Fr </docset:FrenchLoanwords>Lo </dg:chunk>~ </docset:Cr></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 987.5; top: 837.0; width: 723.0; height: 80.5; page: 34;}; "><docset:CrCSIIPatientsStopBasalInsulin /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1710.5; top: 837.0; width: 234.5; height: 80.5; page: 34;}; "><docset:CrSCBolusofStudyDrugViaInjectionFollowedbyMMTT>

                       :----- </docset:CrSCBolusofStudyDrugViaInjectionFollowedbyMMTT></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1945; top: 837.0; width: 245.4; height: 80.5; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2190.4; top: 837.0; width: 494.6; height: 80.5; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2685; top: 837.0; width: 263; height: 80.5; page: 34;}; "><docset:CrRestartPrestudyInsulin /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 386; top: 917.5; width: 2562; height: 117.0; page: 34;}; "><xhtml:td structure="td" style="boundingBox:{left: 386; top: 917.5; width: 360.5; height: 117.0; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 746.5; top: 917.5; width: 241.0; height: 117.0; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 987.5; top: 917.5; width: 723.0; height: 236.0; page: 34;}; " rowspan="3"><docset:CSIIPatientsStopBasalInsulin structure="p">

                                    IV glucose/RHI target BG: <docset:GlucoseTarget>135</docset:GlucoseTarget><docset:GlucoseTarget>+</docset:GlucoseTarget><docset:GlucoseTargetRange>25 </docset:GlucoseTargetRange>mg/dl (<docset:TargetBloodGlucose>7.5</docset:TargetBloodGlucose><dgc:Percent>+</dgc:Percent><docset:GlucoseTargetRange>1.4 </docset:GlucoseTargetRange>mmol/L) </docset:CSIIPatientsStopBasalInsulin></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1710.5; top: 917.5; width: 234.5; height: 117.0; page: 34;}; "><docset:SCBolusofStudyDrugViaInjectionFollowedbyMMTT /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1945; top: 917.5; width: 740; height: 178.2; page: 34;}; " rowspan="2" colspan="2"><dg:chunk structure="h1">

                            BG sampling (until <docset:SamplingTime>300 mins </docset:SamplingTime>postdose) </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2685; top: 917.5; width: 263; height: 117.0; page: 34;}; "><docset:CSIIPatientsStopBasalInsulin /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 386; top: 1034.5; width: 2562; height: 61.2; page: 34;}; "><xhtml:td structure="td" style="boundingBox:{left: 386; top: 1034.5; width: 360.5; height: 61.2; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 746.5; top: 1034.5; width: 241.0; height: 61.2; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1710.5; top: 1034.5; width: 234.5; height: 61.2; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2685; top: 1034.5; width: 263; height: 61.2; page: 34;}; "><docset:SCBolusofStudyDrugViaInjectionFollowedbyMMTT>

                        - </docset:SCBolusofStudyDrugViaInjectionFollowedbyMMTT></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 386; top: 1095.7; width: 2562; height: 57.8; page: 34;}; "><xhtml:td structure="td" style="boundingBox:{left: 386; top: 1095.7; width: 360.5; height: 57.8; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 746.5; top: 1095.7; width: 241.0; height: 57.8; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1710.5; top: 1095.7; width: 234.5; height: 57.8; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1945; top: 1095.7; width: 245.4; height: 57.8; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2190.4; top: 1095.7; width: 494.6; height: 57.8; page: 34;}; ">

                       PK sampling </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2685; top: 1095.7; width: 263; height: 57.8; page: 34;}; "><docset:SCBolusofStudyDrugViaInjectionFollowedbyMMTT /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 386; top: 1153.5; width: 2562; height: 80.6; page: 34;}; "><xhtml:td structure="td" style="boundingBox:{left: 386; top: 1153.5; width: 360.5; height: 80.6; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 746.5; top: 1153.5; width: 241.0; height: 80.6; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 987.5; top: 1153.5; width: 723.0; height: 80.6; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1710.5; top: 1153.5; width: 234.5; height: 80.6; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1945; top: 1153.5; width: 245.4; height: 80.6; page: 34;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2190.4; top: 1153.5; width: 494.6; height: 80.6; page: 34;}; "><docset:RestartPrestudyInsulin>

                  (until <docset:MaximumDuration>420 </docset:MaximumDuration>mins postdose) </docset:RestartPrestudyInsulin></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2685; top: 1153.5; width: 263; height: 80.6; page: 34;}; " /></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 386; top: 1234.0; width: 2562; height: 101.0; page: 34;}; "><xhtml:td structure="td" style="boundingBox:{left: 386; top: 1234.0; width: 360.5; height: 101.0; page: 34;}; "><docset:MDIPatientsLastDoseofNPHInsulinTimeline7AM>

                   Timeline <docset:Timeline>7 </docset:Timeline><docset:Timeline>AM </docset:Timeline></docset:MDIPatientsLastDoseofNPHInsulinTimeline7AM></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 746.5; top: 1234.0; width: 241.0; height: 101.0; page: 34;}; "><docset:Timeline7AM>

                  <docset:StartTime>5 PM </docset:StartTime></docset:Timeline7AM></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 987.5; top: 1234.0; width: 723.0; height: 101.0; page: 34;}; "><docset:Timeline7AMCSIIPatientsStopBasalInsulin>

                         <docset:StartTime>9</docset:StartTime><docset:Time>-</docset:Time><docset:EndTime>10 PM </docset:EndTime></docset:Timeline7AMCSIIPatientsStopBasalInsulin></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1710.5; top: 1234.0; width: 479.9; height: 101.0; page: 34;}; " colspan="2"><docset:Timeline7AMSCBolusofStudyDrugViaInjectionFollowedbyMMTT structure="h1">

                          <docset:HoursofOperation><docset:HoursofOperation>8 </docset:HoursofOperation><docset:MorningHours>AM - </docset:MorningHours><docset:EndTime>11 <docset:MorningHours>AM </docset:MorningHours></docset:EndTime></docset:HoursofOperation></docset:Timeline7AMSCBolusofStudyDrugViaInjectionFollowedbyMMTT></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2190.4; top: 1234.0; width: 494.6; height: 101.0; page: 34;}; "><docset:Timeline7AM structure="h1">

                               <docset:EventHours><docset:EventTime>1 </docset:EventTime><docset:EventTime>PM </docset:EventTime>- <docset:EventTime>4 <dgc:State>PM </dgc:State></docset:EventTime></docset:EventHours></docset:Timeline7AM></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2685; top: 1234.0; width: 263; height: 101.0; page: 34;}; "><docset:Timeline7AMRestartPrestudyInsulin structure="h1">

                    <docset:HoursofOperation><docset:Hours><docset:Hours>3 </docset:Hours><docset:EventTime>PM - 6 </docset:EventTime></docset:Hours><docset:EventTime>PM </docset:EventTime></docset:HoursofOperation></docset:Timeline7AMRestartPrestudyInsulin></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:AdmissiontoStudySite></docset:Page33></docset:Page33-section><dg:chunk><dg:chunk structure="h1">

                (Approximation) </dg:chunk><dg:chunk structure="div"><docset:Abbreviations-section><dg:chunk structure="h1">

                                    Abbreviations: </dg:chunk><docset:Abbreviations structure="div">BG = blood glucose; CSII = continuous subcutaneous <dgm:Medication>insulin </dgm:Medication>infusion; IV = intravenous; MDI = multiple <dgc:Frequency>daily </dgc:Frequency>injection; MMTT = mixed meal <dgm:MedicalTest>tolerance <dgm:_testRef>test</dgm:_testRef></dgm:MedicalTest>; <dgm:Medication>NPH </dgm:Medication>= neutral <dgm:Medication>protamine </dgm:Medication>Hagedorn; PK = pharmacokinetics; RHI = regular human <dgm:Medication>insulin</dgm:Medication>; SC = subcutaneous. </docset:Abbreviations></docset:Abbreviations-section><dg:chunk structure="p">

              Figure <docset:ITSA2>ITSA.2</docset:ITSA2>. </dg:chunk></dg:chunk></dg:chunk></docset:_18B-MC-ITSADClinicalPharmacologyProtocol></docset:_18B-MC-ITSADClinicalPharmacologyProtocol-section></docset:_5121InpatientProceduresforPart></docset:_5121InpatientProceduresforPart-section></docset:IllustrationofStudyDesignforPartA></docset:IllustrationofStudyDesignforPartA-section><dg:chunk><docset:InpatientProcedureinPartA-section><dg:chunk structure="h1">

                                    Inpatient procedure in Part A. </dg:chunk><docset:InpatientProcedureinPartA structure="div"><dg:chunk structure="p">

              <docset:LY900014>LY900014 </docset:LY900014></dg:chunk><docset:LocalTolerabilityAssessment structure="p">

              Assessment of local tolerability at all injection sites will be performed as specified in the Schedule of Activities (Section 2), including inspection of the injection/catheter site for signs such as oedema, <dgm:Condition>erythema</dgm:Condition>, and rash </docset:LocalTolerabilityAssessment></docset:InpatientProcedureinPartA></docset:InpatientProcedureinPartA-section><docset:_512PartB-section><dg:chunk structure="h1">

              <docset:PartB>5.1.2</docset:PartB>. <dg:chunk>Part B </dg:chunk></dg:chunk><docset:_512PartB structure="div"><docset:StudyParticipation structure="p">

              Patients who completed <dg:chunk>Part A </dg:chunk>but discontinued before the beginning of <dg:chunk>Part B </dg:chunk>may be replaced by newly enrolled patients in Part B. Newly enrolled patients will be randomised to <docset:ReplacementPatients>1 </docset:ReplacementPatients>of <docset:TreatmentSequence>2 </docset:TreatmentSequence>treatment sequences after completing the <dgm:_testRef>screening </dgm:_testRef>per the Schedule of Activities (Section 2) and are expected to complete only Part B activities. </docset:StudyParticipation><docset:TreatmentSequence structure="p">

              Patients will receive either <docset:TreatmentAssignment>LY900014 </docset:TreatmentAssignment>or <dgm:Medication>Humalog </dgm:Medication>with an <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>dose level of <docset:InsulinDoseLevel>0.2 </docset:InsulinDoseLevel>U/kg body weight, as a SC bolus dose delivered using the CSII pump per the assigned treatment sequence. Patients will receive the assigned treatment immediately before each of the <dgm:_testRef>test </dgm:_testRef>meals. At the start of dosing period (Day 1), a standardised <dgm:_testRef>test </dgm:_testRef>meal will be administered (see Section 6.3.1). </docset:TreatmentSequence><dg:chunk structure="p">

              Figure <docset:StudyDesign>ITSA.3 </docset:StudyDesign>illustrates the <dgm:_testRef>study </dgm:_testRef>design for Part B. </dg:chunk></docset:_512PartB></docset:_512PartB-section></dg:chunk></dg:chunk></docset:Period2></docset:Period2-section></dg:chunk><docset:Parind1-section><dg:chunk structure="h1">

                                                Parind <docset:Parind1>1 </docset:Parind1></dg:chunk><docset:Period2-section structure="div"><dg:chunk structure="h1">

                                                                             Period <docset:Period2>2 </docset:Period2></dg:chunk><docset:Period2 structure="div"><dg:chunk structure="p">

               Du </dg:chunk><docset:Abbreviations-section><dg:chunk structure="h1">

                       Abbreviations: </dg:chunk><docset:Abbreviations structure="div"><docset:InsulinTransition structure="p">CSII = continuous subcutaneous <dgm:Medication>insulin </dgm:Medication>infusion; MDI = multiple <dgc:Frequency>daily </dgc:Frequency>injection; MMTT = mixed meal <dgm:MedicalTest>tolerance <dgm:_testRef>test</dgm:_testRef></dgm:MedicalTest>; <dgm:Medication>NPH </dgm:Medication>= neutral <dgm:Medication>protamine </dgm:Medication>Hagedorn; SC = subcutaneous; T = telephone visit; <dg:chunk>T1DM </dg:chunk>= type 1 <dgm:Condition><dgm:Condition>diabetes </dgm:Condition>mellitus </dgm:Condition>a Prior to Period 1, patients on MDI therapy with any basal <dgm:Medication>insulin </dgm:Medication>other than <dgm:Medication>NPH </dgm:Medication>twice <dgc:Frequency>daily </dgc:Frequency>will transition to <dgm:Medication>NPH </dgm:Medication>twice <dgc:Frequency>daily </dgc:Frequency>therapy approximately <docset:InsulinTransitionPeriod>7 to 3 days </docset:InsulinTransitionPeriod>prior to Day -1 of Period 1. b <dgm:Medication>Insulin </dgm:Medication>transition is applicable if Period <docset:InsulinTransition>2 </docset:InsulinTransition>occurs &gt;<docset:InsulinTransition>3 </docset:InsulinTransition>to <docset:InsulinTransitionPeriod>7 days </docset:InsulinTransitionPeriod>after Period 1. The second MMTT assessment may occur on consecutive days but no more than <docset:MaximumMMTTAssessmentInterval>22 days </docset:MaximumMMTTAssessmentInterval>after the first MMTT. </docset:InsulinTransition><dg:chunk><docset:FigureITSA3IllustrationofStudyDesignforPartB-section><dg:chunk structure="h1">

              Figure ITSA.3. Illustration of <dgm:_testRef>study </dgm:_testRef>design for Part B. </dg:chunk><docset:FigureITSA3IllustrationofStudyDesignforPartB structure="div"><dg:chunk><dg:chunk><dg:chunk structure="p">

              Patients will be required to attend the <dgm:_testRef>study </dgm:_testRef>site on <docset:NumberofStudyVisits>3 </docset:NumberofStudyVisits>to <docset:NumberofStudyVisits>4 </docset:NumberofStudyVisits>occasions for <dg:chunk>Part B</dg:chunk>: </dg:chunk><docset:StudyVisits structure="ul" style="list-style-type: circle; boundingBox:{left: 444; top: 2265; width: 1640; height: 671; page: 36;}; boundingBox:{left: 443; top: 301; width: 1597; height: 60; page: 37;}; "><dg:chunk structure="li" style="boundingBox:{left: 444; top: 2265; width: 1634; height: 296; page: 36;}; "><dg:chunk structure="lim" style="boundingBox:{left: 444; top: 2267; width: 35; height: 58; page: 36;}; ">

                     • </dg:chunk><docset:ScreeningVisit structure="p">A <dgm:_testRef>screening </dgm:_testRef>visit (may occur up to <docset:ScreeningVisitWindow>28 days </docset:ScreeningVisitWindow>prior to Day <docset:ScreeningVisit>-1 </docset:ScreeningVisit>of Period 1). The informed consent/assent will be obtained from newly enrolled patients during this visit and a diary will be provided to document any AEs and/or hypoglycaemic events. The informed consent/assent is not applicable to patients continuing from Part A. </docset:ScreeningVisit></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 450.0; top: 2595.8; width: 1610.0; height: 183.2; page: 36;}; "><dg:chunk structure="lim" style="boundingBox:{left: 450.0; top: 2595.8; width: 125.0; height: 50.0; page: 36;}; ">

                     • </dg:chunk><docset:TelephoneVisit structure="p">A telephone visit is planned after <dgm:_testRef>screening </dgm:_testRef>and on or before Day <docset:TelephoneVisitDate>-10 </docset:TelephoneVisitDate>to inform patients of their eligibility and address any questions participants and parents may have about the upcoming <dgm:_testRef>test </dgm:_testRef>meal visits. </docset:TelephoneVisit></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 448; top: 2821.1; width: 1636; height: 114.9; page: 36;}; "><dg:chunk structure="lim" style="boundingBox:{left: 448; top: 2824; width: 25; height: 44; page: 36;}; ">

                     • </dg:chunk><docset:InpatientStayRequirements structure="p"><docset:NumberofInpatientOvernightStays>Two </docset:NumberofInpatientOvernightStays>separate inpatient overnight stays from <docset:FirstInpatientStayDate>Day-1 </docset:FirstInpatientStayDate>to Day <dgc:Number>1 </dgc:Number>(<docset:InpatientStay>1 </docset:InpatientStay>in each <dgm:_testRef>study </dgm:_testRef>period for MMTTs). These inpatient stays may occur on consecutive nights. </docset:InpatientStayRequirements></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 443; top: 301; width: 1597; height: 60; page: 37;}; "><dg:chunk structure="lim" style="boundingBox:{left: 443; top: 303; width: 33; height: 56; page: 37;}; ">

                     • </dg:chunk><dg:chunk structure="p">A follow-up visit at least <docset:Follow-upVisit>14 days </docset:Follow-upVisit>after the last dose or early discontinuation </dg:chunk></dg:chunk></docset:StudyVisits></dg:chunk><docset:DischargeCriteria structure="p">

              Patients will be discharged from the <dgm:_testRef>study </dgm:_testRef>site on Day <docset:DischargeDate>1 </docset:DischargeDate>(at least <docset:DischargeTime>7 hours </docset:DischargeTime>after the <dgm:_testRef>test </dgm:_testRef>meal) or later, if deemed necessary for safety monitoring as determined by the investigator. </docset:DischargeCriteria><docset:InsulinTransition structure="p">

              Patients entering the <dgm:_testRef>study </dgm:_testRef>on MDI therapy with any basal <dgm:Medication>insulin </dgm:Medication>other than <dgm:Medication>NPH </dgm:Medication>twice <dgc:Frequency>daily </dgc:Frequency>will transition to <dgm:Medication>NPH </dgm:Medication>twice <dgc:Frequency>daily </dgc:Frequency>therapy approximately <docset:TransitionPeriod>7 to 3 days </docset:TransitionPeriod>prior to Day -1 of Period 1. On Day -1, the last injection of <dgm:Medication>NPH </dgm:Medication>prior to the MMTT will occur in the morning and will resume only after the completion of the MMTT assessment (<docset:MMTTAssessmentTime><dg:chunk>~7 </dg:chunk>hours </docset:MMTTAssessmentTime>postdose on Day 1). </docset:InsulinTransition></dg:chunk><docset:_5121InpatientProceduresforPart-section><dg:chunk structure="h1">

              <docset:InpatientProcedures>5.1.2.1</docset:InpatientProcedures>. <dg:chunk>Inpatient Procedures </dg:chunk>for Part </dg:chunk><docset:_5121InpatientProceduresforPart structure="div"><dg:chunk><docset:StudyProcedures structure="p">B On the day before each MMTT day (i.e ., Day-1 in each of the 2 periods if performed on non-consecutive days), patients will arrive at the <dgm:_testRef>study </dgm:_testRef>site in the early evening (approximately <docset:DinnerTime>05:00 PM)</docset:DinnerTime>. Patients on CSII pump will be advised to bring a spare infusion set for the CSII pump when they arrive at the <dgm:_testRef>study </dgm:_testRef>site. Patients who are not using pump will be switched to a Cl pump during the inpatient procedures. A standardised dinner will be provided where the bolus dose of the patient's usual <dgm:Medication>insulin </dgm:Medication>will be administered via CSII for this meal. Patients on MDI will be started on CCI |pump following the evening meal. The pump reservoir will be filled with the <dgm:_testRef>study </dgm:_testRef><dgm:Medication>insulin</dgm:Medication>, either <docset:StudyInsulin>LY900014 </docset:StudyInsulin>or <dgm:Medication>Humalog</dgm:Medication>, and a new standard infusion set and catheter will be inserted after a priming dose has been given to <dgm:_testRef>test </dgm:_testRef>the catheter. In case of immediate infusion set intolerance, a new needle can be inserted up until <docset:EndofDinnerBolus>12:00 AM (midnight)</docset:EndofDinnerBolus>. Following the evening meal, patients will continue their current pump basal rate until the start of the run-in period at which time a fixed low basal rate of <docset:DinnerBolusDose>0.1 </docset:DinnerBolusDose>U/hour will be maintained until <docset:DinnerBolusAdministration>2 hours </docset:DinnerBolusAdministration>before the scheduled start time of MMTT. For patients transitioning from MDI therapy, the bolus dose used for the evening meal will be based on their usual <dgm:Medication>insulin </dgm:Medication>to carbohydrate ratio and correction factor if applicable. Additionally, the basal <dgm:Medication>insulin </dgm:Medication>rate for the period between dinner and the start of the overnight infusion should be determined using the <docset:DinnerBolusDose>80% </docset:DinnerBolusDose>of the pre-<dgm:_testRef>study </dgm:_testRef>total <dgc:Frequency>daily </dgc:Frequency><dgm:Medication>NPH </dgm:Medication>dose divided by <docset:DinnerBolus>24 hours </docset:DinnerBolus>to obtain the hourly basal <dgm:Medication>insulin </dgm:Medication>infusion rate. The new basal rate may be titrated as needed based on the investigator's discretion. Before the start of a run-in period, the cannulation of the vein will be performed. Start of the run-in period will occur following the evening meal (at approximately <docset:DinnerTime>09:00 </docset:DinnerTime>or <docset:DinnerBolus>10:00 </docset:DinnerBolus>PM). The run-in period will start with a variable IV infusion of glucose (5% <dgm:Medication>dextrose </dgm:Medication>solution) or RHI to reach a target glucose level of <docset:DinnerBolusDose>135</docset:DinnerBolusDose>+25 mg/dL (<docset:DinnerBolusDose>7.5</docset:DinnerBolusDose>+<docset:StudyProcedures>1.4 </docset:StudyProcedures>mmol/L). If this target glucose level is not attained before <docset:StudyInsulin>1100 </docset:StudyInsulin>hours on Day 1, MMTT will be halted and may be performed on a separate visit; an MMTT can only be rescheduled (up to 7 days) once for each <dgm:_testRef>study </dgm:_testRef>period. During the run-in period, blood glucose concentrations will be monitored at a minimum of 30- to 60-minute intervals. </docset:StudyProcedures><dg:chunk><docset:TestMeal structure="p">

              The run-in period will end once the target blood glucose level is attained and remains stable without intervention for at least <docset:Run-InPeriodEndTime>20 minutes </docset:Run-InPeriodEndTime>immediately before the scheduled start time of MMTT on Day 1. The MMTT will start in the early morning at approximately <docset:StartTime>08:00 AM </docset:StartTime>with allowance up to <docset:EndofRun-InPeriod>11:00 AM</docset:EndofRun-InPeriod>, if required, to ensure the patient's blood glucose is stable and at target, with the premeal activities as specified in the Schedule of Activities (Section 2). <dg:chunk>LY900014 </dg:chunk>or <dgm:Medication>Humalog </dgm:Medication>SC bolus will be administered immediately before the start of MMTT via the pump. The liquid <dgm:_testRef>test </dgm:_testRef>meal will be administered on Day 1 for each of the <docset:Run-InPeriodEndDate>2 </docset:Run-InPeriodEndDate>treatment periods. A detailed description of the <dgm:_testRef>test </dgm:_testRef>meal is presented in Section 6.3.1. Patients are expected to complete each <dgm:_testRef>test </dgm:_testRef>meal within <docset:MealAdministrationTime>15 minutes </docset:MealAdministrationTime>of starting the meal. Patients will be without further oral food intake following consumption of liquid <dgm:_testRef>test </dgm:_testRef>meal to completion of blood glucose collection (approximately <docset:TestMealDuration>300 minutes</docset:TestMealDuration>) unless required to treat hypoglycaemia, as defined by the PG level ≤70 mg/dL (<docset:Run-InPeriodEndCriteria>3.9 </docset:Run-InPeriodEndCriteria>mM) with symptoms or any PG &lt;60 mg/dL (<docset:Run-InPeriod>3.0 </docset:Run-InPeriod>mM) during the inpatient period, i.e ., reversed with either rapidly absorbable oral carbohydrates or IV glucose. If a patient's blood glucose concentration rises above 300 mg/dL (<docset:Run-InPeriodEnd>16.7 </docset:Run-InPeriodEnd>mM) for more than <docset:Run-InPeriodEndTime>1 hour</docset:Run-InPeriodEndTime>, RHI will be administered IV. In both cases, blood samples for blood glucose (for safety) will be taken and PK samples will be collected as planned. For each MMTT, the patient should stay in a sitting or semisupine position for <docset:Run-inPeriodEndTime>2 hours </docset:Run-inPeriodEndTime>postdose and the patient will not be allowed to consume water for <dgc:TimeDuration>2 hours </dgc:TimeDuration>after dosing. If necessary, patients may be given a low carbohydrate snack (&lt;20 g carbohydrate), which does not require an <dgm:Medication>insulin </dgm:Medication>dose, after GD assessments (approximately 300 minutes postdose). If Period 2 is performed on non-consecutive days, following completion of the assessment period and sample collection (approximately 420 minutes), the pump will be disconnected. For patients who used CSII pre-<dgm:_testRef>study</dgm:_testRef>, a new reservoir should be filled with their usual pump <dgm:Medication>insulin </dgm:Medication>and a new infusion set should be inserted as directed by the <dgm:_testRef>study </dgm:_testRef>site. The basal rates may be returned to the patient's usual basal settings (see Figure ITSA.4). </docset:TestMeal><docset:InsulinAdministration structure="p">

              For patients who were using MDI therapy, the investigator shall provide guidance on whether they should resume their pre-<dgm:_testRef>study </dgm:_testRef>basal <dgm:Medication>insulin </dgm:Medication>at the end of Period <docset:BasalInsulinResumption>1 </docset:BasalInsulinResumption>or continue with <dgm:Medication>NPH </dgm:Medication>depending on the length of time between Period <dgc:Number>1 </dgc:Number>and Period 2. All patients will be offered a meal at the conclusion of the MMTT assessment period. </docset:InsulinAdministration><docset:StudyInsulinAdministration structure="p">

              For patients who opt to complete Period 2 on consecutive days, the pump reservoir will be filled with the other <dgm:_testRef>study </dgm:_testRef><dgm:Medication>insulin</dgm:Medication>, either LY900014 or <dgm:Medication>Humalog</dgm:Medication>, and a new standard infusion set and catheter will be inserted prior to administration of the evening meal. In case of immediate infusion set intolerance, a new needle can be inserted up until <docset:EndofPeriod2>12:00 AM (midnight)</docset:EndofPeriod2>. A standardised dinner will be provided where the bolus dose for this meal will be administered via <dgc:Org>CSII</dgc:Org>. Following the evening meal, patients will continue their current pump basal rate until the start of the run-in period at which time a fixed low basal rate of <docset:BasalRate>0.1 </docset:BasalRate>U/hour will be maintained until <docset:Run-inPeriod>2 hours </docset:Run-inPeriod>before the scheduled start time of MMTT. A similar approach to that used in Period 1 will be used to manage the evening meal bolus, the run-in period, overnight basal <dgm:Medication>insulin </dgm:Medication>infusion, administration of <dgm:_testRef>study </dgm:_testRef><dgm:Medication>insulin </dgm:Medication>bolus, and conduct of the <docset:MMTTDetails>MMTT</docset:MMTTDetails>. At the end of the MMTT assessment period, patients who used <docset:ContinuousSubcutaneousInsulinInfusion>CSII </docset:ContinuousSubcutaneousInsulinInfusion>pre-<dgm:_testRef>study </dgm:_testRef>should fill a new reservoir with their usual pump <dgm:Medication>insulin </dgm:Medication>and a new infusion set should be inserted as directed by the <dgm:_testRef>study </dgm:_testRef>site. The basal rates may be returned to the patient's usual basal settings. Patients previously treated with MDI therapy should resume their pre-<dgm:_testRef>study </dgm:_testRef>MIDI therapy at the end of Period 2 as directed by the site. All patients will be offered a meal at the conclusion of the MMTT assessment period. Patients will be observed following administration of the meal and discharged at the investigator's discretion. Assessment of local tolerability at all injection sites will be performed as specified in the Schedule of Activities (Section 2), including inspection of the injection/catheter site for signs such as oedema, <dgm:Condition>erythema</dgm:Condition>, and rash </docset:StudyInsulinAdministration><docset:StudyDesign structure="p">

              For each inpatient visit, serial blood samples will be collected over approximately <docset:TestMealDuration>420 minutes </docset:TestMealDuration>to assess the PK and GD response following the start of each <dgm:_testRef>test </dgm:_testRef>meal. 18B-MC-ITSA(d) Clinical Pharmacology Protocol </docset:StudyDesign></dg:chunk></dg:chunk><docset:Page39-section><dg:chunk structure="h1">

                                                                                                                                    Page <docset:PageNumber>39 </docset:PageNumber></dg:chunk><docset:Page39 structure="div"><dg:chunk><dg:chunk structure="p">

                                Admission to <dgm:_testRef>study </dgm:_testRef>site </dg:chunk><docset:AdmissiontoStudySite><xhtml:table structure="table" style="boundingBox:{left: 444.7; top: 405; width: 2516.1; height: 946.3; page: 40;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 444.7; top: 405; width: 2516.1; height: 946.3; page: 40;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 444.7; top: 405; width: 2516.1; height: 184.0; page: 40;}; "><xhtml:td structure="td" style="boundingBox:{left: 444.7; top: 405; width: 508.0; height: 184.0; page: 40;}; " colspan="2"><dg:chunk structure="h1">

                        MDI patients: Last dose of <dgm:Medication><dgm:Medication>NPH </dgm:Medication><dgm:Medication>insulin </dgm:Medication></dgm:Medication></dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 952.7; top: 405; width: 728.8; height: 184.0; page: 40;}; "><dg:chunk structure="p">

                         Basal <dgm:Medication>insulin </dgm:Medication>rate changed to single hourly rate of <docset:BasalInsulinRate>0.1 </docset:BasalInsulinRate>U/hour </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1681.5; top: 405; width: 446.2; height: 184.0; page: 40;}; " colspan="3"><dg:chunk structure="p">

                        SC bolus of <dgm:_testRef>study </dgm:_testRef>drug via CSII followed by <docset:MMTTBolus>MMTT </docset:MMTTBolus></dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2127.7; top: 405; width: 833.2; height: 184.0; page: 40;}; " colspan="2">

                                           Restart prestudy <docset:SCBolusofStudyDrugViaCSIIFollowedbyMMTT>insulin </docset:SCBolusofStudyDrugViaCSIIFollowedbyMMTT></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 444.7; top: 589.0; width: 2516.1; height: 48.5; page: 40;}; "><xhtml:td structure="td" style="boundingBox:{left: 444.7; top: 589.0; width: 288.8; height: 48.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 733.5; top: 589.0; width: 219.2; height: 48.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 952.7; top: 589.0; width: 728.8; height: 48.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1681.5; top: 589.0; width: 213.0; height: 48.5; page: 40;}; "><docset:RestartPrestudyInsulin>

                       <dg:chunk>Stable BG </dg:chunk></docset:RestartPrestudyInsulin></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1894.5; top: 589.0; width: 92.6; height: 48.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1987.1; top: 589.0; width: 140.5; height: 48.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2127.7; top: 589.0; width: 517.3; height: 48.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2645.0; top: 589.0; width: 315.8; height: 48.5; page: 40;}; "><docset:MDIPatientsLastDoseofNPHInsulin /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 444.7; top: 637.5; width: 2516.1; height: 93.0; page: 40;}; "><xhtml:td structure="td" style="boundingBox:{left: 444.7; top: 637.5; width: 288.8; height: 93.0; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 733.5; top: 637.5; width: 219.2; height: 93.0; page: 40;}; "><docset:BasalInsulinRateChangedtoSingleHourlyRateof01UHour>

                         Dinner </docset:BasalInsulinRateChangedtoSingleHourlyRateof01UHour></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 952.7; top: 637.5; width: 728.8; height: 93.0; page: 40;}; "><docset:SCBolusofStudyDrugViaCSIIFollowedbyMMTT>

                                           Rum-in </docset:SCBolusofStudyDrugViaCSIIFollowedbyMMTT></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1681.5; top: 637.5; width: 305.6; height: 93.0; page: 40;}; " colspan="2"><docset:RestartPrestudyInsulin>

                       <docset:Pre-MMTTTime><dg:chunk>≥20 </dg:chunk>mins </docset:Pre-MMTTTime>before MMTT </docset:RestartPrestudyInsulin></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1987.1; top: 637.5; width: 140.5; height: 93.0; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2127.7; top: 637.5; width: 517.3; height: 93.0; page: 40;}; ">

                            <docset:MMTT>MMTT </docset:MMTT></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2645.0; top: 637.5; width: 315.8; height: 93.0; page: 40;}; "><docset:BasalInsulinRateChangedtoSingleHourlyRateof01UHour /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 444.7; top: 730.5; width: 2516.1; height: 34.5; page: 40;}; "><xhtml:td structure="td" style="boundingBox:{left: 444.7; top: 730.5; width: 288.8; height: 34.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 733.5; top: 730.5; width: 219.2; height: 34.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 952.7; top: 730.5; width: 728.8; height: 34.5; page: 40;}; "><docset:SCBolusofStudyDrugViaCSIIFollowedbyMMTT>

                               Cc </docset:SCBolusofStudyDrugViaCSIIFollowedbyMMTT></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1681.5; top: 730.5; width: 213.0; height: 34.5; page: 40;}; "><docset:RestartPrestudyInsulin>

                          “a </docset:RestartPrestudyInsulin></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1894.5; top: 730.5; width: 92.6; height: 34.5; page: 40;}; ">

                      mt </xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1987.1; top: 730.5; width: 140.5; height: 34.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2127.7; top: 730.5; width: 517.3; height: 34.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2645.0; top: 730.5; width: 315.8; height: 34.5; page: 40;}; "><docset:MDIPatientsLastDoseofNPHInsulin /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 444.7; top: 765.0; width: 2516.1; height: 16.5; page: 40;}; "><xhtml:td structure="td" style="boundingBox:{left: 444.7; top: 765.0; width: 288.8; height: 16.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 733.5; top: 765.0; width: 219.2; height: 16.5; page: 40;}; "><docset:BasalInsulinRateChangedtoSingleHourlyRateof01UHour>

                       Fr on </docset:BasalInsulinRateChangedtoSingleHourlyRateof01UHour></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 952.7; top: 765.0; width: 728.8; height: 16.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1681.5; top: 765.0; width: 213.0; height: 16.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1894.5; top: 765.0; width: 92.6; height: 16.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1987.1; top: 765.0; width: 140.5; height: 16.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2127.7; top: 765.0; width: 517.3; height: 16.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2645.0; top: 765.0; width: 315.8; height: 16.5; page: 40;}; "><docset:RestartPrestudyInsulin /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 444.7; top: 781.5; width: 2516.1; height: 20.5; page: 40;}; "><xhtml:td structure="td" style="boundingBox:{left: 444.7; top: 781.5; width: 288.8; height: 20.5; page: 40;}; "><docset:MDIPatientsLastDoseofNPHInsulinCFt>

                              c ft </docset:MDIPatientsLastDoseofNPHInsulinCFt></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 733.5; top: 781.5; width: 219.2; height: 20.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 952.7; top: 781.5; width: 728.8; height: 20.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1681.5; top: 781.5; width: 213.0; height: 20.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1894.5; top: 781.5; width: 92.6; height: 20.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1987.1; top: 781.5; width: 140.5; height: 20.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2127.7; top: 781.5; width: 517.3; height: 20.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2645.0; top: 781.5; width: 315.8; height: 20.5; page: 40;}; "><docset:CFtRestartPrestudyInsulin /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 444.7; top: 802.0; width: 2516.1; height: 50.5; page: 40;}; "><xhtml:td structure="td" style="boundingBox:{left: 444.7; top: 802.0; width: 288.8; height: 50.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 733.5; top: 802.0; width: 219.2; height: 50.5; page: 40;}; "><docset:BasalInsulinRateChangedtoSingleHourlyRateof01UHour>

                        Ww </docset:BasalInsulinRateChangedtoSingleHourlyRateof01UHour></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 952.7; top: 802.0; width: 728.8; height: 50.5; page: 40;}; "><docset:SCBolusofStudyDrugViaCSIIFollowedbyMMTT>

                     i 

                               | </docset:SCBolusofStudyDrugViaCSIIFollowedbyMMTT></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1681.5; top: 802.0; width: 213.0; height: 50.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1894.5; top: 802.0; width: 92.6; height: 50.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1987.1; top: 802.0; width: 140.5; height: 50.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2127.7; top: 802.0; width: 517.3; height: 50.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2645.0; top: 802.0; width: 315.8; height: 50.5; page: 40;}; "><docset:SCBolusofStudyDrugViaCSIIFollowedbyMMTT /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 444.7; top: 852.5; width: 2516.1; height: 29.5; page: 40;}; "><xhtml:td structure="td" style="boundingBox:{left: 444.7; top: 852.5; width: 288.8; height: 29.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 733.5; top: 852.5; width: 219.2; height: 29.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 952.7; top: 852.5; width: 728.8; height: 29.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1681.5; top: 852.5; width: 213.0; height: 29.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1894.5; top: 852.5; width: 92.6; height: 150.0; page: 40;}; " rowspan="2">

                      <dgc:Number>1 </dgc:Number>

                      <dgc:Number>1 </dgc:Number></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1987.1; top: 852.5; width: 140.5; height: 29.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2127.7; top: 852.5; width: 517.3; height: 29.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2645.0; top: 852.5; width: 315.8; height: 29.5; page: 40;}; "><docset:BasalInsulinRateChangedtoSingleHourlyRateof01UHour /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 444.7; top: 882.0; width: 2516.1; height: 120.5; page: 40;}; "><xhtml:td structure="td" style="boundingBox:{left: 444.7; top: 882.0; width: 288.8; height: 120.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 733.5; top: 882.0; width: 219.2; height: 120.5; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 952.7; top: 882.0; width: 728.8; height: 120.5; page: 40;}; "><docset:SCBolusofStudyDrugViaCSIIFollowedbyMMTT structure="h1">

                                        IV glucose/RHI target BG: <docset:GlucoseTarget>135</docset:GlucoseTarget><docset:GlucoseTarget>+</docset:GlucoseTarget><docset:GlucoseTargetRange>25 </docset:GlucoseTargetRange>mg/dL </docset:SCBolusofStudyDrugViaCSIIFollowedbyMMTT></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1681.5; top: 882.0; width: 213.0; height: 120.5; page: 40;}; "><docset:RestartPrestudyInsulin /></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1987.1; top: 882.0; width: 657.9; height: 120.5; page: 40;}; " colspan="2"><dg:chunk structure="h1">

                           BG sampling (until <docset:SamplingTime>300 mins </docset:SamplingTime>postdose) </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2645.0; top: 882.0; width: 315.8; height: 120.5; page: 40;}; " /></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 444.7; top: 1002.5; width: 2516.1; height: 20.0; page: 40;}; "><xhtml:td structure="td" style="boundingBox:{left: 444.7; top: 1002.5; width: 1236.8; height: 348.8; page: 40;}; " rowspan="5" colspan="3"><docset:MDIPatientsLastDoseofNPHInsulinCSIIPatientsChangetoCCIPumpAndNewS><dg:chunk><dg:chunk structure="h1">

                               CSII patients: </dg:chunk><dg:chunk structure="div">Change to <docset:PumpType>CCI </docset:PumpType>pump and new standard infusion set and catheter (<dgm:_testRef>study </dgm:_testRef>dru ?) <docset:MDIPatient>MDI </docset:MDIPatient>patients: start cc pump with <dgm:_testRef>study </dgm:_testRef>drug </dg:chunk></dg:chunk><docset:_7514MmolL-section><dg:chunk structure="h1">

                                                                (<docset:BloodGlucoseLevel>7.5</docset:BloodGlucoseLevel>+<docset:AdditionalGlucose>1.4 </docset:AdditionalGlucose>mmol/L) </dg:chunk><dg:chunk structure="ul" style="list-style-type: circle; boundingBox:{left: 644; top: 1233; width: 12; height: 36; page: 40;}; "><dg:chunk structure="li" style="boundingBox:{left: 644; top: 1233; width: 12; height: 36; page: 40;}; "><docset:_7514MmolL structure="lim" style="boundingBox:{left: 644; top: 1233; width: 12; height: 36; page: 40;}; ">

                              • </docset:_7514MmolL></dg:chunk></dg:chunk></docset:_7514MmolL-section><dg:chunk><dg:chunk structure="h1">

                     Timeline <docset:Timeline><docset:Timeline><docset:Timeline>7 </docset:Timeline><docset:AMPM>AM 5 </docset:AMPM></docset:Timeline><docset:Timeline>PM </docset:Timeline></docset:Timeline></dg:chunk><dg:chunk structure="h1">

                                                    <docset:StartTime>9</docset:StartTime><docset:Time>-</docset:Time><docset:EndTime>10 PM </docset:EndTime></dg:chunk></dg:chunk></docset:MDIPatientsLastDoseofNPHInsulinCSIIPatientsChangetoCCIPumpAndNewS></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1681.5; top: 1002.5; width: 213.0; height: 20.0; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1894.5; top: 1002.5; width: 92.6; height: 20.0; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1987.1; top: 1002.5; width: 140.5; height: 20.0; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2127.7; top: 1002.5; width: 517.3; height: 20.0; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2645.0; top: 1002.5; width: 315.8; height: 20.0; page: 40;}; "><docset:RestartPrestudyInsulinCSIIPatientsChangetoCCIPumpAndNewStandardInfus /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 444.7; top: 1022.5; width: 2516.1; height: 55.1; page: 40;}; "><xhtml:td structure="td" style="boundingBox:{left: 1681.5; top: 1022.5; width: 213.0; height: 55.1; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1894.5; top: 1022.5; width: 92.6; height: 55.1; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1987.1; top: 1022.5; width: 140.5; height: 55.1; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2127.7; top: 1022.5; width: 517.3; height: 55.1; page: 40;}; "><docset:RestartPrestudyInsulin>

                                                                                     PK sampling </docset:RestartPrestudyInsulin></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2645.0; top: 1022.5; width: 315.8; height: 55.1; page: 40;}; "><docset:SCBolusofStudyDrugViaCSIIFollowedbyMMTT /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 444.7; top: 1077.6; width: 2516.1; height: 51.9; page: 40;}; "><xhtml:td structure="td" style="boundingBox:{left: 1681.5; top: 1077.6; width: 213.0; height: 51.9; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1894.5; top: 1077.6; width: 92.6; height: 51.9; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1987.1; top: 1077.6; width: 140.5; height: 51.9; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2127.7; top: 1077.6; width: 517.3; height: 51.9; page: 40;}; "><docset:RestartPrestudyInsulin>

                                                                                (until <docset:MaximumDuration>420 </docset:MaximumDuration>mins postdose) </docset:RestartPrestudyInsulin></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2645.0; top: 1077.6; width: 315.8; height: 51.9; page: 40;}; " /></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 444.7; top: 1129.5; width: 2516.1; height: 113.0; page: 40;}; "><xhtml:td structure="td" style="boundingBox:{left: 1681.5; top: 1129.5; width: 213.0; height: 113.0; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1894.5; top: 1129.5; width: 92.6; height: 113.0; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 1987.1; top: 1129.5; width: 140.5; height: 113.0; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2127.7; top: 1129.5; width: 517.3; height: 113.0; page: 40;}; " /><xhtml:td structure="td" style="boundingBox:{left: 2645.0; top: 1129.5; width: 315.8; height: 113.0; page: 40;}; "><docset:RestartPrestudyInsulin /></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 444.7; top: 1242.5; width: 2516.1; height: 108.8; page: 40;}; "><xhtml:td structure="td" style="boundingBox:{left: 1681.5; top: 1242.5; width: 446.2; height: 108.8; page: 40;}; " colspan="3"><docset:MDIPatientsLastDoseofNPHInsulin8AM-11AM structure="h1">

                                                                                       <docset:HoursofOperation><docset:HoursofOperation>8 </docset:HoursofOperation><docset:MorningHours>AM - </docset:MorningHours><docset:EndTime>11 <docset:MorningHours>AM </docset:MorningHours></docset:EndTime></docset:HoursofOperation></docset:MDIPatientsLastDoseofNPHInsulin8AM-11AM></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2127.7; top: 1242.5; width: 517.3; height: 108.8; page: 40;}; "><docset:_8AM-11AMBasalInsulinRateChangedtoSingleHourlyRateof01UHour structure="h1">

                                                                                              <docset:EventHours><docset:EventTime>1 </docset:EventTime><docset:EventTime>PM </docset:EventTime>- <docset:EventTime>4 <dgc:State>PM </dgc:State></docset:EventTime></docset:EventHours></docset:_8AM-11AMBasalInsulinRateChangedtoSingleHourlyRateof01UHour></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 2645.0; top: 1242.5; width: 315.8; height: 108.8; page: 40;}; "><docset:_8AM-11AMSCBolusofStudyDrugViaCSIIFollowedbyMMTT structure="h1">

                                                                                 <docset:HoursofOperation><docset:Hours><docset:Hours>3 </docset:Hours><docset:EventTime>PM - 6 </docset:EventTime></docset:Hours><docset:EventTime>PM </docset:EventTime></docset:HoursofOperation></docset:_8AM-11AMSCBolusofStudyDrugViaCSIIFollowedbyMMTT></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:AdmissiontoStudySite></dg:chunk><dg:chunk><dg:chunk structure="h1">

                  (Approximation) </dg:chunk><dg:chunk structure="div"><dg:chunk><docset:Abbreviations-section><dg:chunk structure="h1">

                                     Abbreviations: </dg:chunk><docset:Abbreviations structure="div">BG = blood glucose; CSII = continuous subcutaneous <dgm:Medication>insulin </dgm:Medication>infusion; IV = intravenous; MDI = multiple <dgc:Frequency>daily </dgc:Frequency>injection; MMTT = mixed meal <dgm:MedicalTest>tolerance <dgm:_testRef>test</dgm:_testRef></dgm:MedicalTest>; <dgm:Medication>NPH </dgm:Medication>= neutral <dgm:Medication>protamine </dgm:Medication>Hagedorn; PK = pharmacokinetics; RHI = regular human <dgm:Medication>insulin</dgm:Medication>; SC = subcutaneous </docset:Abbreviations></docset:Abbreviations-section><dg:chunk structure="p">

              Figure <docset:ITSA4>ITSA.4</docset:ITSA4>. </dg:chunk></dg:chunk><docset:InpatientProcedureinPartB-section><dg:chunk structure="h1">

                                    Inpatient procedure in Part B. </dg:chunk><docset:InpatientProcedureinPartB structure="div"><dg:chunk structure="p">

              <docset:LY900014>LY900014 </docset:LY900014></dg:chunk><dg:chunk><docset:_52NumberofParticipants-section><dg:chunk structure="h1">

              <docset:NumberofParticipants>5.2</docset:NumberofParticipants>. Number of Participants </dg:chunk><docset:_52NumberofParticipants structure="div"><dg:chunk><docset:StudyEnrollment structure="p">

              Approximately <docset:NumberofPatients>45 </docset:NumberofPatients>patients may be enrolled into the <dgm:_testRef>study </dgm:_testRef>so that approximately <dgc:Number>36 </dgc:Number>patients (<docset:NumberofPatients>12 </docset:NumberofPatients>patients in each age group [<docset:NumberofPatients>6 </docset:NumberofPatients>to &lt;<dgc:TimeDuration>12 </dgc:TimeDuration>years, <dgc:Number>12 </dgc:Number>to &lt;18 years, and <docset:NumberofPatients>18 </docset:NumberofPatients>to &lt;<docset:NumberofPatients>65 </docset:NumberofPatients>years] based on the age at initial <dgm:_testRef>screening</dgm:_testRef>) complete both inpatient periods in both the parts of the <dgm:_testRef>study</dgm:_testRef>. Patients participating in <dg:chunk>Part A </dg:chunk>may continue participation in Part B. If patients from Part A decline participation in <dg:chunk>Part B </dg:chunk>or drop out from <dg:chunk>Part A</dg:chunk>, additional patients will be enrolled to ensure approximately <docset:NumberofPatients>36 </docset:NumberofPatients>patients (<dgc:Number>12 </dgc:Number>patients in each age group) complete both periods in <dg:chunk>Part B </dg:chunk>of the <dgm:_testRef>study</dgm:_testRef>. </docset:StudyEnrollment><docset:StudyDesign structure="ol" style="list-style-type: decimal; boundingBox:{left: 289; top: 923.2; width: 1942; height: 1822.8; page: 41;}; "><dg:chunk structure="li" style="boundingBox:{left: 293; top: 923.2; width: 1948.0; height: 193.8; page: 41;}; "><dg:chunk structure="lim" style="boundingBox:{left: 293; top: 922; width: 114; height: 64; page: 41;}; ">

              5.3. </dg:chunk><docset:EndofStudyDefinition-section><dg:chunk structure="h1">End of <dg:chunk><dgm:_testRef>Study </dgm:_testRef>Definition </dg:chunk></dg:chunk><docset:EndofStudyDefinition structure="div">              End of the <dgm:_testRef>study </dgm:_testRef>is the date of the last visit or last scheduled procedure shown in the Schedule of Activities (Section 2) for the last patient. </docset:EndofStudyDefinition></docset:EndofStudyDefinition-section></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 289; top: 1175; width: 1956; height: 949; page: 41;}; "><dg:chunk structure="lim" style="boundingBox:{left: 289; top: 1176; width: 123; height: 62; page: 41;}; ">

              5.4. </dg:chunk><docset:ScientificRationaleFor-section><dg:chunk structure="h1"><dg:chunk>Scientific Rationale </dg:chunk>for </dg:chunk><docset:ScientificRationaleFor structure="div"><dg:chunk><dgm:_testRef>Study </dgm:_testRef>Design </dg:chunk>Each <dgm:_testRef>study </dgm:_testRef>part consists of a <docset:StudyDesign>2</docset:StudyDesign>-period crossover design to reduce the variability of <dgm:Medication>insulin </dgm:Medication>PK and GD, as each patient will act as his/her own control. The total number of patients needed for a crossover design is less than the number needed for a parallel group design.               Randomisation and blinding are used to avoid bias introduced through an association between allocation order of <dgm:_testRef>study </dgm:_testRef>drug and patient characteristics. In each <dgm:_testRef>study </dgm:_testRef>period, patients will undergo a run-in period before the MMTT using a variable <dgm:Medication>insulin </dgm:Medication>and glucose IV infusion. This run-in will allow for improved comparability of the postprandial glucose response to a mixed meal after treatment with <docset:StudyDesign>LY900014 </docset:StudyDesign>and <dgm:Medication>Humalog </dgm:Medication>administered immediately before the start of the meal. This run-in aims to achieve similar preprandial glucose levels for all patients before the start of the <dgm:_testRef>test </dgm:_testRef>meal and thereby reduces the variability of the postprandial glucose response. Regular human <dgm:Medication>insulin </dgm:Medication>has been chosen for the IV optimisation of PG during the run-in because RHI does not cross-react with the <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro</dgm:Medication>-specific assay used for the PK analysis. </docset:ScientificRationaleFor></docset:ScientificRationaleFor-section></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 296; top: 2170; width: 1858; height: 202; page: 41;}; "><dg:chunk structure="lim" style="boundingBox:{left: 296; top: 2170; width: 111; height: 67; page: 41;}; ">

              5.5. </dg:chunk><docset:JustificationforDose-section><dg:chunk structure="h1">Justification for Dose </dg:chunk><docset:JustificationforDose structure="div">The bolus dose of <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>(<docset:InsulinLispro>LY900014 </docset:InsulinLispro>or <dgm:Medication>Humalog</dgm:Medication>) will be fixed dose by body weight (<docset:InsulinDose>0.2 </docset:InsulinDose>U/kg). Based on previous studies of both <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>(<dgm:Medication>Humalog</dgm:Medication>) and <dgc:Number>LY900014</dgc:Number>, a </docset:JustificationforDose></docset:JustificationforDose-section></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 290; top: 2369; width: 1941; height: 377; page: 41;}; "><dg:chunk structure="lim" style="boundingBox:{left: 298; top: 2372; width: 60; height: 57; page: 41;}; ">

              0.2 </dg:chunk><docset:StudyDesign structure="p">U/kg prandial dose is necessary to provide measurable PK and GD profiles for both <dgm:_testRef>study </dgm:_testRef>insulins. This dose level has been previously examined in paediatric patients with another rapid-acting analogue with no apparent hypoglycaemic risk (<docset:StudyDesign>Fath </docset:StudyDesign>et al. <docset:StudyDesign>2017</docset:StudyDesign>). Furthermore, the occurrence of hypoglycaemia in patients with <dg:chunk>T1DM </dg:chunk>or T2DM participating in previous <dgm:_testRef>test </dgm:_testRef>meal studies with <docset:StudyInsulin>LY900014 </docset:StudyInsulin>was also low, since patients do not receive significant basal <dgm:Medication>insulin </dgm:Medication>coverage during the course of the MMTT. </docset:StudyDesign></dg:chunk></docset:StudyDesign></dg:chunk><dg:chunk><docset:InsulinDoseRequirements structure="p">

              Meal size differs between adults and children. Due to this, the volume of the liquid <dgm:_testRef>test </dgm:_testRef>meal for the MMTT will be adjusted by weight for the child and adolescent patients within the <dgm:_testRef>study</dgm:_testRef>. However, the adult patients in the <dgm:_testRef>study </dgm:_testRef>will receive a set volume for the MMTT. For each patient, the individualised prandial <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>dose in <docset:StudyDrugDose>LY900014 </docset:StudyDrugDose>and <dgm:Medication>Humalog </dgm:Medication>for each <dgm:_testRef>test </dgm:_testRef>meal must be kept identical throughout the crossover periods for both <dg:chunk>Part A </dg:chunk>and Part B. If the investigator determines that it would be unsafe to repeat the same dose, the patient should be discontinued. A minimum <docset:MinimumWeightRequirement><docset:MinimumWeightRequirement>weight </docset:MinimumWeightRequirement>of <docset:MinimumWeightRequirement><docset:MinimumWeightRequirement>25 </docset:MinimumWeightRequirement>kg </docset:MinimumWeightRequirement></docset:MinimumWeightRequirement>is required for this <dgm:_testRef>study </dgm:_testRef>in order to have sufficient doseCCI to characterise both the serum <dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro </dgm:Medication>absorption and elimination following <dgm:_testRef>study </dgm:_testRef>drug administration. </docset:InsulinDoseRequirements><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 962.5; top: 308.3; width: 620.8; height: 66.7; page: 43;}; "><dg:chunk structure="li" style="boundingBox:{left: 962.5; top: 308.3; width: 620.8; height: 66.7; page: 43;}; "><dg:chunk structure="lim" style="boundingBox:{left: 962.5; top: 308.3; width: 54.2; height: 66.7; page: 43;}; ">

                                             6. </dg:chunk><dg:chunk structure="h1"><dgm:_testRef>Study </dgm:_testRef>Population </dg:chunk></dg:chunk></dg:chunk></dg:chunk><docset:PatientEligibilityCriteria structure="p">

              Eligibility of patients for the <dgm:_testRef>study </dgm:_testRef>will be based on the results of <dgm:_testRef>screening </dgm:_testRef>medical history, physical <dgm:_testRef>examination</dgm:_testRef>, <dgm:MedicalTest>vital signs</dgm:MedicalTest>, clinical laboratory tests, and electrocardiogram (<dgm:MedicalTest>ECG</dgm:MedicalTest>). </docset:PatientEligibilityCriteria><docset:PhysicalExaminationFindings structure="p">

              The nature of any conditions present at the time of the physical <dgm:_testRef>examination </dgm:_testRef>and any preexisting conditions will be documented. </docset:PhysicalExaminationFindings><docset:ScreeningPeriod structure="p">

              <dgm:_testRef>Screening </dgm:_testRef>may occur up to <dgc:TimeDuration>28 days </dgc:TimeDuration>prior to Day <docset:ScreeningPeriod>-1 </docset:ScreeningPeriod>of Period 1 for both <dg:chunk>Part A </dg:chunk>and Part B. Patients who are not enrolled within <docset:ScreeningPeriod>28 days </docset:ScreeningPeriod>of <dgm:_testRef>screening </dgm:_testRef>may be subjected to an additional medical assessment and/or clinical measurements to confirm their eligibility. </docset:ScreeningPeriod><dg:chunk><docset:RecruitmentandEnrolmentCriteria structure="p">

              Prospective approval of protocol deviations to recruitment and enrolment criteria, also known as protocol waivers or exemptions, is not permitted. </docset:RecruitmentandEnrolmentCriteria><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 295.8; top: 1137.5; width: 629.2; height: 58.3; page: 43;}; "><dg:chunk structure="li" style="boundingBox:{left: 295.8; top: 1137.5; width: 629.2; height: 58.3; page: 43;}; "><dg:chunk structure="lim" style="boundingBox:{left: 295.8; top: 1137.5; width: 100.0; height: 58.3; page: 43;}; ">

              6.1. </dg:chunk><dg:chunk structure="h1">Inclusion <docset:InclusionCriteria>Criteria </docset:InclusionCriteria></dg:chunk></dg:chunk></dg:chunk></dg:chunk><dg:chunk><docset:InclusionCriteria structure="p">

              Patients are eligible for inclusion in the <dgm:_testRef>study </dgm:_testRef>only if they meet all of the following criteria at <dgm:_testRef>screening </dgm:_testRef>and/or enrolment: </docset:InclusionCriteria><dg:chunk><docset:InclusionCriteria structure="ol" style="list-style-type: lower-alpha; boundingBox:{left: 416.7; top: 1358.3; width: 1675.0; height: 519.4; page: 43;}; boundingBox:{left: 416.7; top: 1358.3; width: 1658.3; height: 1450.0; page: 44;}; boundingBox:{left: 417.0; top: 308.3; width: 1674.7; height: 223.7; page: 45;}; "><dg:chunk structure="li" style="boundingBox:{left: 416.7; top: 1358.3; width: 1675.0; height: 283.3; page: 43;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 1358.3; width: 58.3; height: 50.0; page: 43;}; ">

                    [1] </dg:chunk><docset:InclusionCriteria structure="p">male or female patients with a diagnosis of <dg:chunk>T1DM </dg:chunk>based on medical history for at least <docset:DiagnosisDuration>1 year </docset:DiagnosisDuration>as previously demonstrated by either documented presence of autoimmune antibodies (glutamic acid decarboxylases; <dgm:Medication>insulin</dgm:Medication>-associated tyrosine phosphatase antibody; <dgm:Medication>insulin </dgm:Medication>autoantibody; islet cell antibody) as per medical records, or diagnosis by an endocrinologist (paediatric or adult). </docset:InclusionCriteria></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 448.0; top: 1679.2; width: 1543.7; height: 108.3; page: 43;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 1679.2; width: 83.3; height: 50.0; page: 43;}; ">

                     [1a] </dg:chunk><dg:chunk>no male contraception required except in compliance with specific local government requirements </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 447.6; top: 1829.2; width: 1639.9; height: 720.8; page: 43;}; boundingBox:{left: 545.8; top: 650.0; width: 1479.2; height: 108.3; page: 44;}; "><dg:chunk structure="lim" style="boundingBox:{left: 445.8; top: 1829.2; width: 83.3; height: 50.0; page: 43;}; ">

                     [1b] </dg:chunk><docset:FemalePatients-section><dg:chunk structure="h1">female patients: </dg:chunk><docset:FemalePatients structure="ol" style="list-style-type: lower-roman; boundingBox:{left: 545.8; top: 1916.7; width: 1541.7; height: 633.3; page: 43;}; boundingBox:{left: 545.8; top: 650.0; width: 1479.2; height: 108.3; page: 44;}; "><dg:chunk structure="li" style="boundingBox:{left: 570.8; top: 1916.7; width: 1370.8; height: 105.3; page: 43;}; "><dg:chunk structure="lim" style="boundingBox:{left: 570.8; top: 1916.7; width: 25.0; height: 50.0; page: 43;}; ">

                           i. </dg:chunk><docset:FemaleAgeDefinition structure="p">Post-pubertal females are defined as children and adolescents <docset:AgeofOnset>≥12 </docset:AgeofOnset><docset:AgeatMenarche>years </docset:AgeatMenarche>of age or &lt;<docset:AgeofOnset>12 years </docset:AgeofOnset>of age who have onset of menses </docset:FemaleAgeDefinition></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 558.3; top: 2062.5; width: 1529.2; height: 281.8; page: 43;}; "><dg:chunk structure="lim" style="boundingBox:{left: 558.3; top: 2062.5; width: 37.5; height: 50.0; page: 43;}; ">

                          ii. </dg:chunk><dg:chunk>Post-pubertal females of child-bearing potential – who are abstinent (if this is complete abstinence, as their preferred and usual lifestyle) or in a same sex relationship (as part of their preferred and usual lifestyle) must agree to either remain abstinent or stay in a same sex relationship without sexual relationships with males. </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 545.8; top: 2383.3; width: 1675.0; height: 600.0; page: 43;}; "><dg:chunk structure="lim" style="boundingBox:{left: 545.8; top: 2383.3; width: 50.0; height: 50.0; page: 43;}; ">

                          iii. </dg:chunk><dg:chunk><docset:ContraceptionRequirements structure="p">Otherwise, post-pubertal females of child-bearing potential participating must agree to use <docset:ContraceptionRequirement>1 </docset:ContraceptionRequirement>highly effective method of contraception for the entirety of the <dgm:_testRef>study</dgm:_testRef>. </docset:ContraceptionRequirements><docset:PregnancyPreventionRequirements structure="ol" style="list-style-type: decimal; boundingBox:{left: 745.8; top: 2591.7; width: 1475.0; height: 391.7; page: 43;}; "><dg:chunk structure="li" style="boundingBox:{left: 747.0; top: 2591.7; width: 1473.8; height: 237.5; page: 43;}; "><dg:chunk structure="lim" style="boundingBox:{left: 745.8; top: 2591.7; width: 37.5; height: 50.0; page: 43;}; ">

                                   1. </dg:chunk><docset:PregnancyTestingRequirements structure="p">Post-pubertal females of child-bearing potential must <dgm:_testRef>test </dgm:_testRef>negative for <dgm:Condition>pregnancy </dgm:Condition>prior to initiation of treatment as indicated by a negative serum <dgm:MedicalTest><dgm:Condition>pregnancy </dgm:Condition><dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest>at the <dgm:_testRef>screening </dgm:_testRef>visit followed by a negative urine <dgm:MedicalTest><dgm:Condition>pregnancy </dgm:Condition><dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest>within <docset:PregnancyTesting>24 hours </docset:PregnancyTesting>prior to exposure. </docset:PregnancyTestingRequirements></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 745.8; top: 2870.8; width: 1425.0; height: 112.5; page: 43;}; "><dg:chunk structure="lim" style="boundingBox:{left: 745.8; top: 2870.8; width: 37.5; height: 50.0; page: 43;}; ">

                                   2. </dg:chunk><dg:chunk>One highly effective method of contraception. The patient may choose to use a combined (estrogen and progestogen containing) or progestogen-only hormonal contraception administered orally, intravaginally, or transdermally and is associated with inhibition of ovulation. Alternatively, patients may use either an intrauterine device, intrauterine hormone-releasing system, bilateral tubal <dgm:Condition>occlusion</dgm:Condition>, or the partner should have been vasectomised. </dg:chunk></dg:chunk></docset:PregnancyPreventionRequirements></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 545.8; top: 650.0; width: 1691.7; height: 670.0; page: 44;}; "><dg:chunk structure="lim" style="boundingBox:{left: 545.8; top: 650.0; width: 50.0; height: 50.0; page: 44;}; ">

                          iv. </dg:chunk><dg:chunk><dg:chunk structure="p">post-pubertal females not of child-bearing potential may participate and include those who are </dg:chunk><docset:MenopausalStatus structure="ol" style="list-style-type: decimal; boundingBox:{left: 745.8; top: 804.2; width: 1491.7; height: 515.8; page: 44;}; "><dg:chunk structure="li" style="boundingBox:{left: 748.0; top: 804.2; width: 1489.5; height: 175.0; page: 44;}; "><dg:chunk structure="lim" style="boundingBox:{left: 745.8; top: 804.2; width: 37.5; height: 50.0; page: 44;}; ">

                                   1. </dg:chunk><docset:InfertilityCause structure="p">infertile due to surgical sterilisation (hysterectomy or bilateral oophorectomy or bilateral salpingectomy), congenital anomaly such as Mullerian <dgm:Condition>agenesis</dgm:Condition>; or </docset:InfertilityCause></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 745.8; top: 1020.8; width: 1475.0; height: 299.2; page: 44;}; "><dg:chunk structure="lim" style="boundingBox:{left: 745.8; top: 1020.8; width: 37.5; height: 50.0; page: 44;}; ">

                                   2. </dg:chunk><docset:MenopausalStatus structure="p">post-menopausal – defined as no menses for <docset:Post-MenopausalDefinition>12 months </docset:Post-MenopausalDefinition>without an alternative medical cause. A follicle-stimulating hormone level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. </docset:MenopausalStatus></dg:chunk></docset:MenopausalStatus></dg:chunk></dg:chunk></docset:FemalePatients></docset:FemalePatients-section></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 416.7; top: 1358.3; width: 633.3; height: 50.0; page: 44;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 1358.3; width: 58.3; height: 50.0; page: 44;}; ">

                    [2] </dg:chunk><dg:chunk structure="p">are aged <docset:AgeRange>≥6 </docset:AgeRange>and &lt;<docset:AgeRange>65 years </docset:AgeRange></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 416.7; top: 1445.8; width: 1604.2; height: 165.2; page: 44;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 1445.8; width: 58.3; height: 50.0; page: 44;}; ">

                    [3] </dg:chunk><docset:BMIRequirements structure="p">children and adolescents have a body mass index (BMI) within the 3rd and <docset:BMIPercentile>95th </docset:BMIPercentile>BMI percentiles with a minimum <docset:MinimumWeight><docset:Weight>weight </docset:Weight>of <docset:MinimumWeight><docset:BMIPercentileRange>25 </docset:BMIPercentileRange><docset:MaximumWeight>kg</docset:MaximumWeight></docset:MinimumWeight></docset:MinimumWeight>; adults have a BMI <docset:BMILimit>≤28.0 </docset:BMILimit>kg/m2 </docset:BMIRequirements></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 416.7; top: 1650.0; width: 1658.3; height: 283.3; page: 44;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 1650.0; width: 58.3; height: 50.0; page: 44;}; ">

                    [4] </dg:chunk><docset:InsulinTreatmentRequirements structure="p">continuous treatment with <dgm:Medication>insulin </dgm:Medication>for at least <docset:InsulinTreatmentDuration>12 months </docset:InsulinTreatmentDuration>and with at least <docset:InsulinTreatmentDuration>6 months </docset:InsulinTreatmentDuration>of treatment using <docset:InsulinTreatment>CSII </docset:InsulinTreatment>pump therapy or MDI therapy consisting of treatment with basal <dgm:Medication>insulin </dgm:Medication>(including <dgm:Medication><dgm:Medication>insulin </dgm:Medication>glargine </dgm:Medication><docset:InsulinType>U100</docset:InsulinType>, detemir, degludec <dgc:Number>U100 </dgc:Number>and <dgm:Medication>NPH</dgm:Medication>) and rapid-acting <dgm:Medication>insulin </dgm:Medication>prior to the main meals of the day before <dgm:_testRef>screening </dgm:_testRef></docset:InsulinTreatmentRequirements></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 416.7; top: 1970.8; width: 1429.2; height: 50.0; page: 44;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 1970.8; width: 58.3; height: 50.0; page: 44;}; ">

                    [5] </dg:chunk><dg:chunk structure="p">total <dgc:Frequency>daily </dgc:Frequency>dose of <dgm:Medication>insulin </dgm:Medication>between <docset:MinimumInsulinDose>0.3 </docset:MinimumInsulinDose>and <docset:MaximumInsulinDose>1.5 </docset:MaximumInsulinDose>U/kg/day, inclusive </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 416.7; top: 2058.3; width: 1262.5; height: 50.0; page: 44;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 2058.3; width: 58.3; height: 50.0; page: 44;}; ">

                    [6] </dg:chunk><dg:chunk structure="p">have a glycated haemoglobin (HbA1c) <docset:HbA1cTarget>≤10% </docset:HbA1cTarget>at <dgm:_testRef>screening </dgm:_testRef></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 416.7; top: 2145.8; width: 1550.0; height: 108.3; page: 44;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 2145.8; width: 58.3; height: 50.0; page: 44;}; ">

                    [7] </dg:chunk><dg:chunk structure="p">compliant with prescribed diet and <dgm:Medication>insulin </dgm:Medication>therapy, as determined by the investigator </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 416.7; top: 2291.7; width: 1612.5; height: 225.0; page: 44;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 2291.7; width: 58.3; height: 50.0; page: 44;}; ">

                    [8] </dg:chunk><docset:LaboratoryTestResults structure="p">have clinical laboratory <dgm:_testRef>test </dgm:_testRef>results within normal reference range (with the exception of HbA1c) for the population or investigative site, or results with acceptable deviations that are judged to be not clinically significant by the investigator </docset:LaboratoryTestResults></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 417.0; top: 2554.2; width: 1495.5; height: 108.3; page: 44;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 2554.2; width: 58.3; height: 50.0; page: 44;}; ">

                    [9] </dg:chunk><dg:chunk>have venous access sufficient to allow for glucose infusion and <dgm:MedicalTest>blood sampling </dgm:MedicalTest>procedures as per protocol </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 417.0; top: 2704.2; width: 1549.7; height: 104.2; page: 44;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 2704.2; width: 83.3; height: 50.0; page: 44;}; ">

                    [10] </dg:chunk><docset:StudyParticipationRequirements structure="p">are reliable and willing to make themselves/their wards available for the duration of the <dgm:_testRef>study </dgm:_testRef>and are willing to follow <dgm:_testRef>study </dgm:_testRef>procedures </docset:StudyParticipationRequirements></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 417.0; top: 308.3; width: 1674.7; height: 223.7; page: 45;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 308.3; width: 83.3; height: 50.0; page: 45;}; ">

                    [11] </dg:chunk><docset:InformedConsent structure="p">are able and willing to give signed informed consent approved by <docset:Consent>Lilly </docset:Consent>and the ethical review board (<docset:EthicalReviewBoard>ERB</docset:EthicalReviewBoard>) governing the site or both the child/adolescent and a parent or legal guardian are able to understand and fully participate in the activities of the clinical trial and sign their assent and consent, respectively </docset:InformedConsent></dg:chunk></docset:InclusionCriteria><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 300.0; top: 600.0; width: 641.7; height: 58.3; page: 45;}; "><dg:chunk structure="li" style="boundingBox:{left: 300.0; top: 600.0; width: 641.7; height: 58.3; page: 45;}; "><dg:chunk structure="lim" style="boundingBox:{left: 300.0; top: 600.0; width: 95.8; height: 58.3; page: 45;}; ">

              6.2. </dg:chunk><dg:chunk>Exclusion Criteria </dg:chunk></dg:chunk></dg:chunk></dg:chunk></dg:chunk><dg:chunk><docset:PatientExclusionCriteria structure="p">

              Patients will be excluded from <dgm:_testRef>study </dgm:_testRef>enrolment if they meet any of the following criteria at <dgm:_testRef>screening </dgm:_testRef>and/or enrolment: </docset:PatientExclusionCriteria><dg:chunk><docset:StudyExclusionCriteria structure="ol" style="list-style-type: lower-alpha; boundingBox:{left: 417.0; top: 820.8; width: 1678.8; height: 1508.3; page: 45;}; boundingBox:{left: 411.3; top: 302; width: 1689.7; height: 2689; page: 46;}; boundingBox:{left: 412.4; top: 302; width: 1693.6; height: 903; page: 47;}; "><dg:chunk structure="li" style="boundingBox:{left: 417.0; top: 820.8; width: 1545.5; height: 108.3; page: 45;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 820.8; width: 83.3; height: 50.0; page: 45;}; ">

                    [12] </dg:chunk><docset:DiabetesMedication structure="p">receiving any oral or injectable medication intended for the treatment of <dgm:Condition><dgm:Condition>diabetes </dgm:Condition>mellitus </dgm:Condition>other than insulins in the <docset:TreatmentMedication>12 months </docset:TreatmentMedication>prior to <dgm:_testRef>screening </dgm:_testRef></docset:DiabetesMedication></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 417.0; top: 970.8; width: 1662.2; height: 220.8; page: 45;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 970.8; width: 83.3; height: 50.0; page: 45;}; ">

                    [13] </dg:chunk><docset:SevereHypoglycaemia structure="p">more than <docset:SevereHypoglycaemia>1 </docset:SevereHypoglycaemia><docset:SevereHypoglycaemiaEpisodes>episode </docset:SevereHypoglycaemiaEpisodes>of severe hypoglycaemia (defined as requiring assistance due to neurologically disabling hypoglycaemia, indicated by <dgm:Condition>coma </dgm:Condition>or convulsion and/or use of IV glucose or <dgm:Medication>glucagon</dgm:Medication>) within <docset:HypoglycaemiaSeverity>6 months </docset:HypoglycaemiaSeverity>prior to <dgm:_testRef>screening </dgm:_testRef></docset:SevereHypoglycaemia></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 420.0; top: 1229.2; width: 1596.7; height: 166.7; page: 45;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 1229.2; width: 83.3; height: 50.0; page: 45;}; ">

                    [14] </dg:chunk><dg:chunk><docset:NumberofEmergencyRoomVisits>two </docset:NumberofEmergencyRoomVisits>or more emergency room visits or hospitalisations due to poor glucose control (hyperglycaemia or diabetic <dgm:Condition>ketoacidosis</dgm:Condition>) within <docset:EmergencyRoomVisits>6 months </docset:EmergencyRoomVisits>of <dgm:_testRef>screening </dgm:_testRef></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 418.0; top: 1433.3; width: 1677.8; height: 111.7; page: 45;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 1433.3; width: 83.3; height: 50.0; page: 45;}; ">

                    [15] </dg:chunk><dg:chunk structure="p">post-pubertal females not using a reliable method of birth control, or intending to become pregnant </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 418.0; top: 1583.3; width: 1636.2; height: 220.8; page: 45;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 1583.3; width: 83.3; height: 50.0; page: 45;}; ">

                    [16] </dg:chunk><docset:ConcomitantDiseases structure="p">one of the following concomitant diseases: presence of clinically significant hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease, proliferative <dgm:Condition>retinopathy</dgm:Condition>, uncontrolled celiac disease, uncontrolled hyperthyroidism or <dgm:Condition>hypothyroidism</dgm:Condition>, or adrenal insufficiency </docset:ConcomitantDiseases></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 418.3; top: 1845.8; width: 1665.0; height: 221.2; page: 45;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 1845.8; width: 83.3; height: 50.0; page: 45;}; ">

                    [17] </dg:chunk><dg:chunk>have a history of renal impairment (exclusion only if glomerular filtration rate [estimated GFR] &lt;<docset:RenalImpairmentExclusion>60 </docset:RenalImpairmentExclusion>mL/<docset:RenalImpairmentExclusion>minute/1.73 </docset:RenalImpairmentExclusion>m2 [GFR is estimated according to the Chronic Kidney Disease Epidemiology Collaboration creatinine equation]) (<docset:ExclusionCriteria>Schwartz </docset:ExclusionCriteria>et al. <docset:ExclusionCriteria>2009</docset:ExclusionCriteria>). </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 419.2; top: 2108.3; width: 1780.8; height: 745.8; page: 45;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416.7; top: 2108.3; width: 83.3; height: 50.0; page: 45;}; ">

                    [18] </dg:chunk><dg:chunk><docset:LiverDiseaseCriteria structure="p">hepatic: Have obvious clinical signs or symptoms of liver disease (e.g., acute or chronic <dgm:Condition>hepatitis </dgm:Condition>as indicated by evidence and/or positive antibody/surface antigen to <dgm:Condition><dgm:Condition>hepatitis </dgm:Condition>B</dgm:Condition>/C, or <dgm:Condition>cirrhosis</dgm:Condition>) or elevated liver enzyme measurements as indicated below at <dgm:_testRef>screening</dgm:_testRef>: </docset:LiverDiseaseCriteria><docset:LiverFunctionTestingRequirements structure="ol" style="list-style-type: lower-alpha; boundingBox:{left: 525.0; top: 2375.0; width: 1675.0; height: 479.2; page: 45;}; "><dg:chunk structure="li" style="boundingBox:{left: 525.0; top: 2375.0; width: 1545.8; height: 204.2; page: 45;}; "><dg:chunk structure="lim" style="boundingBox:{left: 525.0; top: 2375.0; width: 33.3; height: 50.0; page: 45;}; ">

                         a. </dg:chunk><docset:BilirubinLevelRequirements structure="p">total bilirubin level (TBL) <docset:TotalBilirubinLevel>≥2× </docset:TotalBilirubinLevel>the upper limit of normal (ULN) (with the exception of <docset:GilbertsDisease>Gilberts </docset:GilbertsDisease>disease) as defined by the central laboratory, OR </docset:BilirubinLevelRequirements></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 525.0; top: 2620.8; width: 1641.7; height: 141.7; page: 45;}; "><dg:chunk structure="lim" style="boundingBox:{left: 525.0; top: 2620.8; width: 33.3; height: 50.0; page: 45;}; ">

                         b. </dg:chunk><dg:chunk structure="p">alanine aminotransferase (ALT) <docset:ALTUpperLimit>≥3× </docset:ALTUpperLimit>ULN as defined by the central laboratory OR </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 525.0; top: 2804.2; width: 1675.0; height: 50.0; page: 45;}; "><dg:chunk structure="lim" style="boundingBox:{left: 525.0; top: 2804.2; width: 33.3; height: 50.0; page: 45;}; ">

                         c. </dg:chunk><dg:chunk>aspartate aminotransferase (AST) <docset:ASTLevel>≥3× </docset:ASTLevel>ULN as defined by the central laboratory </dg:chunk></dg:chunk></docset:LiverFunctionTestingRequirements></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 420; top: 302; width: 1657; height: 178; page: 46;}; "><dg:chunk structure="lim" style="boundingBox:{left: 420; top: 303; width: 85; height: 59; page: 46;}; ">

                    [19] </dg:chunk><docset:ConflictofInterest structure="p">are <dgm:_testRef>study </dgm:_testRef>site personnel directly affiliated with this <dgm:_testRef>study </dgm:_testRef>and their immediate families. Immediate family is defined as a spouse, biological or legal guardian, child, or sibling </docset:ConflictofInterest></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 413; top: 499; width: 1563; height: 69; page: 46;}; "><dg:chunk structure="lim" style="boundingBox:{left: 413; top: 501; width: 89; height: 67; page: 46;}; ">

                   [20] </dg:chunk><dg:chunk structure="p">are Lilly employees or are employees of the <dgm:_testRef>study </dgm:_testRef>site and their children </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 415.0; top: 595.0; width: 1649.0; height: 179.0; page: 46;}; "><dg:chunk structure="lim" style="boundingBox:{left: 411; top: 595; width: 95; height: 58; page: 46;}; ">

                   [21] </dg:chunk><dg:chunk>are currently enrolled in a clinical <dgm:_testRef>study </dgm:_testRef>involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this <dgm:_testRef>study </dgm:_testRef></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 422; top: 796; width: 1679; height: 176.0; page: 46;}; "><dg:chunk structure="lim" style="boundingBox:{left: 422; top: 796; width: 80; height: 63; page: 46;}; ">

                    [22] </dg:chunk><docset:InvestigationalProductParticipation structure="p">have participated, within the past <docset:ParticipationTimeframe>30 days</docset:ParticipationTimeframe>, in a clinical <dgm:_testRef>study </dgm:_testRef>involving an investigational product. If the previous investigational product has a long half-life (<docset:Half-Life>t12</docset:Half-Life>), <docset:InvestigationalProductHalf-Life>5 </docset:InvestigationalProductHalf-Life>half-lives or <dgc:TimeDuration>30 days </dgc:TimeDuration>(whichever is longer) should have passed </docset:InvestigationalProductParticipation></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 417; top: 1003; width: 1246; height: 63; page: 46;}; "><dg:chunk structure="lim" style="boundingBox:{left: 417; top: 1003; width: 85; height: 63; page: 46;}; ">

                    [23] </dg:chunk><dg:chunk>have previously completed or withdrawn from this <dgm:_testRef>study </dgm:_testRef></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 414.6; top: 1089; width: 1656.4; height: 178; page: 46;}; "><dg:chunk structure="lim" style="boundingBox:{left: 411; top: 1089; width: 89; height: 62; page: 46;}; ">

                   [24] </dg:chunk><docset:AllergyAlert structure="p">have known allergies to <dgm:Medication>treprostinil </dgm:Medication><dgm:Medication><dgm:Medication>insulin </dgm:Medication>lispro</dgm:Medication>, RHI, related compounds, or any components of the formulation, or a history of significant atopy </docset:AllergyAlert></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 414; top: 1300; width: 1679; height: 376; page: 46;}; "><dg:chunk structure="lim" style="boundingBox:{left: 414; top: 1300; width: 93; height: 59; page: 46;}; ">

                    [25] </dg:chunk><docset:StudyEligibilityCriteria structure="p">Adults <docset:AgeEligibility>≥18 years </docset:AgeEligibility>of age who have donated blood of more than <docset:BloodDonationHistory>450 </docset:BloodDonationHistory>mL or more in the past <dgc:TimeDuration>3 months </dgc:TimeDuration>before <dgm:_testRef>screening </dgm:_testRef>or any prospective <dgm:_testRef>study </dgm:_testRef>participant who has experienced severe <dgm:Condition>blood loss </dgm:Condition>within <docset:BloodLossCriteria>3 months </docset:BloodLossCriteria>prior to <dgm:_testRef>screening </dgm:_testRef>or have known haemoglobinopathy, haemolytic anaemia, or sickle cell anaemia, or any other traits of haemoglobin abnormalities known to interfere with the HbA1c measurement </docset:StudyEligibilityCriteria></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 415; top: 1708; width: 1657; height: 233; page: 46;}; "><dg:chunk structure="lim" style="boundingBox:{left: 415; top: 1708; width: 88; height: 59; page: 46;}; ">

                    [26] </dg:chunk><docset:GlucocorticoidUse structure="p">receiving chronic (lasting longer than <docset:GlucocorticoidTherapyDuration>14 consecutive days</docset:GlucocorticoidTherapyDuration>) systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, and inhaled preparations) or have received such therapy within <docset:GlucocorticoidTherapyWindow>8 weeks </docset:GlucocorticoidTherapyWindow>immediately before <dgm:_testRef>screening </dgm:_testRef></docset:GlucocorticoidUse></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 415.2; top: 1972.1; width: 1568.8; height: 168.9; page: 46;}; "><dg:chunk structure="lim" style="boundingBox:{left: 415; top: 1968; width: 90; height: 60; page: 46;}; ">

                    [27] </dg:chunk><docset:InsulinRegimenChanges structure="p">any significant changes in <dgm:Medication>insulin </dgm:Medication>regimen and/or unstable blood glucose control within the past <docset:InsulinRegimenStability>3 months </docset:InsulinRegimenStability>prior to <dgm:_testRef>screening </dgm:_testRef>as assessed by the investigator </docset:InsulinRegimenChanges></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 412; top: 2171; width: 1642; height: 174.8; page: 46;}; "><dg:chunk structure="lim" style="boundingBox:{left: 412; top: 2171; width: 91; height: 61; page: 46;}; ">

                   [28] </dg:chunk><dg:chunk>have a history of in-patient psychiatric treatment, emotional, behavioural, or other untreated conditions that would interfere with proper participation in routine <dgm:Condition>diabetes </dgm:Condition>control and management in the past <docset:TreatmentHistory>6 months </docset:TreatmentHistory></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 411.3; top: 2382.0; width: 1649.7; height: 167.0; page: 46;}; "><dg:chunk structure="lim" style="boundingBox:{left: 410; top: 2383; width: 98; height: 53; page: 46;}; ">

                   [29] </dg:chunk><docset:DietaryCompliance structure="p">are unwilling to comply with the dietary requirements/restrictions during the <dgm:_testRef>study</dgm:_testRef>: (<docset:DietaryCompliance>1</docset:DietaryCompliance>) comply with the fasting requirements of the <dgm:_testRef>study</dgm:_testRef>, (ii) consume only the meals/snacks provided during the inpatient visits </docset:DietaryCompliance></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 414; top: 2588.0; width: 1683; height: 403.0; page: 46;}; "><dg:chunk structure="lim" style="boundingBox:{left: 414; top: 2583; width: 88; height: 59; page: 46;}; ">

                    [30] </dg:chunk><docset:MedicationUse structure="p">have, except for current regimen of <dgm:Medication>insulin </dgm:Medication>therapy and concomitant medication(s) (e.g ., antihypertensive medication, <dgm:Medication>lipid</dgm:Medication>-lowering agent, <dgm:Medication>thyroid </dgm:Medication>hormone replacement medication, hormonal contraception, hormonal replacement therapy), regular use of or intended use of any over-the-counter or prescription medications or nutritional supplements that treat hyperglycaemia or <dgm:Medication>insulin </dgm:Medication>resistance or that promote weight loss within <docset:MedicationUseWindow>14 days </docset:MedicationUseWindow>before dosing </docset:MedicationUse></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 418.0; top: 302; width: 1595.0; height: 116; page: 47;}; "><dg:chunk structure="lim" style="boundingBox:{left: 412; top: 304; width: 90; height: 57; page: 47;}; ">

                   [31] </dg:chunk><dg:chunk structure="p">regularly use known drugs of abuse and/or show positive findings on drug <dgm:_testRef>screening </dgm:_testRef></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 416.0; top: 450.0; width: 1579.0; height: 114.0; page: 47;}; "><dg:chunk structure="lim" style="boundingBox:{left: 410; top: 450; width: 93; height: 55; page: 47;}; ">

                   [32] </dg:chunk><dg:chunk structure="p">show evidence of human <dgm:Condition>immunodeficiency </dgm:Condition>virus (<dgm:Condition>HIV</dgm:Condition>) <dgm:Condition>infection </dgm:Condition>and/or positive human <dgm:Condition>HIV </dgm:Condition>antibodies </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 416.0; top: 596; width: 689.0; height: 59; page: 47;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416; top: 598; width: 89; height: 54; page: 47;}; ">

                    [33] </dg:chunk><dg:chunk structure="p">are women who are lactating </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 417.8; top: 686.0; width: 1688.2; height: 287.0; page: 47;}; "><dg:chunk structure="lim" style="boundingBox:{left: 415; top: 683; width: 89; height: 59; page: 47;}; ">

                    [34] </dg:chunk><docset:AlcoholConsumptionRequirements structure="p">have an average <dgc:Frequency>weekly </dgc:Frequency>alcohol intake that exceeds <docset:AlcoholConsumption>21 </docset:AlcoholConsumption>units per week (males) and <docset:AlcoholConsumption>14 </docset:AlcoholConsumption>units per week (females), or are unwilling to stop alcohol consumption for the duration of the <dgm:_testRef>study </dgm:_testRef>(<docset:AlcoholConsumption>1 </docset:AlcoholConsumption>unit = <docset:AlcoholConsumption>12 </docset:AlcoholConsumption>oz or <docset:AlcoholConsumption>360 </docset:AlcoholConsumption>mL of beer; <docset:AlcoholConsumption>5 </docset:AlcoholConsumption>oz or 150 mL of wine; <docset:AlcoholConsumption>1.5 </docset:AlcoholConsumption>oz or 45 mL of distilled spirits) </docset:AlcoholConsumptionRequirements></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 412.4; top: 1003; width: 1391.6; height: 61; page: 47;}; "><dg:chunk structure="lim" style="boundingBox:{left: 409; top: 1005; width: 98; height: 57; page: 47;}; ">

                   [35] </dg:chunk><dg:chunk>are unable to comply with smoking restrictions during the <dgm:_testRef>study </dgm:_testRef></dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 417.0; top: 1090; width: 1684.2; height: 115; page: 47;}; "><dg:chunk structure="lim" style="boundingBox:{left: 414; top: 1090; width: 91; height: 59; page: 47;}; ">

                    [36] </dg:chunk><dg:chunk structure="p">in the opinion of the investigator or sponsor, are unsuitable for inclusion in the <dgm:_testRef>study </dgm:_testRef></dg:chunk></dg:chunk></docset:StudyExclusionCriteria><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 298; top: 1262; width: 1713; height: 71; page: 47;}; "><docset:StudyExclusionCriteria structure="li" style="boundingBox:{left: 298; top: 1262; width: 1796; height: 1151; page: 47;}; "><dg:chunk structure="lim" style="boundingBox:{left: 298; top: 1262; width: 158; height: 65; page: 47;}; ">

              6.2.1. </dg:chunk><dg:chunk><dg:chunk structure="p"><dg:chunk>Additional Exclusion Criteria </dg:chunk>for <dg:chunk>Inpatient Dosing Days </dg:chunk></dg:chunk><docset:StudyExclusionCriteria structure="ol" style="list-style-type: lower-alpha; boundingBox:{left: 409; top: 1336.5; width: 1685; height: 1076.5; page: 47;}; "><dg:chunk structure="li" style="boundingBox:{left: 418.0; top: 1336.5; width: 1284.0; height: 54.5; page: 47;}; "><dg:chunk structure="lim" style="boundingBox:{left: 414; top: 1335; width: 89; height: 57; page: 47;}; ">

                    [37] </dg:chunk><dg:chunk structure="p">consumption of alcohol within <docset:AlcoholConsumption>24 hours </docset:AlcoholConsumption>prior to admission </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 417; top: 1425; width: 1654; height: 111.3; page: 47;}; "><dg:chunk structure="lim" style="boundingBox:{left: 417; top: 1425; width: 86; height: 57; page: 47;}; ">

                    [38] </dg:chunk><docset:PregnancyTest structure="p">positive serum <dgm:MedicalTest><dgm:Condition>pregnancy </dgm:Condition><dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest>at <dgm:_testRef>screening </dgm:_testRef>or positive urine <dgm:MedicalTest><dgm:Condition>pregnancy </dgm:Condition><dgm:_testRef>test </dgm:_testRef></dgm:MedicalTest>at admission to the <dgm:_testRef>study </dgm:_testRef>site </docset:PregnancyTest></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 415.0; top: 1570; width: 1633.0; height: 170; page: 47;}; "><dg:chunk structure="lim" style="boundingBox:{left: 411; top: 1570; width: 92; height: 56; page: 47;}; ">

                   [39] </dg:chunk><docset:CaffeineConsumption structure="p">consumption of coffee, tea, chocolate, cola, and/or energy drinks containing methyl xanthine (<dgm:Medication>caffeine</dgm:Medication>, <dgm:Medication>theophylline</dgm:Medication>, or theobromine) within <docset:ConsumptionWindow>12 hours </docset:ConsumptionWindow>before each <dgm:_testRef>test </dgm:_testRef>meal assessment. </docset:CaffeineConsumption></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 410; top: 1770; width: 1650; height: 61; page: 47;}; "><dg:chunk structure="lim" style="boundingBox:{left: 410; top: 1770; width: 93; height: 61; page: 47;}; ">

                   [40] </dg:chunk><dg:chunk structure="p">strenuous exercise within the past <docset:ExerciseRestriction>24 hours </docset:ExerciseRestriction>before each <dgm:_testRef>test </dgm:_testRef>meal assessment </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 416.0; top: 1863.0; width: 1663.0; height: 116.0; page: 47;}; "><dg:chunk structure="lim" style="boundingBox:{left: 416; top: 1864; width: 91; height: 55; page: 47;}; ">

                    [41] </dg:chunk><dg:chunk>any medical condition or AE that could interfere with glucose metabolism, as judged by the investigator </dg:chunk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 417; top: 2008.0; width: 1653; height: 118.0; page: 47;}; "><dg:chunk structure="lim" style="boundingBox:{left: 417; top: 2006; width: 91; height: 61; page: 47;}; ">

                    [42] </dg:chunk><docset:ExcludedMedication structure="p">any use of excluded prescription or nonprescription medication from <docset:ExcludedMedicationUsePeriod>14 days </docset:ExcludedMedicationUsePeriod>prior to dosing and throughout the <dgm:_testRef>study </dgm:_testRef></docset:ExcludedMedication></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 413; top: 2151.0; width: 1681; height: 119.0; page: 47;}; "><dg:chunk structure="lim" style="boundingBox:{left: 413; top: 2149; width: 88; height: 68; page: 47;}; ">

                   [43] </dg:chunk><docset:HypoglycaemiaRisk structure="p">hypoglycaemia during the MMTT period and less than <docset:HypoglycaemiaRiskPeriod>24 hours </docset:HypoglycaemiaRiskPeriod>before dosing that poses a significant risk to patient's safety, as judged by the investigator </docset:HypoglycaemiaRisk></dg:chunk><dg:chunk structure="li" style="boundingBox:{left: 409; top: 2295; width: 1671; height: 118; page: 47;}; "><dg:chunk structure="lim" style="boundingBox:{left: 409; top: 2295; width: 97; height: 65; page: 47;}; ">

                   [44] </dg:chunk><docset:InsulinBolusInjection structure="p">injection of a bolus of more than <docset:InsulinBolus>6 </docset:InsulinBolus><docset:InsulinBolus>U </docset:InsulinBolus>of a fast-acting <dgm:Medication>insulin </dgm:Medication>analogue <docset:InsulinBolusTiming>6 hours </docset:InsulinBolusTiming>before dosing prior to the <dgm:_testRef>test </dgm:_testRef>meal </docset:InsulinBolusInjection></dg:chunk></docset:StudyExclusionCriteria></dg:chunk></docset:StudyExclusionCriteria></dg:chunk></dg:chunk></dg:chunk></docset:_52NumberofParticipants></docset:_52NumberofParticipants-section><docset:_622RationaleforExclusionofCertainStudyCandidates-section><dg:chunk structure="h1">

              <docset:RationaleforExclusion>6.2.2</docset:RationaleforExclusion>. Rationale for Exclusion of <dg:chunk>Certain <dgm:_testRef>Study </dgm:_testRef>Candidates </dg:chunk></dg:chunk><docset:_622RationaleforExclusionofCertainStudyCandidates structure="div">

              The blood volume to be withdrawn per patient in each part of this <dgm:_testRef>study </dgm:_testRef>is approximately <docset:BloodVolumeWithdrawal>170 </docset:BloodVolumeWithdrawal>mL which would be a challenge in children &lt;<dgc:TimeDuration>6 years </dgc:TimeDuration>of age. Additionally, <dgm:Medication>insulin </dgm:Medication>is individually titrated and therefore, the understanding of PK and GD in the proposed patients (<docset:AgeRange>≥6 years </docset:AgeRange>to <docset:AgeRange><dg:chunk>≤64 </dg:chunk>years</docset:AgeRange>) should be sufficient to inform dosing in children &lt;<docset:AgeLimit>6 years </docset:AgeLimit>of age under the supervision of a qualified endocrinologist. Therefore, this <dgm:_testRef>study </dgm:_testRef>will not include paediatric patients with <dg:chunk>T1DM </dg:chunk>from birth to &lt;<dgc:TimeDuration>6 years </dgc:TimeDuration>of age. </docset:_622RationaleforExclusionofCertainStudyCandidates></docset:_622RationaleforExclusionofCertainStudyCandidates-section></dg:chunk></docset:InpatientProcedureinPartB></docset:InpatientProcedureinPartB-section></dg:chunk></dg:chunk></docset:Page39></docset:Page39-section></docset:_5121InpatientProceduresforPart></docset:_5121InpatientProceduresforPart-section></docset:FigureITSA3IllustrationofStudyDesignforPartB></docset:FigureITSA3IllustrationofStudyDesignforPartB-section><docset:_18B-MC-ITSADClinicalPharmacologyProtocol-section><dg:chunk structure="h1">

              <docset:ClinicalPharmacologyProtocol>18B</docset:ClinicalPharmacologyProtocol>-MC-ITSA(d) Clinical Pharmacology Protocol </dg:chunk><docset:Page47-section structure="div"><dg:chunk structure="h1">

                                                                                                 Page <docset:PageNumber>47 </docset:PageNumber></dg:chunk><docset:LifestyleAndOrDietaryRequirements-section structure="div"><dg:chunk structure="h1">

              <docset:LifestyleandorDietaryRequirements>6.3</docset:LifestyleandorDietaryRequirements>. Lifestyle and/or Dietary Requirements </dg:chunk><docset:LifestyleAndOrDietaryRequirements structure="div"><docset:StudyParticipationRequirements structure="p">

              Throughout the <dgm:_testRef>study</dgm:_testRef>, patients may undergo medical assessments and review of compliance with requirements before continuing in the <dgm:_testRef>study</dgm:_testRef>. </docset:StudyParticipationRequirements><dg:chunk><docset:_631MealsAndDietaryRestrictions-section><dg:chunk structure="h1">

              <docset:MealsandDietaryRestrictions>6.3.1</docset:MealsandDietaryRestrictions>. Meals and <dg:chunk>Dietary Restrictions </dg:chunk></dg:chunk><docset:_631MealsAndDietaryRestrictions structure="div"><dg:chunk><docset:TestMeal structure="p">

              Patients will be provided standardised liquid meals for the MMTTs, as outlined in the Schedule of Activities (Section 2). An evening meal on the day prior to the MMTT and a meal following completion of the MMTT will also be provided. Patients will be fasted (except for water) for at least <docset:FastingPeriod>10 hours </docset:FastingPeriod>before each <dgm:_testRef>test </dgm:_testRef>meal and consume each meal within approximately <docset:TestMealConsumptionTime>15 minutes</docset:TestMealConsumptionTime>. The standardised liquid <dgm:_testRef>test </dgm:_testRef>meal will use For children and adolescents in the <dgm:_testRef>study</dgm:_testRef>, the volume of the liquid <dgm:_testRef>test </dgm:_testRef>me ed on the patient's body weight 

              (kg) during the <dgm:_testRef>study </dgm:_testRef>(Period 1 of <dg:chunk>Part A </dg:chunk>or Period 1 of <dg:chunk>Part B </dg:chunk>if patients did not participate in <dg:chunk>Part A </dg:chunk>of the <dgm:_testRef>study</dgm:_testRef>) as described in Table <docset:TestMealVolume>ITSA.2</docset:TestMealVolume>. For adults, the liquid <dgm:_testRef>test </dgm:_testRef>meal will consist of </docset:TestMeal><docset:StudyDiet structure="p">

                                                  (pproximately <docset:MealCalorieContent>100 </docset:MealCalorieContent>g of carbohydrates total in <dgm:_testRef>test </dgm:_testRef>meal). pt consistent with regard to calorie and nutrient content across all MMTT assessments in the <dgm:_testRef>study</dgm:_testRef>. For both parts of the <dgm:_testRef>study</dgm:_testRef>, the patient will not be allowed to consume water for <docset:NoWaterConsumption>2 hours </docset:NoWaterConsumption>after dosing apart from fluid provided with the meal; however, water may be consumed freely afterwards. </docset:StudyDiet></dg:chunk><dg:chunk><dg:chunk structure="p">

              Table <docset:ITSA2>ITSA.2</docset:ITSA2>. </dg:chunk><dg:chunk><dg:chunk structure="p">

                                     Volume of <dg:chunk>Standardised Meal </dg:chunk>According to <dg:chunk>Body Weight </dg:chunk></dg:chunk><docset:VolumeofStandardisedMealAccordingtoBodyWeight><xhtml:table structure="table" style="boundingBox:{left: 300; top: 1577; width: 1950; height: 448; page: 48;}; "><xhtml:tbody structure="tbody" style="boundingBox:{left: 300; top: 1577; width: 1950; height: 448; page: 48;}; "><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1577; width: 1950; height: 54; page: 48;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1577; width: 933; height: 54; page: 48;}; "><dg:chunk structure="h1">

                            <dg:chunk>Body Weight </dg:chunk>(kg) </dg:chunk></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1233; top: 1577; width: 1017; height: 54; page: 48;}; "><docset:BodyWeightKg structure="h1">

                             Volume of Meal (mL) </docset:BodyWeightKg></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1632; width: 1950; height: 57; page: 48;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1631; width: 933; height: 58; page: 48;}; "><docset:BodyWeightKg>

                                  <dgc:Number>25</dgc:Number>-<dgc:Number>29 </dgc:Number></docset:BodyWeightKg></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1233; top: 1631; width: 1017; height: 58; page: 48;}; "><docset:VolumeofMealMl>

                                    <dgc:Number>230 </dgc:Number></docset:VolumeofMealMl></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1690; width: 1950; height: 55; page: 48;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1689; width: 933; height: 56; page: 48;}; "><docset:BodyWeightKg>

                                  <dgc:Number>30</dgc:Number>-<dgc:Number>34 </dgc:Number></docset:BodyWeightKg></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1233; top: 1689; width: 1017; height: 56; page: 48;}; "><docset:VolumeofMealMl>

                                    <dgc:Number>272 </dgc:Number></docset:VolumeofMealMl></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1746; width: 1950; height: 53; page: 48;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1745; width: 933; height: 54; page: 48;}; "><docset:BodyWeightKg>

                                  <dgc:Number>35</dgc:Number>-<dgc:Number>39 </dgc:Number></docset:BodyWeightKg></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1233; top: 1745; width: 1017; height: 54; page: 48;}; "><docset:VolumeofMealMl>

                                     <dgc:Number>315 </dgc:Number></docset:VolumeofMealMl></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1800; width: 1950; height: 57; page: 48;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1799; width: 933; height: 58; page: 48;}; "><docset:BodyWeightKg>

                                  <dgc:Number>40</dgc:Number>-<dgc:Number>44 </dgc:Number></docset:BodyWeightKg></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1233; top: 1799; width: 1017; height: 58; page: 48;}; "><docset:VolumeofMealMl>

                                    <dgc:Number>357 </dgc:Number></docset:VolumeofMealMl></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1858; width: 1950; height: 55; page: 48;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1857; width: 933; height: 56; page: 48;}; "><docset:BodyWeightKg>

                                  <dgc:Number>45</dgc:Number>-<dgc:Number>49 </dgc:Number></docset:BodyWeightKg></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1233; top: 1857; width: 1017; height: 56; page: 48;}; "><docset:VolumeofMealMl>

                                     <dgc:Number>400 </dgc:Number></docset:VolumeofMealMl></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1914; width: 1950; height: 53; page: 48;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1913; width: 933; height: 54; page: 48;}; "><docset:BodyWeightKg>

                                 <dgc:Number>50</dgc:Number>-<dgc:Number>54 </dgc:Number></docset:BodyWeightKg></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1233; top: 1913; width: 1017; height: 54; page: 48;}; "><docset:VolumeofMealMl>

                                    <dgc:Number>442 </dgc:Number></docset:VolumeofMealMl></xhtml:td></xhtml:tr><xhtml:tr structure="tr" style="boundingBox:{left: 300; top: 1968; width: 1950; height: 57; page: 48;}; "><xhtml:td structure="td" style="boundingBox:{left: 300; top: 1967; width: 933; height: 58; page: 48;}; "><docset:BodyWeightKg>

                                  &gt;<dgc:Number>55 </dgc:Number></docset:BodyWeightKg></xhtml:td><xhtml:td structure="td" style="boundingBox:{left: 1233; top: 1967; width: 1017; height: 58; page: 48;}; "><docset:VolumeofMealMl>

                                oz </docset:VolumeofMealMl></xhtml:td></xhtml:tr></xhtml:tbody></xhtml:table></docset:VolumeofStandardisedMealAccordingtoBodyWeight></dg:chunk></dg:chunk><docset:DietaryRestrictions structure="p">

              While resident in the <dgm:_testRef>study </dgm:_testRef>site, patients may not consume any food or caloric drinks other than that provided by the <dgm:_testRef>study </dgm:_testRef>site. When not resident in the <dgm:_testRef>study </dgm:_testRef>site, patients may resume their regular diet. </docset:DietaryRestrictions><docset:InsulinAdministration structure="p">

              Following completion of <dgm:_testRef>study </dgm:_testRef>procedures, patient will be offered a meal. The <dgm:_testRef>study </dgm:_testRef>site will record dose and time of prandial <dgm:Medication>insulin </dgm:Medication>administered with end-of-<dgm:_testRef>study </dgm:_testRef>meal. </docset:InsulinAdministration></docset:_631MealsAndDietaryRestrictions></docset:_631MealsAndDietaryRestrictions-section><docset:_632CaffeineAlcoholAndTobacco-section><dg:chunk structure="h1">

              <docset:CaffeineAlcoholandTobacco>6.3.2</docset:CaffeineAlcoholandTobacco>. <dgm:Medication>Caffeine</dgm:Medication>, Alcohol, and Tobacco </dg:chunk><docset:_632CaffeineAlcoholAndTobacco structure="div"><docset:CaffeineRestriction structure="p">

              Patients should refrain from <dgm:Medication>caffeine</dgm:Medication>-containing food/beverages (e.g ., cola, chocolate drinks, tea, coffee, energy drinks containing methylxanthine [<dgm:Medication>caffeine</dgm:Medication>, <dgm:Medication>theophylline</dgm:Medication>, or theobromine]) for at least <docset:CaffeineRestrictionPeriod>12 hours </docset:CaffeineRestrictionPeriod>before each <dgm:_testRef>test </dgm:_testRef>meal and throughout the duration of each <dgm:_testRef>study </dgm:_testRef>site visit, excluding the <dgm:_testRef>test </dgm:_testRef>meal when CC may be given. </docset:CaffeineRestriction><docset:AlcoholandSmokingRestrictions structure="p">

              No alcohol will be allowed at least <docset:AlcoholRestriction>24 hours </docset:AlcoholRestriction>before each <dgm:_testRef>study </dgm:_testRef>site admission (<docset:AlcoholRestrictions>Day-1</docset:AlcoholRestrictions>) and throughout the duration of each <dgm:_testRef>study </dgm:_testRef>site visit. Between <dgm:_testRef>study </dgm:_testRef>site visits, <dgc:Frequency>daily </dgc:Frequency>alcohol consumption should not exceed <docset:AlcoholandSmokingRestrictions>21 </docset:AlcoholandSmokingRestrictions>units per week for males and <docset:AlcoholandSmokingRestrictions>14 </docset:AlcoholandSmokingRestrictions>units per week for females. No cigarette smoking will be permitted during the inpatient visits. </docset:AlcoholandSmokingRestrictions></docset:_632CaffeineAlcoholAndTobacco></docset:_632CaffeineAlcoholAndTobacco-section><docset:_633Activity-section><dg:chunk structure="h1">

              <docset:Activity>6.3.3</docset:Activity>. Activity </dg:chunk><docset:_633Activity structure="div"><dg:chunk><docset:ExerciseRestriction structure="p">

              Patients will be encouraged to maintain their regular exercise and <dgm:Medication>insulin </dgm:Medication>regimen adaptation related to exercise during the outpatient period; however, they should not undertake vigorous or prolonged exercise at least <docset:ExerciseRestriction>24 hours </docset:ExerciseRestriction>before each dosing day at the <dgm:_testRef>study </dgm:_testRef>site. Movement will be restricted to retain the integrity of connections to infusion(s) and the <dgm:_testRef>study </dgm:_testRef>procedures. </docset:ExerciseRestriction><dg:chunk structure="ol" style="list-style-type: decimal; boundingBox:{left: 293; top: 794; width: 585; height: 59.9; page: 49;}; "><dg:chunk structure="li" style="boundingBox:{left: 293; top: 794; width: 585; height: 59.9; page: 49;}; "><dg:chunk structure="lim" style="boundingBox:{left: 293; top: 794; width: 116; height: 62; page: 49;}; ">

              6.4. </dg:chunk><dg:chunk structure="h1"><dgm:_testRef>Screen </dgm:_testRef>Failures </dg:chunk></dg:chunk></dg:chunk></dg:chunk><docset:Re-screeningCriteria structure="p">

              Individuals who do not meet the criteria for participation in this <dgm:_testRef>study </dgm:_testRef>(<dgm:_testRef>screen </dgm:_testRef>failure) may be re-screened once. The interval between re-screenings should be at least <docset:Re-screeningInterval>28 days</docset:Re-screeningInterval>. Each time re-<dgm:_testRef>screening </dgm:_testRef>is performed, a new informed consent or assent form (see Appendix 3 for details) must be signed and participants will be assigned a new identification number.</docset:Re-screeningCriteria></docset:_633Activity></docset:_633Activity-section></dg:chunk></docset:LifestyleAndOrDietaryRequirements></docset:LifestyleAndOrDietaryRequirements-section></docset:Page47-section></docset:_18B-MC-ITSADClinicalPharmacologyProtocol-section></dg:chunk></docset:Abbreviations></docset:Abbreviations-section></docset:Period2></docset:Period2-section></docset:Parind1-section></docset:LY900014></docset:LY900014-section></docset:ApprovalofEliLillyAndCompanyOrItsSubsidiaries-section></docset:NotetoRegulatoryAuthorities></docset:NotetoRegulatoryAuthorities-section></dg:chunk></dg:chunk></dg:chunk>